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1. Introduction 
 
1.1 ATP-Binding Cassette Transporter Superfamily  
 
The ATP-binding cassette, ABC, transporter superfamily is one of the largest protein 
classes known. ABC-transporters are found in all cell types from archaebacteria to 
mammalian cells and they translocate different substrates, ranging from small ions to large 
polypeptides across the lipid bilayer either into or out of cell and organelles. ABC-
transporters are involved in diverse cellular processes such as maintenance of osmotic 
homeostasis, nutrient uptake, resistance to xenotoxins, cell division, pathogenesis and 
sporulation, cholesterol and lipid trafficking, and developmental stem cell biology. ABC-
transporters utilize the energy released from ATP hydrolysis for solute translocation (1-4). 
Despite the differences in transported solutes and whether they are transported in or 
out of cells, all ABC-transporters appear to have a conserved domain structure which 
comprises two transmembrane domains, TMDs, and two nucleotide binding domains, 
NBDs. The TMDs contain several membrane-spanning α-helices and provide the 
specificity for the transported solute. The amino acid sequence of TMDs varies 
considerably trough ABC-transporters most likely due to the wide variety in transported 
solutes (3, 4).  
The classification as ABC-transporters is based on the sequence and organization of 
the NBDs. The amino acid sequence in the NBDs is highly conserved through the whole 
superfamily (25-30 % identity) (1). The NBDs contain characteristic motifs (Walker A and 
B), and the signature C motif, also called as ABC- or LSGGQ-motif (2). The signature C 
motif is specific for ABC-transporters and distinguishes them from the other ATP-binding 
proteins. The hydrophilic NBDs are located in cytoplasm and function as molecular motors 
by transferring the energy of ATP binding and hydrolysis to the TMDs. Most ABC-
transporters are unidirectional (2, 3).  
In eukaryotes, most ABC-transporters move compounds from the cytoplasm to the 
outside of cell or into an intracellular compartment (endoplasmic reticulum, mitochondria, 
peroxisome) (2). At present 48 ABC-transporter genes are known in humans (5). They 
have been classified into seven subfamilies (A-G) by the Human Genome Organization. 
The human ABC-transporters are either full transporters where four domains are in one 
single polypeptide chain or half-transporters where one TMD is linked to one NBD. A half-
transporter has to form a homo- or heterodimer to be a functional unity (2). In bacteria, 
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ABC-transporters are mainly involved in the import of essential compounds that cannot 
enter into the cell by diffusion (sugars, amino acids, vitamins, small peptides, metal, 
anions, vitamin B12 etc.). Prokaryote importers or permeases generally contain four 
separate subunits in the core configuration together with a periplasmic-binding protein, 
which binds and presents solute to the membrane-bound transporters (3).  
Here we focus on one member of the ABC-transporter superfamily, namely P-
glycoprotein (Pgp, ABCB1). Pgp is often described as a double-edged sword (6), since it 
has an important role in the cellular defense system protecting us from xenobiotic toxins 
(7). On the other hand it limits the bioavailability of drugs during chemotherapy and 
contributes to the multidrug resistance phenomenon (6, 8).   
 
 
1.2 Multidrug Resistance and P-glycoprotein 
 
Cancer cells have the ability to become simultaneously resistant to different drugs. After 
initial resistance to a single anticancer drug, cells may develop cross-resistance to other 
structurally and mechanistically unrelated drugs. This phenomenon is known as multidrug 
resistance, MDR. There are several ways how cancer cells can become resistant to 
anticancer drugs. i) One way is to reduce the accumulation of drugs into cancer cells. This 
can occur e.g. by increasing the activity of efflux transporters such as Pgp. ii) If the drug 
accumulation is unchanged, activation of drug metabolizing enzymes, cytochrome P450s, 
can promote drug resistance. iii) Cells can also activate drug-induced DNA damage 
repairing mechanisms or iv) disrupt the apoptotic signaling pathways which diminish the 
drug-induced cell death (9). 
The best understood mechanism causing MDR is the reduced accumulation of 
hydrophobic anticancer drugs into cancer cells resulting from the overexpression of 
multidrug resistance proteins. The best known multidrug resistance protein is P-
glycoprotein (Pgp, ABCB1) (for review cf. (10, 11)). Subsequently, other multidrug 
resistance proteins were discovered such as the mitoxantrone resistance protein (MXR, 
ABCG2) and a family of multidrug-resistance-associated proteins 1 which currently 
contains 10 members from which at least seven have shown to confer resistance to 
anticancer drugs (MRP1-7, ABCC1-6, ABCC10) (12). All these proteins prevent sufficient 
accumulation of hydrophobic anticancer drugs within cancer cells due to their ability to 
transport many anticancer drugs out of the cell membrane. The presence of multidrug 
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resistance proteins in various types of human cancers including leukemia and solid tumors 
has been demonstrated (13-16). The MDR phenomenon is not only restricted to cancer but 
it can also hamper the chemotherapy of HIV (17, 18), epilepsy (19), bacterial (20), fungal 
(21), and parasitic diseases (22).  
To overcome MDR is a challenging area in pharmaceutical sciences. The 
pharmacological approach is to design molecules which are not recognized by multidrug 
resistance proteins or compounds which modulate or inhibit their activity. This can be 
achieved by using non-competitive or competitive inhibitors, which interact directly with 
the drug-binding site(s) of the proteins (23). A lot of effort has been made in order to find 
suitable Pgp-inhibitors for clinical use, but either due to their poor modulatory activity, 
toxicity at high concentration, or unpredictable pharmacokinetic interactions in the 
presence of chemotherapeutic agents (24-28), only a few significant advances have been 
made. Clinical trials with the third generation of Pgp-inhibitors developed specifically for 
MDR reversal are ongoing but a number of investigations have demonstrated that also they 
display cross-reactivity at least with MXR and drug-metabolizing enzymes (29).  
The difficulty to design a suitable Pgp-inhibitor for clinical use has led to the search 
for other strategies to overcome MDR (29, 30). One of those is the MDR gene silencing 
method where the aim is selectively block the expression of individual multidrug resistance 
proteins in human cancer cells. Recently, the feasibility of RNA interference, RNAi, 
technology to ‘knockdown’ Pgp expression in mice was demonstrated (31). Immunological 
methods have also been applied to inhibit Pgp. Binding of the monoclonal antibody (e.g. 
UIC2) abolishes conformational changes required for drug transport and thus reduces the 
MDR phenotype of tumor cells (32). Monoclonal antibodies themselves effect also on the 
proliferation of Pgp-expressing tumor cells (33). One concept to overcome MDR is to 
introduce Pgp into the bone marrow cells which do not widely express Pgp. The idea is to 
protect bone marrow cells from the side effects of anticancer drugs, thus allowing the 
elevation in the doses of anticancer drugs during the chemotherapy treatment of cancer 
patients (9).  
 
 
1.3 Tissue Distribution and Physiological Role of P-glycoprotein 
 
The properties of Pgp, such as its tissue distribution and the drug transport activity, suggest 
that its physiological function is the protection of the organism against natural xenobiotics 
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(7). Pgp is found on the apical surface of endothelial cells at important physiological 
barriers, such as the blood-brain barrier, BBB, blood-testis barrier, blood-nerve barrier, and 
fetal-maternal barrier (34-39), where it limits the entry of xenobiotics. Furthermore, Pgp is 
highly expressed on the apical surface of the small and large intestine epithelium, on the 
biliary canalicular membrane of liver hepatocytes, and on the apical surface of epithelial 
cells of the kidney proximal tubules (38). In these locations Pgp contributes to the 
excretion of xenobiotics into the intestinal lumen, bile and, urine, respectively. The 
knockout mice studies support the idea of the protective function of Pgp. The mice lacking 
the Abcb1a- and Abcb1b-genes were hypersensitive to the several xenobiotic toxins but 
otherwise they did not show dramatic physiological abnormalities (7, 40). These studies 
revealed that even if Pgp has some further physiological roles they are not vital. As other 
possible physiological functions e.g. transport of lipids (41), regulation of apoptosis (42), 
indirect modulation of chloride channel activity (43), and involvement in cholesterol 
esterification (44) have been postulated. 
Pgp is not only expressed in plasma membranes but it is also localized 
subcellularly. In cancer and in multi-drug resistance cells functional Pgp is found e.g. in the 
Golgi apparatus, mitochondrial, and nuclear membranes. It was proposed that the 
subcellular Pgp contributes to the protection of DNA (45-48).  
 
 
1.4 Effect of P-glycoprotein on Pharmacokinetics 
 
Pgp modulates the administration, distribution, metabolism and excretion of the drugs.   
After oral administration most drugs enter to the blood circulation mainly within the small 
intestine via passive diffusion. However, as discussed in Chapter 1.3 Pgp is highly 
expressed in the walls of small intestine thus hampering the absorption of drugs. 
Consequently, the net amount of drugs absorbed into the blood circulation is the difference 
between the amount absorbed by passive influx and the amount extruded by Pgp together 
with amount metabolized (49).  
Absorbed drugs have to be transported from the site of administration to the site of 
action in order to be effective. The brain for example is frequently targeted by drugs. 
However, the brain is separated from the blood circulation by the BBB which is composed 
of tightly connected endothelial cells by tight junctions (50). The hydrophilic drugs 
therefore have to be small enough to pass the tight junctions by passive diffusion or they 
1. Introduction 7
need special carrier systems. In contrary, the hydrophobic drugs can freely diffuse across 
the BBB and enter the brain compartment (7). However, the penetration of hydrophobic 
drugs is limited mainly by two factors. One is the cross-sectional area of the drug molecule 
which has to be > 80 Å2 (51) and the other is Pgp which is highly expressed in the BBB 
and thus exports its substrates back to the bloodstream (52, 53).  
Drugs are metabolized mainly in the liver (49, 54). In addition, the small intestine 
and the kidney may contribute to the overall drug metabolism (55). The effect of Pgp on 
the metabolism of drugs in the liver and kidney is small because of its exit site localization 
in hepatocytes and renal epithelial cells. Therefore Pgp mostly interacts with compounds 
that have already undergone cellular uptake, intracellular distribution and metabolism. In 
contrary, in intestine Pgp is localized at the entrance site of epithelial cells and thus the 
drugs are exposed to Pgp prior to intracellular distribution and metabolism. The intestinal 
Pgp extrudes drugs from the inside of epithelial cells back to the intestinal lumen after the 
drugs have gained access across the luminal surface of the epithelial cells. However, a 
portion of the extruded drugs reabsorb back into the epithelial cells. In this way Pgp 
prolongs the intracellular residence time of drugs and increases the probability that drugs 
get caught by the metabolizing enzymes (49, 56, 57).  
The elimination of the drugs from the body occurs generally via metabolism and/or 
excretion. Unchanged drugs and their metabolites are excreted by the liver and kidney. For 
biliary excretion drugs have to first diffuse passively or via hepatic uptake transporters 
through the basolateral membrane of hepatocytes. Once in the hepatocytes the drugs can 
diffuse to the apical membrane, where Pgp then transports them into bile. Similarly in renal 
excretion drugs at first cross the basolateral membrane of renal epithelial cells and then 
diffuse to the apical membrane where Pgp contributes to the excretion of drugs into the 
urine (49, 57). 
 
 
1.5 P-glycoprotein – Structure and Function 
 
The MDR phenomenon in cancer cells was first described in literature more than thirty 
years ago (58-60). The drug-resistant mammalian cell lines were established to study this 
phenomenon. The cell lines, which were initially selected for resistance to one anticancer 
drug showed cross-resistance to other structurally diverse drugs (58, 60). Some years later 
this phenomenon was linked to the overexpression of a surface phosphoglycoprotein in 
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multidrug resistance Chinese hamster ovary cells (61), which was named as a P-
glycoprotein (P for permeability) (62). Subsequently, it was shown that P-glycoprotein 
transports structurally unrelated compounds out of the cell at the expense of ATP (63). 
P-glycoprotein (Pgp, ABCB1), a member of ABC-transporter superfamily, is a 
transmembrane protein composed of 1280 amino acids (170 kDa). In humans Pgp is 
encoded by the ABCB1-gene (old nomenclature MDR1-gene) and in mice Abcb1a- and 
Abcb1b-genes (old nomenclature Mdr1a and Mdr1b-genes). The sequence analysis predicts 
that Pgp is composed of two homologues halves which are linked together by an 
intracellular flexible polypeptide loop (63, 64). Amino acid sequence identity of both 
halves is 43 % (64). Each half of the protein contains a transmembrane domain, TMD, 
which is composed of six hydrophobic α-helices and a hydrophilic cytoplasmically located 
nucleotide binding domain, NBD. TMDs form a pathway through which drug molecules 
cross the membrane. The necessity of both homologues halves and the intracellular linker 
region for drug transport and ATPase activity has been demonstrated (65-67). 
Pgp is glycolysated at three sites, N91, N94, and N99, in the first extracellular loop 
but glycolysation is not required for drug transport (68). Pgp has also four phosphorylation 
sites, S661, S667, S671, and S683, located in the linker region. Phosphorylation sites have 
shown to be phosphorylated by several kinases eg. protein kinase C and cAMP-dependent 
kinase A (69). The functional significance of phosphorylation is not well understood. 
However, mutational studies where Pgp lacked all phosphorylation sites suggested that 
phosphorylation is not essential for the overall ability of Pgp to interact with different 
cytotoxic agents (70). The hypothetical 2D model of human Pgp is shown in Figure 1. 
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Figure 1. Hypothetical 2D-model of human P-glycoprotein. The N-linked glycolysation sites are shown as 
tortuous lines and the phosphorylation sites as a P surrounded with a circle. Conserved sequence motifs in 
NBDs, Walker A, Walker B and Signature C, are indicated as A, B, and C. Adapted from (10). 
 
 
The high resolution crystal structure of Pgp is still unsolved but low- to medium resolution 
structures exist. Three dimensional structures with ~20 Å resolution were determined by 
electron crystallography of negatively stained 2D crystals in the absence of ATP and in the 
presence of non-hydrolysable analog of ATP (AMP-PNP) (71). Recently, also ~8 Å 
resolution 3D structure of Pgp in the presence of AMP-PNP was reported (72). These 
structures revealed that in the absence of ATP the TMDs form a single barrel within the 
membrane with a diameter of 5-6 nm and a depth of about 5 nm. The barrel contains a 
central pore which appeared to be open to the extracellular surface and spanning much of 
the membrane depth. Binding of non-hydrolysable ATP led to the repacking of TMDs and 
the opening the central pore along its length (71). Changes on the conformation at 
extracellular face of TMDs was also observed at vanadate, Vi-trapped state (Pgp·ADP·Vi) 
(73). Vi-trapped state is explained in more details in Chapter 1.5.2. 
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1.5.1 Substrate Binding to P-glycoprotein 
 
Perhaps the most intriguing and long-lasting question related to Pgp is how a single 
transmembrane protein can bind and transport hundreds of structurally dissimilar 
compounds including chemotherapeutic drugs, natural products, detergents and peptides. 
Progress in this field has been made recently, but it is still far away from complete 
understanding. Typically Pgp substrates are hydrophobic, neutral or positively charged 
molecules, which often carry an aromatic ring, but not always. Recent surface activity 
measurements revealed that also hydrophilic compounds can function as Pgp substrates 
suggesting that not the hydrophobicity but the amphiphilicity is a requirement for Pgp 
substrates (51). Also the importance of the hydrogen bond acceptor groups in the substrate 
recognition has been reported recently (74-78). 
The amphiphathic nature of Pgp substrates allows them to partition into the lipid 
bilayer. This is consistent with the fact that the drug-binding sites of Pgp are accessible 
from the lipid bilayer or more exactly from the intracellular leaflet of the lipid bilayer (79-
81). This led to the proposal of two models which could partially explain the broad 
substrate specificity of Pgp (82). In the hydrophobic vacuum cleaner model Pgp binds its 
substrates from the inner leaflet of the lipid bilayer and transports them out to the 
extracellular bulk water phase. In the flippase model drugs are flipped from the inner to the 
outer leaflet of lipid bilayer where they can diffuse to the extracellular medium. Electron 
paramagnetic resonance studies with spin-labeled verapamil demonstrated that Pgp can 
actively generate a 25-fold aqueous phase gradient suggesting that the Pgp substrates are 
directly transported out of the lipid membrane (83). On to other hand, it has been shown 
that Pgp is able to carry out the ATP-driven flipping of NBD (nitrobenzo-2-oxa-1,3-
diazole)-labelled phospholipids, NBD-derivatives of sphingomyelin, and simple 
glycosphingolipids supporting the flippase model (84, 85). Furthermore, the flippase model 
is supported by the fact that an isoform of Pgp, ABCB4, which shares >75 % sequence 
similarity with Pgp, functions as phosphotidylcholine (PC) flippase in liver canalicular 
cells (86). It is possible that Pgp functions as a transporter and a flippase depending on the 
hydrophobicity of the transported compound. However, to proof this further investigations 
are required. 
It is important to consider the influence of the lipids as non-polar solvent on the 
drug-binding step since that is the environment where Pgp binds its substrates. The lipid 
bilayer accumulates drug molecules due to their lipid-water partitioning coefficient. 
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Therefore, the hydrophobic drugs are highly concentrated in lipid bilayer whereas in 
aqueous phase they are present at a low concentration. The lipid bilayer also orients 
amphiphilic molecules in such a way that the hydrophilic part of the molecule remains in 
the water-lipid head group interface whereas the hydrophobic part inserts into the 
membrane. Furthermore, the low dielectric constant of lipid environment, ε ≈ 2, determines 
the nature of substrate-Pgp binding interactions. The electrostatic interactions are 
especially enhanced in a non-polar environment resulting also in weak electrostatic 
interactions such as the π-electrons of aromatic ring and a cation may play a role. Also 
hydrogen bonding can become relevant (75, 78). Sharom et al. (87) found a relationship 
between the octanol-water partition coefficient, LogP, and the concentration of half-
maximum Pgp activity for three Pgp substrates suggesting that the lipid bilayer is important 
in drug recognition. LogP, however, did not sufficiently correlate with the large set of 
structurally unrelated compounds (88) but an excellent linear correlation was found 
between the concentration of half-maximum Pgp activity and the air-water partition 
coefficient (77). The air-water interface mimics better the lipid bilayer than the octanol-
water system because it orders the compounds similarly as lipid bilayer and secondly, the 
dielectric constant of air (ε ≈ 1) is closer to the dielectric constant of the hydrophocic core 
region of the membrane than the dielectric constant of octanol (ε ≈ 10) (78).  
The location and the number of drug-binding site(s) of Pgp has been the interest of 
many research groups. The site-directed mutagenesis and the photoaffinity labeling 
experiments suggested that the different substrates have different, but maybe overlapping 
binding sites and that the major sites of drug interactions are located in several 
transmembrane α-helices, especially clustered in TM5, TM6, TM11, and TM12 (10, 12, 
89-93). However, the mutations that effected substrate specificity were found throughout 
the Pgp molecule including extra- and intracellular loops, and even NBDs (10). Similar 
findings were reported from the photoaffinity labeling studies (90, 91). Loo et al.(94-97) 
used cysteine-scanning mutagenesis to identify the amino acid residues which line the 
drug-binding site(s). In initial studies they worked with cysteine-less Pgp mutant and 
introduced systematically a single cysteine residue into the TMDs of Pgp and probed it 
with thiol-reactive Pgp substrates. Their results supported the photoaffinity and other site-
directed mutagenesis studies suggesting that transmembrane α-helices TM4, TM5, TM6, 
TM10, TM11, and TM12 contribute to drug-binding. Recently, they reported that also 
TM1 and TM7 are contributing to the drug-binding domain (98, 99).  
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The clear consensus from the studies described above is that the drug-binding site(s) of Pgp 
are located within TMDs. However, the number and the nature of drug binding site(s) has 
been subject to much controversy. The results of some studies have suggested the existence 
of two drug-binding sites, some three and some even four binding sites (80, 100, 101). 
Shapiro et al. (102) showed that Pgp substrates hoechst 33342 and rhodamine 123 bound 
two different binding-sites (called as H- and R-site). H-site drugs stimulated transport of R-
site drugs whereas two drugs which bind to the same site caused a mutual inhibition of 
transport. Progesterone and prazosin did not bind either site leading to the suggestion of the 
existence of a third binding site (80). As an alternative idea, compared to the distinct drug-
binding sites, the existence of a single large binding site or broader binding regions has 
been proposed (103-105). Loo et al. (105) proposed that the drug-binding pocket involves 
amino acid residues from several transmembrane α-helices and the diverse substrates 
create their own binding sites by using a combination of residues from different TMs. Lugo 
et al. (106) showed that two R-site drugs, rhodamine 123 and LDS-751, which compete 
with each other for transport, are able to bind simultaneously within Pgp supporting further 
the idea of a large flexible drug binding site. The dimension of the drug-binding pocket has 
been estimated with the crosslinking studies. It was proposed that the drug-binding domain 
is funnel shaped and narrow in the cytoplasmic region. The central diameter of the drug-
binding region was estimated as 9-25 Å, and at the extracellular side as ~50 Å (95).  
The concept of broader binding regions is also supported by the quantitative 
structure-activity-relationship, QSAR, analysis. It was suggested that Pgp recognizes its 
substrates via specific hydrogen bond formation patterns (75). The concept was based on 
two facts. First, it was noticed that transmembrane α-helices of Pgp have a high density of 
hydrogen bond donor side chains which are arranged in amphiphathic manner. It was 
proposed that the hydrogen bonding side of TM helices are facing the drug transport route 
and the non-hydrogen bonding side is located in the lipid environment (75, 76). Secondly, 
three dimensional structural analysis of hundred Pgp-substrates revealed that all Pgp 
substrates carried at least two hydrogen bond acceptor groups in a specific distance of 2.5 ± 
0.5 Å (type I unit) or three with a distance of 4.6 ± 0.6 Å between the two outer hydrogen 
bond acceptor groups (type II unit). The hydrogen bond acceptor patterns are shown in 
Figure 2. Furthermore, it was proposed that the strength of substrate binding to Pgp 
increases with the number and strength of individual hydrogen bond formed. The hydrogen 
bond hypothesis as recognition element between Pgp and its substrates is investigated 
further in the studies summarized in Chapters 3.1 and 3.6. 
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Figure 2. Hydrogen bond acceptor patters in Pgp substrates suggested functioning as binding modules with 
hydrogen bond donor rich transmembrane α-helices of Pgp. A represents a hydrogen bond acceptor (such as 
O, N, S, or X= F, Cl, and unsaturated system with π-electrons e.g. phenyl ring). Numbers in brackets shows 
1st and nth atom with free electron pair. Adopted from (75).  
 
 
1.5.2 Nucleotide Binding to P-glycoprotein 
 
Pgp requires ATP hydrolysis for its drug transport activity (107-109). ATP binding and 
hydrolysis occurs in two NBDs, which are located in cytosol. It has been shown that both 
NBDs can bind and hydrolyze ATP (110, 111) and that the binding affinity of ATP to Pgp 
is low (Km ≈ (0.3–0.8) mM) (112-115). Mutations and covalent modifications that 
inactivated ATP hydrolysis in one NBD prevented the ATP hydrolysis also in other NBD 
(116-118). Similarly, vanadate, Vi, permitted ATP hydrolysis in one NBD, but after 
dissociation of inorganic phosphate, Pi, the vanadate entered the active site forming a stable 
complex with ADP (ATP·Pgp·ADP·Vi) and, thus, impeded ATP hydrolysis in other NBD 
(111). Moreover, photoaffinity labeling suggested that 1 mol of Mg-8-azido-ADP/1 mol 
Pgp is bound after hydrolysis of Mg-8-azido-ATP (119). All these experiments suggests 
that there is a strong catalytic cooperativity between two NBDs and based on these kinds of 
observations Senior et al. (119) proposed an alternating catalysis site model for Pgp, where 
type I unit type II unit 
2.5 ± 0.5 Å                               4.6 ± 0.6 Å             
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two NBDs alternate in carrying out ATP hydrolysis in such a way that only one NBD is 
active at a time.  
 In recent years considerable progress has been made in the understanding of the 
ATP binding pocket and the mechanism of how ATP is hydrolyzed since several crystal 
structures of isolated NBDs of ABC transporters have been solved (HisP (120), Rad50 
(121), MJ0796 (122), and MutS (123)). All crystallized NBDs showed a similar tertiary 
structure which was also seen in the crystal structure of bacterial full-length ABC-
transporter, BtuCD (124). An important observation from the structures was that a 
functional ATP binding site is formed by the interaction of amino acid residues from both 
NBDs. Moreover, the structures revealed that two NBDs form a ‘’nucleotide sandwich 
dimer’’ with two ATP molecules bound between the dimer interface (Figure 3). Because 
NBDs of all ABC-transporters share an extensive amino acid sequence identity it was 
postulated that the tertiary structure may be conserved within the whole ABC-transporter 
superfamily (4). By merging now the structural, mutational and biochemical data together a 
more detailed picture of the ATP binding pocket of Pgp has started to evolve.   
 
 
Figure 3. The closed NBD dimer with two ATP molecules and two Mg2+-ions viewed from above trough the 
membrane and TMDs. TMDs are not shown for clarity. Two NBDs are colored as cyan and gold, the two 
ATP molecules are presented as stick models and two Mg2+-ions as black spheres. The picture is adopted 
from (4). 
 
Each NBD of Pgp consists of the highly conserved Walker A, Walker B, Signature C 
motifs, and the Q-, D-, and H-loops (125). Recently, the importance of tyrosine residues at 
positions 401 in N-terminal NBD and 1044 in C-terminal NBD of human Pgp to ATP 
binding and hydrolysis was demonstrated. Tyrosine was shown to form the π−π stacking 
interaction with an aromatic ring of ATP and therefore it was named the A-loop (aromatic 
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residue interacting with adenine ring of ATP). It was proposed that this conserved aromatic 
residue should be considered as an integral part of NBD (126, 127). Figure 4 displays in 
detail the major molecular interactions between ATP molecule and the conserved motifs. 
ATP is sandwiched between the Walker A, Walker B, H-loop, Q-loop and A-loop of one 
NBD on one side and the signature C motif and D-loop of the other NBD on the other side 
(121, 122). The structures of ABC proteins showed that Walker A binds to negatively 
charged triphosphate moiety of ATP and Walker B shows hydrogen bonding with a 
coordinating Mg2+-cation (120, 122). There is no high-resolution structure of Pgp available 
yet but this kind of molecular architecture of NBDs is supported by biochemical studies 
(128, 129). Qu et al (129) showed with the FRET studies that NBDs are in close contact 
with each other. Loo et al. (128) demonstrated with the crosslinking studies that the 
signature C motif in each NBD is adjacent to the opposing Walker A sequence. 
Furthermore, the recent 8Å resolution electron crystallographic structure of Pgp confirmed 
the close proximity of NBDs (72). The physical contact of NBDs could explain the 
experimentally observed cooperation between two NBDs. 
 
 
Figure 4. Interactions between NBDs of Pgp and ATP, Mg2+ and H2O based on the X-ray crystallographic 
structure of MJ0796 and HlyB. Adapted from (130). Amino acid residues which are part of conserved motifs 
are indicated with colors. Walker A motif (green), Walker B (blue), Q-loop glutamine (down lachs), H-loop 
histidine (upper lachs), A-loop (yellow) are part of one NBD and Signature motif (lila) is part of the other 
NBD.  
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1.6 Coupling of ATP hydrolysis to Drug Translocation 
 
To fully understand the mechanism of Pgp knowledge of how ATP hydrolysis in the NBDs 
is coupled to the drug translocation through the TMDs is mandatory. The connection of 
these two processes is evident from the ability of Pgp substrates to stimulate the ATP 
hydrolysis rate (107-109). In order to mediate drug transport, Pgp has to couple the energy 
from drug binding, ATP binding and hydrolysis to the conformational changes that most 
probably alter the drug binding affinity and/or the accessibility of drug-binding sites (131). 
The technique of vanadate, Vi, trapping has been useful in dissecting the catalytic cycle of 
Pgp. Vi-trapping technique was created to solve the difficulties in kinetic analysis, which 
arose from the low affinity of ATP to Pgp (111). When ATP is hydrolyzed in the presence 
of Vi, that has a similar size and charge as Pi, a stable noncovalent complex with ADP is 
formed in one NBD of Pgp (Pgp·ADP·Vi) and the further ATP hydrolysis events are 
abolished. The geometry of Vi-complex is thought to mimic the transient catalytic 
transition state formed with ADP and Pi  (132). The relatively long life-time of the Vi-
trapped complex allows e.g to determine the dissociation constant for the drugs (133) and 
to study the conformational changes in Pgp during the different steps of the catalytic cycle 
of Pgp (73, 134). These types of measurements are usually coupled with the measurements 
done in the presence of non-hydrolysable ATP to determine the effect of ATP binding on 
the drug binding affinity and the tertiary structure of Pgp (71, 135).  
The global changes in Pgp conformation upon ATP binding, ATP hydrolysis, Vi-
trapping and upon drug binding has been detected with spectroscopic techniques (134, 
136), with cross-linking experiments (137), with FACS analysis in the presence of 
monoclonal antibody UIC2 (138) as well as with cryoelectron microscopy (71). The 
conclusion from these studies was that Pgp possesses different conformations which are 
associated with the different steps in the drug transport process. In some studies the 
question was addressed how the conformational changes are effecting on the binding 
affinity of drugs (133, 135, 139). The goal was to identify the step at which the switch in 
drug-binding site from high to low affinity occurs. Different techniques have been used and 
the reported results are partially controversial. The initial photoaffinity labeling studies 
showed that the photolabeling of Pgp with Pgp-substrate analog [125I]-
iodoarylazidoprozosin, IAAP, was significantly reduced in Vi-trapped form (139, 140). 
This was intepretated that the drug-binding site is still in low affinity state and the model 
was proposed where two ATP are hydrolyzed per one drug transported. One ATP was used 
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to change the drug-binding site from high to low affinity and the second ATP was used to 
reset Pgp back to its high binding affinity conformation (139, 140). However, the liability 
of these results has been contradicted (133, 141). In contrast, Qu et al (133, 142) used 
several fluorescence spectroscopic approaches to study the changes in the drug-binding 
affinity to Pgp in Vi-trapped conformation compared to the resting state conformation. It 
was shown that the binding affinity of six different drugs was not changed in the Vi-trapped 
form and thus it was proposed that the drugs were released before the formation of post-
hydrolysis transition state (Pgp·ADP·Vi). Furthermore, Qu et al (133, 142) suggested a 
mechanism which involves concerted conformational changes and predicted that the 
relaxation from the transition state drives simultaneous movement of the drug across the 
membrane. This mechanism is consistent with the alternative catalytic model (119). In the 
third study performed with the equilibrium radioligand binding assay it was demonstrated 
that the binding of the non-hydrolysable nucleotide caused a reduction in the fraction of 
transported substrate (vinblastine) bound to Pgp (135). Vi-trapped conformation showed a 
similar affinity for vinblastine than the nucleotide bound state suggesting that the change in 
the affinity of the drug-binding site from high to low occurred via the nucleotide binding. 
This led to the third possible model suggestion, the ‘’ATP switch model’’ where the main 
differences being when compared to the two previous models is that the release of drug 
occurs via ATP binding and dimerization of NBDs and the energy from ATP hydrolysis is 
used for resetting Pgp back to its high affinity conformation (4, 143). As demonstrated 
above the clarification of the detailed steps in the drug transport cycle of Pgp is still a 
matter of intensive research. More experimental data is needed to judge which of the 
proposed models or whether any of them is correct. In the study summarized in Chapter 3.5 
we addressed this question and studied the interplay between NBDs and TMDs of Pgp 
further.  
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2. Rationale and Aims of Research 
 
As discussed in the Introduction (Chapter 1.3) Pgp has an important function to protect our 
sensitive and important organs such as the CNS against xenobiotics. Unfortunately, the 
overexpression of Pgp is also related to multidrug resistance, MDR, which is a serious 
problem in cancer chemotherapy (Chapter 1.2). Moreover, MDR also hampers the 
chemotherapy of other drug-treatable diseases such as AIDS, epilepsy, bacterial, parasital 
and fungal diseases. One strategy to overcome MDR is to design Pgp-inhibitors or 
eventually drugs that are not recognized by Pgp. In order to achieve this, it is mandatory to 
better understand the interactions between Pgp and its substrates better. Therefore, the 
main aim of this thesis was the quantitative characterization of the thermodynamics and the 
kinetics of Pgp-substrate interactions. Special emphasis was placed on better understanding 
of the effect of lipid bilayers on Pgp-substrate interactions.  
Pgp is a transmembrane protein, which transports hundreds of structurally diverse 
compounds out of the cell membrane using the energy released in ATP hydrolysis. As 
pointed out in the Introduction (Chapter 1.5.1) it has been known already for years that Pgp 
extracts its substrates from the lipid bilayer and not from the aqueous phase, like many 
other membrane transporters. This complicated the determination of the intrinsic drug 
binding constants to Pgp (the binding constant of drug to Pgp from the lipid phase, Ktl), and 
consequently the evaluation of the strength of Pgp-substrate interactions. Drug binding 
constants to Pgp reported in literature are the products of two binding constants, namely the 
lipid-water partition coefficient, Klw, and the binding constant of drug to Pgp from the lipid 
phase, Ktl. Thus, they are apparent values (the binding constants of drug to Pgp from the 
aqueous phase, Ktw). No intrinsic binding constants, Ktl, were available. Therefore the main 
goal in our first investigation was to separate the two binding constants and to determine 
the intrinsic drug binding constant to Pgp, Ktl, and the corresponding free energies, 0tlGΔ , 
for the 15 structurally diverse Pgp-substrates (summarized in Chapter 3.1, full study in 
Chapter 7.1). Additionally, we tested the relevance of the hydrogen bond hypothesis as 
recognition mechanism between Pgp and its substrates (cf. Chapter 1.5.1).  
It is also important to know how fast the drugs are transported by Pgp. Therefore, in 
the next three parts of this thesis (summarized in Chapters 3.2-3.4, full reports in Chapters 
7.2-7.4) we studied the kinetics of Pgp and analyzed the influence of the physicochemical 
properties of drugs on Pgp activity. Recently, in our laboratory a new method was 
described where Pgp activity was studied for the first time in living MDR1-transfected cells 
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by monitoring the extracellular acidification rate, ECAR, with a Cytosensor 
microphysiometer (144). Previously, Pgp activity has been measured in inverted plasma 
membrane vesicles formed from MDR1-transfected cells or in reconstituted Pgp-
proteoliposomes by determining the rate of ATP hydrolysis spectroscopically (88, 114, 
116). The conventionally used spectroscopic assay detects directly the ATP dependent drug 
transport activity of Pgp, whereas the ECAR describes the efflux rate of acidic metabolites 
and, thus, reflects the overall energy metabolism of cells. Therefore the question arose, 
how the general mechanism of the ECAR under the conditions where Pgp is activated by 
drugs is related to the specific drug-stimulated ATP hydrolysis rate of Pgp. This question 
was mainly addressed in the studies summarized in Chapters 3.2-3.3 (full reports in 
Chapters 7.2-7.3).  
In Chapter 3.2 (full report in Chapter 7.2) Pgp activity measured for a large set of 
structurally diverse Pgp substrates in plasma membrane vesicles was compared with the 
Pgp activity investigated in living cells (Chapter 7.1). In the present study the Pgp activity 
was determined in the same membrane environment in contrast to the previously reported 
results (144). This is relevant since Pgp activity depends on the lipid membrane (Chapter 
7.1, (87, 145)). Moreover, we tested experimentally the soundness of the relationship 
reported earlier for the maximum Pgp activity, V1, and for the hypothetical free energy of 
hydrogen bond formed (EUH) between Pgp and drugs (Introduction, Chapter 1.5.1, (26, 76, 
78)). It was shown previously for the smaller set of compounds that the maximum Pgp 
activity, V1, is decreasing exponentially with increasing EUH. In the present study the larger 
set of compounds were used with wider variation in their structures and hydrophobicity 
(Chapter 7.2).  
The influence of the cell metabolic state on Pgp activity was described in Chapter 
7.3. The results revealed a linear correlation between the basal and the verapamil-
stimulated ECAR under low nutritional conditions. The correlation, however, flattened out 
under high nutritional conditions. To better understand this phenomenon we further studied 
the metabolic rate of cells with 13C-NMR spectroscopy (summarized in Chapter 3.4, full 
report in Chapter 7.4). The advantages in the 13C-NMR technique compared to the 
Cytosensor measurements are that all lactate molecules can be detected and that the 
measurements can be performed in a solution with a high buffer concentration. The 
Cytosensor microphysiometer only detects the extruded lactate molecules outside the cells. 
The ultimate goal in understanding the drug transport mechanism of Pgp is to 
understand how ATP hydrolysis in the nucleotide binding domains of Pgp, NBDs, is 
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coupled to the drug translocation step through the transmembrane domains of Pgp, TMDs 
(Introduction, Chapter 1.6). In the study summarized in Chapter 3.5 (full report in Chapter 
7.5) we aimed at getting further insight to the interplay between TMDs and NBDs by 
analyzing the transition state parameters (the activation enthalpy ‡HΔ , the activation 
entropy ‡SΔ , and the free energy of activation ‡GΔ ) of ATP hydrolysis by Pgp in the 
absence and presence of several Pgp substrates. Furthermore, since the Pgp activity 
depends on the properties of the lipid bilayer (Chapter 7.1, (87, 145)), and Pgp is found in 
many organs that have significantly different membrane properties, we were interested in 
getting further information about the relationship between Pgp and lipids.  
In the last part of this thesis we worked with four dyes, which are widely used in 
histological studies. Furthermore, the applicability of dyes as potential photosensitizers for 
the treatment of cancer and microbial infections together with photodynamic therapy has 
been tested. In this context it is important to know if the dyes are Pgp substrates. 
Furthermore, our aim was to test whether the established rules (146) for the intrinsic Pgp 
substrates holds for methylene blue, acridine orange, basic fuchsin, and ethyl eosin. The 
predictions were then tested experimentally.       
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3.1 Quantification and Characterization of P-glycoprotein-Substrate 
Interactions 
 
Pgp binds its substrates from the inner leaflet of the lipid bilayer (Introduction Chapter 
1.5). This means that drug molecules have to first partition into the lipid bilayer before they 
reach the site of interaction. After binding to Pgp they are exported either directly to the 
extracellular medium or flipped to the outer leaflet of the lipid bilayer. The first hints of the 
weak interactions between Pgp and its substrates came from the observation that Pgp 
transports hundreds of structurally diverse compounds and in general all of them were 
hydrophobic in their nature. This suggests that Pgp substrates accumulate inside the 
membrane and therefore the concentrations, which Pgp senses, are much higher than that in 
the aqueous phase. The two-step drug binding model to Pgp was introduced recently (77, 
78), however, the quantitative evaluation for the drug binding constants from the lipid 
phase to Pgp, Ktl, and the corresponding free energies, 0tlGΔ , were still missing. 
Therefore in the first part of this thesis we separated the two binding processes, the 
lipid-water partition of the drug and the drug binding to Pgp from the lipid phase, and 
quantified for the first time the drug binding constants from the lipid phase to the activating 
(inhibitory) binding region of Pgp, Ktl(1) (Ktl(2)), and the corresponding free energies 0 )1(tlGΔ  
( 0 )2(tlGΔ ). This was done for the 15 structurally diverse well-known Pgp substrates. The 
free energy of drug partitioning into the lipid phase, 0lwGΔ , was determined from surface 
activity measurements (cf. Appendix 7.1.1) which allows estimation of the lipid-water 
partition coefficient of the drug, Klw, when the packing density of the lipid bilayer, πM, in 
which Pgp is embedded, is known. The free energy of the drug binding from the aqueous 
phase to the activating (inhibitory) binding region of Pgp, 0 )1(twGΔ  ( 0 )2(twGΔ ), was estimated 
from steady-state Pgp activity measurements. Pgp activity measurements were performed 
in living MDR1-transfected mouse embryo fibroblasts by monitoring the extracellular 
acidification rate, ECAR, with a Cytosensor microphysiometer. The free energy of drug 
binding from the lipid phase to the activating (inhibitory) binding region of Pgp, 0 )1(tlGΔ  
( 0 )2(tlGΔ ), was determined as the difference of 0 )1(twGΔ  ( 0 )2(twGΔ ) and 0lwGΔ . Moreover, we 
evaluated the drug concentrations in the lipid phase at half-maximum Pgp activity, Cb, and 
tested the energetic soundness of the hydrogen bond hypothesis as a recognition 
mechanism between Pgp and its substrates (Introduction, Chapter 1.5). 
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The substrate concentrations in the lipid phase at half-maximum Pgp activity were Cb(1) = 
(0.02 to 67) mM/L lipid. These are by a factor of 102 to 104 higher than that in the aqueous 
phase revealing that the interactions between Pgp and its substrates are relatively weak. 
The lowest value was determined for cyclosporin A and the highest for lidocaine. The free 
energy of drug binding from the aqueous phase to the transporter, the free energy of drug 
partitioning into the lipid phase, and the free energy of drug binding from the lipid phase to 
the activating binding region of Pgp for the 15 drugs studied ranged from ( 0 )1(twGΔ  = (-30 to 
-54) kJ/mol), ( 0lwGΔ  = (-23 to -34 kJ/mol)), and ( 0 )1(tlGΔ  = (-7 to -27 kJ/mol)), respectively. 
For all drugs 0lwGΔ  were more negative than 0 )1(tlGΔ , however, 0 )1(tlGΔ  varied more strongly 
suggesting that the drug-membrane interactions for the studied compounds are stronger 
than the Pgp-drug interactions. The Pgp-drug interactions, however, are more specific.  
Knowledge of the free energy of the drug binding from the lipid phase to the 
activating binding region of Pgp, 0 )1(tlGΔ , allowed to test the validity of the hydrogen bond 
hypothesis. The hydrogen bond hypothesis suggests that the hydrogen bonds can form 
between the hydrogen bond acceptor groups of the substrate and the hydrogen bond donor 
groups of transmembrane domains, TMDs, of Pgp and that hydrogen bond acceptor groups 
in specific distances in substrate molecules can thus serve as recognition element for Pgp 
(Introduction, Chapter 1.5). By dividing the experimentally determined 0 )1(tlGΔ  values by 
the weighted number of hydrogen bond acceptors, the free energy per potential hydrogen 
bonds formed was estimated as ( 0HiGΔ  = (-2.3 to -7.8) kJ/mol). These values are reasonable 
for weak hydrogen bonds and suggest that the hydrogen bond formation contributes 
significantly to the energetics of Pgp-substrate interactions within the lipid phase. 
Furthermore, the results presented here support the hypothesis that Pgp has a large binding 
region(s) rather than specific drug binding sites.  
A difficulty in Pgp activity measurements with a Cytosensor microphysiometer is 
that the drug solutions have to flow through long tubing and along the debubbler 
membrane before they reach the cells. Considerable amount of drug was lost because of 
adsorption to the tubes and the debubbler membranes and therefore the drug concentrations 
had to be corrected. In the present study the drug adsorption for the 14 drugs studied was 
quantified by UV-spectroscopy. The adsorption varied from compound to compound and 
was especially high for the phenothiazines and relatively low for verapamil. The 
cyclosporin A concentration could not be corrected since it does not contain UV-detectable 
amino acid residues. The quantification of drug adsorption to the tubing of the Cytosensor 
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microphysiometer was my contribution to this work. I further contributed to the Pgp 
activity measurements with a Cytosensor microphysiometer for nine out of the fifteen 
drugs. 
 
This study is described in detail in the following publication (Chapter 7.1, page 53): 
Gatlik-Landwojtowicz, E., Aanismaa, P., and Seelig, A. (2006), Quantification and 
Characterization of P-glycoprotein-Substrate Interactions. Biochemistry, 45(9), 3020-3032. 
 
 
3.2 P-Glycoprotein Kinetics Measured in Plasma Membrane Vesicles and 
Living Cells  
 
To understand Pgp in more detail it is important to elucidate its drug transport activity in 
the cellular ensemble as well as in an isolated environment. The drug transport rate of Pgp 
has been frequently assayed by means of transport measurement across the confluent cell 
monolayers that express high levels of Pgp. These measurements, however, reveal only the 
apparent drug transport rate of Pgp since they combine the passive influx rate of drug and 
the active efflux rate of drug by Pgp (146). The intrinsic drug transport rate of Pgp can be 
determined with greater reliability by monitoring the ATP hydrolysis rate because it is 
directly proportional to the intrinsic drug transport rate of Pgp.  
 Conventionally, the ATP hydrolysis rate of Pgp has been measured 
spectroscopically by detecting the ATP hydrolysis rate in inverted plasma membrane 
vesicles formed from MDR1-transfected cells or in reconstituted Pgp-proteoliposomes. 
Recently, our laboratory reported a new method where Pgp activity was studied in living 
MDR1-transfected cells by measuring the extracellular acidification rate, ECAR, with a 
Cytosensor microphysiometer (144). These two assays, however, bare distinct differences. 
In living cells drugs have to partition into the lipid bilayer and diffuse across the membrane 
to the cytosolic leaflet in order to reach the activating binding region of Pgp. In inverted 
plasma membrane vesicles the drugs merely have to intercalate between the lipids since the 
activating drug binding region of Pgp is now located towards extracellular medium. In an 
earlier investigation made by our laboratory the kinetics of Pgp activity measured in living 
MDR1-transfected pig kidney cell (144) was compared to Pgp activity measured in plasma 
membrane vesicles formed from Chinese hamster ovary cells (88). The results were in 
reasonable agreement. However, it is known that Pgp activity depends on the lipid 
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environment (Chapter 7.1, (87, 145)). Therefore, for a more rigorous comparison it is 
important to use Pgp embedded in the same membrane environment for both types of 
experiments.  
In the second part of this thesis we characterized Pgp activity in living MDR1-
transfected mouse embryo fibroblast cells and in plasma membrane vesicles formed from 
the same cells. In the study summarized in Chapter 3.3 this comparison was made only for 
the one well-known Pgp substrate, verapamil. Here, we extended the comparison for the 
same 15 drugs investigated earlier in living MDR1-transfected mouse embryo fibroblasts 
(summarized in Chapter 3.1). Furthermore, four other drugs were added in order to get an 
even broader range of drugs. Data was evaluated according to the modified Michaelis-
Menten equation yielding the concentration of half-maximum Pgp activation (inhibition), 
K1 (K2), and maximum (minimum) Pgp activity, V1 (V2). The obtained kinetic parameters 
were then compared with the corresponding values determined in living cells.  
The study revealed that the concentrations of half-maximum Pgp activation, K1, 
determined in living cells and in plasma membrane vesicles were in good agreement 
provided that the two systems were at the same pH and that possible artifacts such as the 
drug adsorption, drug and vesicle association and cytotoxic effect of drugs could be 
eliminated. The concentrations of half-maximum Pgp activation, K1, spread over a broad 
concentration range from (K1 = (10-8 to 103) M. The lower values were determined for 
hydrophobic drugs and the higher values for more hydrophilic drugs. A reasonably linear 
correlation was also found for the relative maximum Pgp activities, V1, obtained in living 
cells and in plasma membrane vesicles. The deviations were mainly due to artifacts. In 
order to compare the absolute drug-stimulated rate enhancement the turnover numbers 
were calculated by dividing the maximum Pgp activity, V1, by the estimated amount of Pgp 
molecules per sample. The turnover numbers from both systems were in reasonable 
agreement when the measurements in living cells performed in the presence of pyruvate. 
However, in the absence of pyruvate they seem to be higher in living cells. This issue is 
furthermore addressed in other parts of this thesis (Chapters 7.3-7.4).  
Additionally, we tested the soundness of the relationship found previously between 
the maximum activity of Pgp, V1, and the hypothetical hydrogen bonding energy of the 
drug (EUH). It was shown earlier for a smaller set of compounds that the maximum Pgp 
activity, V1, decreases exponentially with increasing EUH (26, 76, 78). To this purpose we 
determined the total free energy of drug binding to Pgp from the aqueous phase, 0 )1(twGΔ , 
and from the lipid-phase, 0 )1(tlGΔ , according to the two step-drug binding model. We found 
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that the logarithm of the maximum Pgp activity, lnV1, depends linearly on the binding 
affinity of drug to the transporter from the aqueous phase, 0 )1(twGΔ . The correlation between 
the logarithm of the maximum Pgp activity, lnV1, and the EUH (or 0 )1(tlGΔ ) was valid for the 
compounds whose 0 )1(twGΔ and 0 )1(tlGΔ  were linearly correlated. The third generation 
inhibitor OC144-093 was an exception. It has a high affinity to the lipid phase but a low 
affinity from the lipid phase to Pgp. Its behavior was distinctly different than the behavior 
of the first-generation inhibitor, cyclosporin A, which has an intermediate affinity to the 
lipid phase but high affinity from the lipid phase to the transporter. Because both of them 
are effective inhibitors functioning already at low nM concentration this suggests that the 
inhibition mechanism for OC144-093 and cyclosporin A are different. Furthermore, the 
linear correlation found for the logarithm of maximum Pgp activity, lnV1 and the free 
energy of drug binding from the aqueous phase to the transporter, 0 )1(twGΔ , suggests that the 
drug release determines the rate of Pgp activity. 
  
This study was the main topic of my PhD thesis. Details of these results are described in 
the following publication (Chapter 7.2, page 71): 
Aanismaa, P., and Seelig, A. (2007), P-Glycoprotein Kinetics Measured in Plasma 
Membrane Vesicles and Living Cells. Biochemistry, 46(11), 3394-3404. 
 
 
3.3 The Rate of P-glycoprotein Activation Depends on the Metabolic State 
of the Cell  
 
In the first Pgp activity investigation performed in living cells by monitoring the 
extracellular acidification rate, ECAR, with a Cytosensor microphysiometer the molecular 
origin of the proton efflux was not known (144). All energy consuming processes in living 
cells produce acidic metabolites such as protons and the lactate molecules which need to be 
excreted outside of cells in order to maintain cellular homeostasis. The Cytosensor 
microphysiometer detects the changes in the acidity of the medium where cells are bathing 
and, thus, the ECAR reflects the overall energy metabolism of cells. Because measuring 
the changes in the ECAR is a rather indirect method to detect drug transport activity of Pgp 
the question raised how the general mechanism of the ECAR under the conditions where 
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Pgp is activated by drugs is related to the specific drug-stimulated ATP hydrolysis rate of 
Pgp. This was my main topic in the study reported in Chapter 7.3.    
To answer this question a method had to be established by which the ATP 
hydrolysis rate of Pgp could be detected alone. Because this is not feasible in living cells 
another approach was necessary. To this purpose we established the conventional ATPase 
assay, where the rate of ATP hydrolysis by Pgp is measured spectroscopically in inverted 
plasma membrane vesicles. The plasma membrane vesicles were prepared from the same 
MDR1-transfected mouse embryo fibroblasts as used in the ECAR measurements since it is 
important to use Pgp embedded in same lipid environment in both assays. The comparison 
of the proton efflux rate in living MDR1-transfected cells and the phosphate release rate 
from ATP hydrolysis by Pgp revealed a reasonable agreement between the verapamil-
stimulated ATP hydrolysis rate of Pgp and the verapamil-stimulated ECAR suggesting that 
ATP hydrolysis of Pgp is kinetically linked to the ECAR.  
 
Details of this study are described in the following publication (Chapter 7.3, page 85): 
Gatlik-Landwojtowicz, E., Aanismaa, P., and Seelig, A. (2004), The Rate of P-
glycoprotein Activation Depends on the Metabolic State of the Cell. Biochemistry, 43(46), 
14840-14851. 
 
 
3.4 Metabolic Rate of Mouse Embryo Fibroblasts Determined by 13C-NMR 
 
The metabolic rate of the mouse embryo fibroblast, wild-type and MDR1-transfected, cells 
was determined previously with a Cytosensor microphysiometer by monitoring the 
extracellular acidification rate, ECAR. It was shown that the ECAR is identical to the rate 
of lactate export via monocarboxylate transporters leading to the conclusion that the ECAR 
reflects the ATP synthesis rate via glycolysis (Chapter 7.3). The results further revealed 
that the basal ECAR of MDR1-transfected cells was linearly correlated with the verapamil-
stimulated ECAR under the conditions where the metabolic state of cells was low, whereas 
under conditions where the metabolic state of cells was high the linear correlation flattened 
out. The increase in the verapamil-stimulated ECAR was suppressed compared to the 
increase in the basal ECAR.  
Glycolysis is a highly regulated metabolic pathway which among other things is 
sensitive to pH. An increase in the extracellular proton concentration causes a reduction in 
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glycolysis probably through a reduced lactate efflux (147). Therefore, the question arose, 
whether the flattening of the linear correlation between the basal and verapamil-stimulated 
ECAR, observed under the conditions where the metabolic state of cells were high, is due 
to the acidification of the flow medium and to the suppression of glycolysis via feedback 
mechanism. Another possibility which could explain the decrease in the verapamil-
stimulated ECAR under the conditions of the high metabolic state of cells is the limited 
transport capacity of the monocarboxylate transporters. If more lactate is produced than can 
be exported by the cell, the lactate accumulates inside the cells, the pH of the cytosol 
decreases leading to the inhibition of phosphofructokinase and hence glycolysis (148).   
These questions were mainly addressed in the fourth part of this thesis. We used 
13C-NMR spectroscopy to determine the metabolic rate of wild-type and MDR1-transfected 
mouse embryo fibroblasts in the presence and absence of verapamil by monitoring the rate 
of glucose consumption and the lactate production. The measurements were carried out 
under anaerobic conditions in the presence of 13C-labeled glucose. In contrast to the 
Cytosensor measurements, where the flow medium with the low buffer concentration has 
to be used in order to detect small changes in pH caused by extruded metabolites of cells, 
the 13C-NMR measurements could be performed in solution with a high buffer 
concentration. Furthermore, because all lactate molecules can be detected with a 13C- NMR 
whereas the Cytosensor only detects the extruded lactates outside the cells, the relationship 
between the intra- and extracellular lactate and the transport capacity of monocarboxylate 
transporters were addressed using a lactate specific shift reagent (Pr-DO3A). Pr-DO3A is a 
new shift-reagent and we thus simultaneously tested its bio-compatibility with living cells. 
This study revealed that the relative enhancement in the lactate production of 
MDR1-transfected cells by verapamil measured with a 13C-NMR was in good agreement 
with the values obtained earlier with a Cytosensor microphysiometer during longtime 
verapamil stimulation (~ 150-160 % relative to the basal metabolic rate). The absolute 
basal metabolic rate of the wild-type and the MDR1-transfected cells determined with 13C-
NMR was (~10·107 proton/cell/s). This value is about threefold higher than that determined 
earlier from the ECAR measurements (~3·107 proton/cell/s). Also the absolute rate 
enhancement stimulated by verapamil in MDR1-transfected cells was higher than that 
observed from the ECAR measurements. The shift reagent Pr-DO3A clearly separated the 
intra- and extracellular lactate NMR signals. The intracellular lactate concentration 
increased as the total lactate concentration increased. Furthermore, it was shown that the 
estimated intra- and extracellular lactate concentrations were similar suggesting that the 
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transmembrane lactate transport is fast enough to avoid accumulation of the lactate inside 
the cells.  
Taking together these results demonstrates that the flattening of the linear 
correlation between the basal and the verapamil-stimulated ECAR, observed under the 
conditions where the metabolic state of cells were high, is due to the suppression of 
glycolysis by the feedback mechanism. The NMR results further suggest that the flattening 
does not arise from the saturated transport capacity of monocarboxylate carriers. However, 
further investigations are needed to confirm these arguments. Furthermore, we showed that 
the shift reagent Pr-DO3A can be used to observe the intracellular lactate concentration in 
living cells without effecting on the metabolic rate and the cell viability.  
 
Details of this study are described in unpublished manuscripts (Chapter 7.4, page 99). This 
study was made in collaboration with Dr. Götz Kohler. 
 
 
3.5 P-Glycoprotein Senses Its Substrates and the Lateral Membrane 
Packing Density: Consequences for the Catalytic Cycle 
 
Pgp is composed of two homologous halves which are connected by a flexible linker 
region to a single functional unity. Each half contains a transmembrane domain, TMD, 
which is composed of six hydrophobic α-helices and a hydrophilic nucleotide binding 
domain, NBD (Introduction, Chapter 1.5). The TMDs are responsible for the substrate 
recognition and binding whereas the NBDs bind and hydrolyze ATP. The interplay 
between the TMDs and NBDs drives the substrate translocation across the lipid bilayer.  
The first catalytic cycle model of Pgp known as a ‘’alternative catalytic cycle’’ was 
proposed by Senior et al. (119). It hypothyzed that during the ATP hydrolysis, a transition 
state is generated and that the relaxation of transition state causes a change in the drug 
binding site from high to low affinity thus powering the extrusion of the drug. Recently, 
this model has been reevaluated and as a new possibility it was suggested that the change 
in the affinity of the drug to the binding site from high to low state is catalyzed by ATP 
binding and dimerization of the NBDs of Pgp (4, 143). The energy from ATP hydrolysis 
was proposed to be utilized for the transition of the NBDs from the closed dimer to the 
open dimer configuration (Introduction, Chapter 1.6). Therefore, our aim was to understand 
the interplay between the TMDs and the NBDs of Pgp during the drug transport cycle in 
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more detail. Furthermore, we aimed at getting additional information about the influence of 
the lipid environment, especially the lateral packing density of membrane, πM, on the 
transition state parameters (the activation enthalpy ‡HΔ , the activation entropy ‡SΔ , and 
the free energy of activation ‡GΔ ) of ATP hydrolysis by Pgp and thus on the mechanism 
of Pgp. It was shown in the study summarized in Chapter 3.1, that the lateral packing 
density of the membrane, πM, has an important role in Pgp activity, since it determines the 
lipid-water partitioning step of the drug and, thus, it effects the concentration of half-
maximum Pgp activity, K1. Furthermore, Pgp has an important protective function in many 
organs that have different membrane packing densities, πM, such as blood brain barrier (πM 
@ 35 mN/m) and intestine barriers (πM @ 28 mN/m) (146). It is, thus, relevant to understand 
better how the Pgp activity is affected by the lipid environment.  
 For this purpose we measured the temperature dependence of Pgp activity in plasma 
membrane vesicles obtained from MDR1-transfected mouse embryo fibroblasts. The 
measurements were done in the absence (= basal Pgp activity) and in the presence of 
exogenous Pgp substrates. Three different Pgp substrates where chosen (promazine, 
verapamil and PSC833) in order to study the effect of drug, its concentration and its 
binding affinity to the transporter on the transition state parameters of ATP hydrolysis by 
Pgp.  
Data obtained from the temperature dependence measurement were evaluated with 
the Eyring’s transition state theory. The Eyring’s plots were apparently linear for ATP 
hydrolysis by Pgp in the absence and presence of drugs if measured in the plasma 
membrane vesicles in a relatively small temperature range (T = 25 – 37 oC). From the 
linear fit of the Eyring’s plots the activation enthalpy ‡HΔ , the activation entropy ‡SΔ , 
and the free energy of activation ‡GΔ  of ATP hydrolysis by Pgp were determined. The 
free energy of activation of ATP hydrolysis by Pgp, ‡GΔ , decreased slightly at low and 
increased at high verapamil and promazine concentration, whereas the free energy of 
activation, ‡GΔ , for PSC833 only increased, thus, revealing the mirror image of the Pgp 
activity profiles. The activation enthalpy of ATP hydrolysis by Pgp, ‡HΔ , did not correlate 
with the drug dependent ATP hydrolysis rate. It decreased in the presence of drugs 
independently whether the drug caused an increase or decrease in Pgp activity relative to 
the basal rate. By comparing the transition state parameters for basal Pgp activity measured 
in plasma membranes of NIH-MDR1-G185 cells with the literature data, it was found that 
the activation enthalpy, ‡HΔ , decreased significantly with the decreasing lateral membrane 
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packing density, πM, whereas the decrease in the free energy of activation, ΔG‡, was much 
smaller as expected from the rate measurements.  
Taking together the present data and the results from our previous investigations 
(the study summarized in Chapter 3.2) we discussed two different catalytic cycle models 
proposed originally by Senior et al. (119) and Higgins et al. (4, 143). We assumed that the 
Pgp activity cycle consists of several steps where each step is described by a free energy of 
activation, ΔG‡i. The free energy of activation obtained from the steady-state Pgp activity 
measurements is a sum of all individual free energies of activation, ΔG‡. Since it was 
observed that the drugs modulated the free energy of activation, ΔG‡, in specific manner, 
the drugs have to be present at the rate-limiting step. Whether the rate-limiting step is the 
ATP hydrolysis or conformational change of Pgp driven by ATP binding, is not possible 
conclusively solve at the present. Therefore, further experiments are still needed.  
 
These results are described in detail in the following manuscript (Chapter 7.5, page 115): 
Aanismaa, P., Gatlik-Landwojtowicz, E., and Seelig, A., P-Glycoprotein Senses Its 
Substrates and the Lateral Membrane Packing Density: Consequences for the Catalytic 
Cycle, Biochemistry, in press  
 
 
3.6 Prediction and Validation of P-glycoprotein-Substrates Exemplified by 
Ehrlich´s Dyes 
 
Synthetic dyes have been widely used in histological studies since they were invented in 
the 19th century. Furthermore, due to their selectivity and biological activity they formed a 
basis for chemotherapy initiated Paul Erlich. In 1891 methylene blue was used for the first 
time for the treatment of malaria in humans (149). Moreover, the applicability of dyes as 
photosensitizers to treat cancer and microbial infections with photodynamic therapy has 
been tested.  
In this context it is important to know if dyes are Pgp substrates. Therefore, in the 
last part of this thesis we worked with four dyes, methylene blue, acridine orange, basic 
fuchsin, and ethyl eosin. By applying the established rules for intrinsic Pgp-substrates (146) 
we predicted that methylene blue, acridine orange, and basic fuchsin should be, whereas 
ethyl eosin should not be intrinsic substrates for Pgp. We tested the predictions by 
measuring the Pgp activity in plasma membrane vesicles formed from MDR1-trasfected 
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cells spectroscopically. Furthermore, their effect on Pgp activity was investigated in living 
MDR1-transfected mouse embryo fibroblasts by monitoring the ECAR with a Cytosensor 
microphysiometer. Simultaneously, the cytotoxicity of the dyes was tested.    
Our results indicated that methylene blue, acridine orange, and basic fuchsin are 
intrinsic substrates for Pgp, whereas ethyl eosin most likely is not. The same conclusion 
was drawn from both assays and this was in good agreement with the prediction. However, 
by measuring the Pgp activity in living cells by monitoring the ECAR revealed that 
methylene blue, acridine orange, and ethyl eosin affect the energy metabolism of cells in a 
complex manner. Methylene blue and acridine orange increased the ECAR above basal 
values in the wild-type and in MDR1-transfected cells. However, a clear difference 
between the ECARs of wild-type and MDR1-transfected cells was observed demonstrating 
the protective function of Pgp. Ethyl eosin, on the other hand, caused a decrease in the 
ECARs of both cells to the similar extent. To give an conclusive answer, whether this is 
due to the interaction of eosin with NDBs of other ATPases or also with NBDs of Pgp, 
further experiments are needed.  
 
These results are described in detail in unpublished manuscript (Chapter 7.6, page 149) 
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P-glycoprotein (Pgp, ABCB1) is a transmembrane protein, which extrudes a large number 
of structurally diverse compounds out of the cell membrane at the expense of ATP 
hydrolysis. The overexpression of Pgp strongly contributes to multidrug resistance, which 
hampers the chemotherapy of cancer and some other drug-treatable diseases. Therefore, the 
general aim of this thesis was to quantitatively characterize the thermodynamics and the 
kinetics of Pgp-substrate interactions. Specific emphasis was placed on the understanding 
the influence of the lipid bilayer since Pgp binds its substrates from the cytosolic leaflet of 
the membrane.  
Drug binding to Pgp can be divided into two steps. The first step is the drug 
partitioning into the lipid bilayer described by the lipid-water partition coefficient, Klw, and 
the second step is the drug binding to Pgp from the lipid phase depicted by the binding 
constant of drug to Pgp from the lipid phase, Ktl. The binding constant of the drug from the 
aqueous phase to Pgp, Ktw, is thus the product of these two binding constants. Since the 
separation of drug binding to the lipid bilayer and to Pgp from the lipid bilayer has not 
been done satisfactorily a question mark was still hanging above the strength of the Pgp-
drug interactions. Therefore, the aim of the first part of this thesis was to quantify the 
binding constant of drugs to Pgp from the lipid phase, Ktl and furthermore to test the 
energetic soundness of the previously suggested hydrogen bond hypothesis. The lipid-
water partition coefficient, Klw, and the drug binding constant from water to Pgp, Ktw, were 
determined independently for the 15 drugs and for the first time the binding constant of 
drugs to Pgp from the lipid phase and the corresponding free energies 0tlGΔ  were reported. 
We found that the free energy of lipid-water partitioning 0lwGΔ  is more negative than the 
free energy of drug-binding to Pgp from the lipid phase 0tlGΔ  for all 15 drugs studied but 
0
tlGΔ  varied more strongly than 0lwGΔ . This suggests that the drug interactions to Pgp are 
weaker but more specific than to the lipid bilayer. Furthermore, the higher concentration of 
drugs in the membrane than in the aqueous phase at the concentration of half-maximum 
Pgp activity supports the relative weak interactions. The results are well explained with the 
hydrogen bond hypothesis and they indicate the existence of large drug binding region(s) in 
transmembrane domains of Pgp. In addition, we demonstrated that the binding constant of 
drug to Pgp from the aqueous phase, Ktw, depends exponentially on the lateral packing 
density of the membrane, πM. This finding can explain the diverse concentrations of half-
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maximum Pgp activity, K1, reported in literature for the same drug but determined in the 
different membrane environments. 
The common aim of the next three parts of this thesis was to elucidate Pgp activity 
in the cellular ensemble as well as in an isolated environment. This was done by measuring 
the Pgp activity for 15 structurally diverse Pgp substrates in living MDR1-transfected 
mouse embryo fibroblasts by monitoring the extracellular acidification rate, ECAR, and in 
plasma membrane vesicles formed from the same cells by monitoring the rate of ATP 
hydrolysis. Because these two systems exhibit several differences such as the direction of 
drug approaching Pgp, it was interesting to compare the kinetics of Pgp activity measured 
in both systems. We found that the concentrations of half-maximum Pgp activation, K1, for 
15 drugs were identical as long as the pH of the environment was identical and the possible 
artifacts such as vesicle and the drug association in the phosphate release measurements 
and cytotoxic effects of drugs in the ECAR measurements could be excluded. We, 
therefore, concluded that whether the drugs approach Pgp from the extracellular or 
cytosolic side of the membrane does not play a role as long as the drugs can deprotonate 
and cross the membrane in their uncharged form. A reasonably linear correlation was also 
found for the relative maximum Pgp activities, V1. The observed outliers were mainly due 
to artifacts. In order to compare the absolute rate enhancements stimulated by various 
drugs the turnover numbers were estimated. The drug-stimulated turnover numbers were in 
good agreement if the Pgp activity in living cells was measured in the presence of 
pyruvate. In the absence of pyruvate the turnover numbers in living cells is however 
higher. Furthermore, it was found that the logarithm of maximum Pgp activity, lnV1, 
decreases linearly with decreasing free energy of drug binding to Pgp from the aqueous 
phase, 0 )1(twGΔ . Thus, we concluded that the drug release to the extracellular leaflet of the 
lipid bilayer is the rate-determining step for Pgp activity.  
 The previous studies about the influence of the metabolic state of the cells on Pgp 
activity revealed that the verapamil-stimulated ECAR was linearly correlated with the basal 
ECAR under the nutritional condition where the metabolic state of cells was low. However, 
when the metabolic state of cells was high (in the presence of glucose) the drug-stimulated 
ECAR flattened out. The increase in the drug-stimulated ECAR was suppressed compared 
to the increase in the basal ECAR. To better understand the influence of the metabolic state 
of the cell on the basal and the drug-stimulated ECAR we further studied the metabolic rate 
of mouse embryo fibroblasts by measuring the glucose consumption and the lactate 
production rate by means of 13C-NMR spectroscopy. We found that the relative verapamil-
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stimulated enhancement in the metabolic rate of NIH-MDR1-G185 cells was in good 
agreement with the values obtained from the ECAR measurements upon longtime 
verapamil stimulation. However, the 13C-NMR measurements revealed that the absolute 
metabolic rate of wild-type and MDR1-transfected cells in the absence of drugs were about 
three-fold higher than those observed by monitoring the ECAR of the same cells. Also the 
absolute metabolic rate of MDR1-transfected cells stimulated with verapamil was distinctly 
higher. Furthermore, it was demonstrated by separating the intra- and the extracellular 
lactate NMR signals with a novel shift reagent that the lactate concentrations inside and 
outside of MDR1-transfected cells were similar. These results support the assumption that 
the flattening observed between the basal and the verapamil-stimulated ECAR under 
conditions of high ECARs, is due to the suppression of glycolysis. The experiments further 
indicate that it is not due to the saturation of monocarboxylate transporters.  
The drug transport activity of Pgp is coupled to ATP hydrolysis but how these two 
steps are connected is still a matter of debate. Therefore, the goal in the fifth part of this 
thesis was to study the interplay between the transmembrane domains, TMDs, of Pgp, 
which bind and release the drugs, and the nucleotide binding domains, NBDs, of Pgp, 
which bind and hydrolyze ATP. Moreover, we aimed at getting additional information 
about the influence of the lateral membrane packing density, πM, on the transition state 
parameters of ATP hydrolysis by Pgp (the activation enthalpy ‡HΔ , the activation entropy 
‡SΔ , and the free energy of activation ‡GΔ ) and, thus, on the mechanism of Pgp activity. 
For this purpose we measured the temperature dependence of steady-state Pgp activity in 
the plasma membrane vesicles of NIH-MDR1-G185 cells in the absence and presence of 
several exogenous Pgp substrates and analyzed the transition state parameters for ATP 
hydrolysis by Pgp (the activation enthalpy ‡HΔ , the activation entropy ‡SΔ , and the free 
energy of activation ‡GΔ ). We found that the activation enthalpy, ‡HΔ , of ATP hydrolysis 
by Pgp was relatively large for the basal and drug-stimulated Pgp activity and decreased in 
the presence of all drugs investigated, even in the presence of drugs that reduce Pgp 
activity. The free energy of activation, ‡GΔ , in contrary, decreased at low and increased at 
high drug concentrations of verapamil and promazine, whereas it only increased for 
PSC833. Thus, by plotting the free energy of activation, ‡GΔ , as function of drug 
concentration revealed the mirror images of Pgp activation profiles, in good agreement 
with the Eyring’s transition state theory. Furthermore, by comparing the transition state 
parameters for basal Pgp in plasma membrane vesicles of NIH-MDR1-G185 cells with the 
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literature data measured in different membrane environments, we found that the activation 
enthalpy, ‡HΔ , of ATP hydrolysis by Pgp decreases significantly with decreasing lateral 
membrane packing density, πM, whereas the free energy of activation, ‡GΔ , decreased only 
slightly. The Pgp activity cycle contains several steps and each step has its own free energy 
of activation, ‡iGΔ . The sum of these individual free energies is the free energy of 
activation, ‡GΔ , obtained from the steady-state Pgp activity measurements. The 
experimental data revealed that the different drugs affected the free energy of activation, 
‡GΔ , in characteristic manner. However, whether the rate-limiting step is the ATP 
hydrolysis or the conformational change of Pgp could not be decided conclusively from the 
present data and further experiments are needed. 
In the last part of this thesis we aimed at identifying whether the dyes, methylene 
blue, acridine orange, basic fuchsin, and ethyl eosin are substrates for Pgp. This is relevant 
since they are widely used in histological studies. Furthermore, their applicability for the 
treatment of cancer and microbial infections with photodynamic therapy has been tested. In 
accordance with the established rules for the intrinsic Pgp substrates we predicted that 
methylene blue, acridine orange and basic fuchsin are intrinsic substrates for Pgp whereas 
ethyl eosin is not. The Pgp activity measurements in plasma membrane vesicles and in 
living MDR1-transfected mouse embryo fibroblasts supported the prediction. Furthermore, 
the Pgp activity measurements in living cells revealed that methylene blue, acridine orange 
and ethyl eosin influenced the energy metabolism of wild-type and MDR1-transfected 
mouse embryo fibroblasts in a complex manner. Thus, the evaluation of Pgp activity in 
living cells gave further valuable information about the cytotoxicity of drugs.  
In conclusion. We evaluated the thermodynamics and the kinetics of Pgp-substrate 
interactions. Since Pgp binds its substrates from the lipid phase the influence of the lipid 
bilayer on both of them was emphasized. The intrinsic drug binding constants, the binding 
constants of drug to Pgp from lipid phase, Ktl, for the 15 Pgp-substrates were evaluated 
quantitatively for the first time and revealed the weak interactions between Pgp and its 
substrates. The thermodynamic evaluation further indicated that the hydrogen bonds 
contribute significantly on the energetics of Pgp-substrate interactions supporting the 
hydrogen bond hypothesis and the existence of large drug binding region(s). Furthermore, 
it was shown that the concentration of half-maximum Pgp activity, K1, of a specific drug 
depends on the lipid-water partition coefficient of the drug, Klw, which in turns depends on 
the lateral packing density of the membrane, πM, and therefore is dependent on the lipid 
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membrane where Pgp activity is determined. The rate of Pgp activity evaluated in living 
cells and in inverted plasma membrane vesicles revealed that Pgp activity is controlled by 
the binding affinity of the drug to Pgp from the aqueous phase, 0 )1(twGΔ . In living cells the 
metabolic state of cells further affected the rate of Pgp activity. By evaluating the transition 
state parameters from the temperature dependence of Pgp activity in the absence and 
presence of Pgp substrates and comparing the data with the available literature values 
suggested that the membrane packing density seems to slightly affect the basal Pgp 
activity, whereas the effective drug transport rate seems not to be affected. Moreover, the 
mode of Pgp action changed from entropy-driven to enthalpy-driven in the membrane with 
decreasing membrane packing density suggesting that Pgp and the membrane form a 
functional unity.  
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Quantification and Characterization of P-Glycoprotein-Substrate Interactions
Ewa Gatlik-Landwojtowicz, Pa¨ivi A¨a¨nismaa, and Anna Seelig*
Biophysical Chemistry, Biozentrum, UniVersity of Basel, Klingelbergstrasse 70, CH-4056, Basel, Switzerland
ReceiVed July 15, 2005; ReVised Manuscript ReceiVed NoVember 29, 2005
ABSTRACT: It is generally accepted that P-glycoprotein binds its substrates in the lipid phase of the
membrane. Quantification and characterization of the lipid-transporter binding step are, however, still a
matter of debate. We therefore selected 15 structurally diverse drugs and measured the binding constants
from water to the activating (inhibitory) binding region of P-glycoprotein, Ktw(1) (Ktw(2)), as well as the
lipid-water partition coefficients, Klw. The former were obtained by measuring the concentrations of
half-maximum activation (inhibition), K1 (K2), in living NIH-MDR-G185 mouse embryo fibroblasts using
a Cytosensor microphysiometer, and the latter were derived from surface activity measurements. This
allowed determination of the membrane concentration of drugs at half-maximum P-glycoprotein activation
(Cb(1) ) (0.02 to 67) mmol/L lipid), which is much higher than the corresponding aqueous concentration
(K1 ) (0.02 to 376) μM). Moreover we determined the free energy of drug binding from water to the
activating binding region of the transporter (ΔG°tw(1) ) (-30 to -54) kJ/mol), the free energy of drug
partitioning into the lipid membrane (ΔG°lw ) (-23 to -34) kJ/mol), and, as the difference of the two,
the free energy of drug binding from the lipid membrane to the activating binding region of the transporter
(ΔG°tl(1) ) (-7 to -27) kJ/mol). For the compounds tested ΔG°tl(1) was less negative than ΔG°lw but
varied more strongly. The free energies of substrate binding to the transporter within the lipid phase,
ΔG°tl(1), are consistent with a modular binding concept, where the energetically most efficient binding
module comprises two hydrogen bond acceptor groups.
Various lines of evidence indicate that the P-glycoprotein-
ATPase, Pgp1 (ABCB1), binds its substrates within the
plasma membrane (1, 2) and, more precisely, within the
cytosolic lipid leaflet of the plasma membrane (3-7) (for
review see ref 8). Exogenous substrates such as drugs and
toxins are thus caught by Pgp after partitioning into the
plasma membrane but before reaching the cytosol and are
then exported or flipped at the expense of ATP hydrolysis
(3, 4, 9).
The environment from which substrates bind to the
transporter is decisive for the type of binding interactions
(10, 11). Little is known on the role of the lipid membrane
for substrate-transporter interactions since most well-
investigated transporters bind their substrates from the
aqueous phase (e.g. fucose transporter (12)). To investigate
the relationship between lipid partitioning and drug binding
Romsicki and Sharom (13) reconstituted Pgp into various
well-defined lipid bilayers and measured the transporter
dissociation constants, Kd (i.e. the release of the drug from
Pgp into the aqueous phase), as well as the lipid-water
partition coefficients, Plw. For the three drugs investigated,
the binding affinity to Pgp from the aqueous phase increased
in parallel to the lipid-water partition coefficient, suggesting
that the concentration of the drug in the membrane is
important for the interaction with the transporter (13). A
linear correlation between binding affinity to Pgp and
membrane partitioning (estimated from the octanol-water
partition coefficient, log Pow) was also observed for pro-
pafenone analogues (6). However, for structurally more
diverse drugs no correlation between binding affinity to Pgp
and membrane affinity (log Pow) was observed. Instead, an
approximately linear dependence of the binding affinity to
Pgp on the van der Waals surface area of drugs was noticed
(14). For the same drugs, a linear correlation between drug
affinity to Pgp and the logarithm of the air-water partition
coefficient, log Kaw, was demonstrated (15), suggesting that
both the lipid-water partition coefficient, Klw, and the cross-
sectional area, AD, of a given drug molecule play a role for
drug-Pgp interactions (11).
The question as to how Pgp accommodates molecules of
different size is still a matter of debate. It has been suggested
that Pgp has at least two substrate binding sites (1, 13, 16).
Our kinetic data (17, 18) could be well fitted with a model
(14) that assumes two binding sites, one for activation and
one for inhibition. Evidence for three (19) and even four
binding sites has also been reported (20). As an alternative
to specific binding sites, broader binding regions have been
proposed (21). The concept of binding regions is consistent
with a search for possible drug interaction sites in the
* Corresponding author. Phone: +41-61-267-22-06. Fax: +41-61-
267-21-89. E-mail: Anna.Seelig@unibas.ch.
1 Abbreviations: DMPC, 1,2-dimyristoyl-sn-glycero-3-phosphati-
dylcholine; ECAR, extracellular acidification rate; K1 (K2), aqueous
substrate concentration at half-maximum Pgp activation (inhibition);
Kaw, air-water partition coefficient; Klw, lipid-water partition coef-
ficient; Ktl(1) (Ktl(2)), binding constant of the drug from the lipid
membrane to the activating (inhibitory) binding region of the transporter;
Ktw(1) (Ktw(2)), binding constant of the drug from water to the activating
(inhibitory) binding region of the transporter; MDR, multidrug resis-
tance; Pgp, P-glycoprotein-ATPase (MDR1, ABCB1); POPC, 1-palmi-
toyl-2-oleoyl-sn-glycero-3-phosphatidylcholine; πM, lateral membrane
packing density; V1 (V2), maximum (minimum) transporter activity.
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predicted transmembrane sequences of Pgp (22). The latter
investigation revealed a high density of amino acids with
hydrogen bond donor side chains in the transmembrane
sequences of Pgp which could interact with characteristic
hydrogen bond acceptor patterns present in all Pgp substrates
(10, 23, 24). Moreover, clusters of phenyl residues were
observed which could interact either with π-electron systems
(π-π interactions) or with cationic residues in drugs
(cation-π interactions) (22). Recently, Sauna et al. (25) also
suggested a variable number of binding interactions between
substrate and transporter, however, without specifying the
type of interactions. Concepts with a variable number of
binding modules contrast with classical quantitative structure-
activity relationship, QSAR, approaches (for review see refs
26, 27) or multivariant procedures (e.g. ref 28) that are both
based on “key-lock” concepts and consider one single “key”
or “pharmacophore” per Pgp substrate.
Drug partitioning into the lipid membrane and drug
binding to Pgp within the lipid membrane are tightly coupled
processes which have not yet been deconvoluted satisfacto-
rily. In the following we demonstrate that the binding
constant of a given substrate in the lipid phase to the
activating (inhibitory) binding region of Pgp, Ktl(1) (Ktl(2)),
can be calculated provided the corresponding lipid-water
partition coefficient, Klw, and the binding constant of the drug
from the aqueous phase to the activating (inhibitory) binding
region of Pgp, Ktw(1) (Ktw(2)), are known. The binding
constants from water to the transporter, Ktw(1) (Ktw(2)), were
determined in living NIH-MDR-G185 cells as the inverse
of the concentrations of half-maximum Pgp activation, K1
(inhibition, K2) (11). The concentrations of half-maximum
Pgp activation, K1 (inhibition, K2) were measured by means
of a Cytosensor microphysiometer (29) that monitors the
extracellular acidification rate, ECAR (17, 18). As a control,
we also measured the phosphate release rates upon drug-
induced Pgp-ATPase activation in inside-out membrane
vesicles and showed that the ECARs and the phosphate
release rates are identical ((18), A¨a¨nismaa and Seelig, in
preparation). The lipid-water partition coefficients, Klw, were
derived from the air-water partition coefficients, Kaw, and
the cross-sectional area, AD, of the drug taking into account
the lateral packing density, πM (30, 31), and the surface
potential, ψ, of the cytosolic membrane leaflet. The lipid-
water partition coefficients, Klw, obtained by means of this
approach were in excellent agreement with the lipid-water
partition coefficients obtained by means of isothermal
titration calorimetry using model membranes of known lateral
packing density (for the present compounds, Li-Blatter and
Seelig, in preparation).
We selected 15 chemically diverse drugs (antidepressants,
an antineoplastic, antipsychotics, a calcium channel blocker,
local anesthetics, an immunosuppressant, a steroid hormone,
a tyrosine kinase inhibitor) and report for the first time the
binding constants of the drugs from the lipid membrane to
the activating (inhibitory) binding region of the transporter
in the lipid phase, Ktl(1) (Ktl(2)). The corresponding free
energies of binding, ΔG°tl(1) (ΔG°tl(2)), reflect the effectiVe
interactions between the substrates and the activating (inhibi-
tory) binding region of Pgp. We show that the substrate
concentrations in the membrane are higher by a factor of
102 to 104 than those in the aqueous phase, which implies
that the interactions between drugs and Pgp in the lipid
membrane are relatively weak. Our results further indicate
that binding of drugs to Pgp is not compatible with a classical
“key-lock” or “one-pharmacophore” model but can be well
explained with a modular binding concept, where the
energetically most relevant binding module seems to consist
of two hydrogen bond acceptor groups.
MATERIALS AND METHODS
Materials. Amitriptyline‚HCl, cis-flupenthixol‚2HCl,
daunorubicin‚HCl, dibucaine‚HCl, diltiazem‚HCl, lidocaine‚
HCl, progesterone, promazine‚HCl, trifluoperazine‚2HCl, and
triflupromazine‚HCl were from Sigma-Aldrich (Steinheim,
Germany), and (R/S)-verapamil‚HCl was from Fluka (Buchs,
Switzerland). Chlorpromazine‚HCl and reserpine‚HCl‚H2O
were generous gifts from Merck (Darmstadt, Germany), and
cyclosporin A and glivec mesylate from Novartis AG (Basel,
Switzerland). For Cytosensor measurements cyclosporin A,
progesterone, reserpine, and (R/S)-verapamil were dissolved
in DMSO, where the final DMSO concentration did not
exceed 0.5% (v/v). The remaining drugs were directly
dissolved in medium. To test the influence of DMSO on
membrane partitioning and Pgp binding, (R/S)-verapamil and
glivec were measured with and without DMSO. The results
were identical within error limits (A¨a¨nismaa and Seelig, in
preparation). Cell culture medium DMEM with pyruvate
(liquid and dry, Cat. No. 21969 and Cat. No. 52100,
respectively) as well as other compounds required for cell
culture such as fetal bovine serum, FBS, L-glutamine, and
antibiotics were from Gibco-BRL (Basel, Switzerland).
Buffers. Buffers were adjusted to pH 7.4 at ambient
temperature. For Cytosensor measurements (performed at 37
°C), a flow medium with low buffer capacity is required.
The flow medium was prepared from dry powder Dulbecco’s
modified Eagle medium (Gibco-BRL, Basel, Switzerland)
which contains 0.91 mM phosphate but no sodium bicarbon-
ate. Flow medium was supplemented with 1 mM sodium
pyruvate to decrease the basal ECAR of cells and to enhance
the relative ECAR changes due to Pgp activation in particular
(18). In order to preserve osmotic balance the lacking sodium
bicarbonate was replaced by sodium chloride (2.6 g/L of
NaCl instead of 3.7 g/L of NaHCO3).
Cell Lines and Cell Culture. The mouse embryo fibroblast
cell lines NIH3T3 and NIH3T3 transfected with the human
MDR1 gene, NIH-MDR-G185 (grown in the presence of 0.15
μM colchicine), were generous gifts from Dr. M. M.
Gottesman and Dr. S. V. Ambudkar (The National Institutes
of Health, Bethesda, MD). Cells were maintained as de-
scribed earlier (17, 18).
Cytosensor Measurements. In short, the Cytosensor mi-
crophysiometer measures the rate of proton excretion from
104 to 106 cells in a flow chamber with diffusive contact to
a pH sensitive silicon chip. Due to the flow chambers it is
possible to maintain approximately constant drug concentra-
tions, which allows the establishment of steady state condi-
tions. Cytosensor measurements with NIH3T3 and NIH-
MDR-G185 cells and the quantification of extracellular
acidification are described elsewhere in detail (17, 18). In
the present study the drug concentrations were corrected for
adsorption to the walls of the fluid supply tubes, the
debubbler membranes, and the flexible tubing (∼65 cm)
which connect the fluid supply tubes with the Cytosensor
P-Glycoprotein-Substrate Interactions Biochemistry, Vol. 45, No. 9, 2006 3021
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chamber. Corrections were made in separate control runs by
sampling the drug solution just before entering the sensor
chamber and measuring the drug concentration by UV
spectroscopy. To mimic the time schedule of Cytosensor
measurements the drug solutions were let to flow through
Cytosensor tubing 6 min before the samples were collected
during the 3 min. Adsorption varied strongly from compound
to compound and was small for verapamil and high for
phenothiazines. Cyclosporin A concentrations could not be
corrected for adsorption by UV because the molecule does
not contain UV-detectable amino acid residues.
Lipid-Water and Air-Water Partition Coefficient. Mea-
surement of the lipid-water partition coefficient, Klw, in
intact cells is not possible since other structures e.g. the
glycocalix or proteins also attract cationic compounds. We
have therefore developed an approach that allows determi-
nation of the lipid-water partition coefficient, Klw, from the
air-water partition coefficient, Kaw, and the cross-sectional
area, AD, of the drug, by taking into account the relevant
lateral membrane packing density, πM (30, 31), and the
surface potential of the membrane, ψ. The air-water
partition coefficient, Kaw, and the cross-sectional area, AD,
of the drug were derived from measurements of the surface
pressure, π, as a function of concentration (Gibbs adsorption
isotherm) as described previously ((30, 31), for the present
compounds, Li-Blatter and Seelig, in preparation).
The Kinetic Models. The kinetics of Pgp activation has
been discussed in detail elsewhere (11, 17) and is sum-
marized briefly. The model used to analyze Pgp-drug
interactions is outlined in the scheme depicted in eq 1. In
the absence of exogenous substrates Pgp shows basal activity,
with kbas as the catalytic rate constant (1st arrow down).
Substrates in the aqueous phase, Sw, partition into the lipid
membrane, where k0 and k-0 are the partitioning rate
constants, and Klw ) k0/k-0 is the lipid-water partition
coefficient. The substrate in the lipid membrane, Sl, binds
to the transporter, T, forming the transporter-ATP-substrate
complex, T(ATP)St (for simplicity only one ATP (ADP)
molecule per Pgp is shown in eq 1); St is the substrate bound
to the activating binding region of the transporter, k1 and
k-1 are the rate constants for association to and dissociation
from the activating binding region, and Ktl(1) ) k1/k-1 is the
binding constant of the substrate for the activating binding
region of the transporter within the lipid membrane. The 2nd
arrow down shows the substrate transport step which is
driven by hydrolysis of ATP to ADP and phosphate, Pi,
where kcat′ denotes the catalytic rate constant and Srel the
substrate released. At high substrate concentrations a second
substrate molecule is bound to the inhibitory binding region
forming the complex T(ATP)StSt, where k2 and k-2 are the
association and dissociation rate constants, respectively, Ktl(2)
) k2/k-2 reflects the binding constant to the inhibitory binding
region of the transporter, and kcat′′ is the catalytic rate constant
of the inhibitory binding step. The association/dissociation
reactions are rapid compared to the catalytic steps (cf. ref
32) (k-1 and k-2 . kbas, kcat′, kcat′′). To a first approximation,
the concentration of half-maximum (minimum) activation
K1 (K2) can therefore be assumed to correspond to the
dissociation constant of the activating (inhibitory) binding
region of Pgp and the inverse, 1/K1 (1/K2), to the transporter-
water binding constant for the activating (inhibitory) binding
region, Ktw(1) (Ktw(2)).
Based on this mechanism the following rate equation for
ATP hydrolysis has been developed by Litman et al. (14):
where Vsw is the rate of Pi release as a function of the
substrate concentration in aqueous solution, Csw, Vbas is the
basal activity of Pgp in the absence of drug, V1 is the
maximum transporter activity (if only activation occurred),
and V2 is the minimum activity at infinite substrate concen-
tration. At a substrate concentration, Csw ) K1, half-
maximum binding of the activating binding region is reached,
and at a substrate concentration, Csw ) K2, half-maximum
binding of the inhibitory binding region is reached. Equation
2 is thus based on the concept of substrate inhibition (or
uncompetitive inhibition) which was extended to allow for
basal activation in the absence of a substrate and for
breakdown of the complex T(ATP)StSt (eq 1). The kinetic
data given in Table 1 were analyzed using this model.
For comparison we discuss a simplified version of the
above model (14) that does not allow for catalytic activity
of the complex T(ATP)StSt (V2 ) 0) and shows the following
rate equation:
A related model was proposed by Al-Shawi et al. (33, 34).
It also considers basal activation of Pgp in the absence of
drugs, drug activation, and drug inhibition. However, it is
based on the concept of noncompetitive inhibition and shows
the following rate equation:
The influence of the different models on the kinetic data
will be discussed.
The Thermodynamics of Substrate Binding. As shown
previously (11), the binding constant of the drug from water
to the transporter, Ktw(1), is the product of the lipid-water
partition coefficient, Klw, and the binding constant of the drug
from the lipid membrane to the transporter, Ktl(1),
This leads to the corresponding free energy relationship
where the degree symbol refers to a biological standard state
Vsw )
K1K2Vbas + K2V1Csw + V2Csw
2
K1K2 + K2Csw + Csw
2 (2)
Vsw )
K1K2Vbas + K2V1Csw
K1K2 + K2Csw + Csw
2 (3)
Vsw )
K1K2Vbas + K2V1Csw
K1K2 + K1Csw + K2Csw + Csw
2 (4)
1/K1 = Ktw(1) = Ktl(1)Klw (5)
ΔG°tw(1) = ΔG°tl(1) + ΔG°lw (6)
3022 Biochemistry, Vol. 45, No. 9, 2006 Gatlik-Landwojtowicz et al.
 
 
                                                                                7. Reprints and Unpublished Manuscripts 58
 
 
(pH 7.4 and 37 °C). The free energy of substrate binding
from water to the transporter, ΔG°tw(1), and the free energy
of partitioning into the lipid membrane, ΔG°lw, are defined
as
and
respectively, where Cw corresponds to the molar concentra-
tion of water. Analogous equations can be formulated for
the binding constant and the free energy of binding to the
second binding region,
and
where K2 is the dissociation constant, Ktw(2) and Ktl(2) are the
binding constant from water and from the lipid membrane
to the inhibitory binding region of Pgp, respectively, and
ΔG°tw(2) and ΔG°tl(2) are the corresponding free energies.
RESULTS
Drug-Induced Pgp ActiVation Measured in MDR1-Trans-
fected and Wild-Type Cells. MDR1-transfected (NIH-MDR-
G185) and wild type (NIH3T3) mouse embryo fibroblasts
were exposed to 15 chemically diverse drugs (cf. Table 1),
and the extracellular acidification rate, ECAR, was measured
by means of the Cytosensor. Figure 1 shows a comparison
of the raw data (A and B, where A is an enlargement of B)
and the rate data (C) obtained upon exposure of NIH-MDR-
G185 and wild-type cells to chlorpromazine (3.4 μM). During
each 120 s pump cycle, buffer was superfused for 100 s,
then the pumps were switched off for the remaining 20 s,
and the pH change was measured during 13 s within this
time. When the pumps were on, the acidic metabolites
excreted by the cells were washed away by the flow of
medium, and the pH at the cell surface therefore remained
constant and was identical to the pH of the flow medium.
During pump-off periods (20 s) acidic products accumulated
in the sensor chambers, causing a decrease of the pH. The
ECAR was determined during 13 s of the pump-off period
as the slope of a linear least-squares fit to voltage versus
time data (-μV/s) (rate data), where -1 μV/s corresponds
to an acidification rate of 1 mpH unit/min at pH 7.4 (Figure
1A). During the first four pump cycles cells were exposed
to the flow medium without chlorpromazine and the basal
ECAR was measured as seen in Figure 1B and 1C. Next
NIH-MDR-G185 and NIH3T3 cells were exposed to a
chlorpromazine-containing (3.4 μM) medium for a 40 s pulse
and the ECAR was measured. Perfusion with chlorpromazine
solution was continued for another 100 s and the ECAR was
measured again. The hatched region in Figures 1B and 1C
indicates the drug-stimulation period of 180 s comprising
two measuring points. In the following, the second measuring
point (filled symbol) was used for data evaluation for all
compounds except cyclosporin A which was stimulated for
a longer period of time (11 min). Drug stimulation for longer
periods of time generally did not change the ECAR indicating
that steady state conditions were reached.
After stimulation with drug-containing medium the cells
were again perfused with flow medium and the ECAR
measurements were continued every two minutes until basal
Table 1: Thermodynamic and Kinetic Parameters for 15 Drugsa
no. compound pKa
Kaw
[mM-1]
pH 7.4
AD
[Å2]
pH 8.0
K1
[μM]
K2
[μM]
V1
[fold]
V2
[fold]
Xb(1)
[mmol/
mol]
Xb(2)
[mmol/
mol]
weighted
number
H-bond
acceptors
ΔG°Hi
[kJ/mol]
1 amitriptyline 9.4(53) 7.1(30) 52(15) 6.4 ( 0.2 57.2 ( 11.3 1.9 ( 0.01 0.2 ( 0.2 3.6 33.5 2 -7.0
2 chlorpromazine 9.2(54) 21.5(30) 42(30) (pH 7.4) 5.7 ( 0.0 16.4 ( 3.0 2.0 ( 0.3 0.0 ( 0.0 20.2 58.1 2 -4.9
3 cis-flupenthixol 7.8(55) 453(30) 60(30) 3.0 ( 1.8 33.8 ( 18.1 1.4 ( 0.2 0.0 ( 0.0 47.0 523.0 2.5 -3.1
4 cyclosporin A - 19952.6(15) 140 0.02 ( 0.01 1.5 ( 1.0 1.1 ( 0.1 0.8 ( 0.3 0.02 1.6 10.5 -2.6
5 daunorubicin 8.4(56) 588.8(15) 106(15) 0.6 ( 0.3 19.0 ( 4.0 1.1 ( 0.05 0.1 ( 0.1 0.6 19.1 7 -2.6
6 dibucaine 8.5(57) 11.3 52 10.9 ( 1.0 21.0 ( 7.8 2.0 ( 0.2 1.0 ( 0.1 9.4 18.2 1.5 -7.8
7 diltiazem 8.9(58) 26.9(15) 70(15) 3.5 ( 0.4 296.8 ( 107.6 1.8 ( 0.2 0.8 ( 0.2 2.2 182.0 3.5 -4.4
8 glivec 8.07 198 98 2.9 ( 2.7 117.8 ( 25.3 1.2 ( 0.1 0.0 ( 0.0 1.6 63.1 3 -5.4
9 lidocaine 7.6(59) 2.9(30) 50 375.6 ( 91.3 nd 1.5 ( 0.1 nd 66.7 nd 1.5 -4.5
10 progesterone - 157 40b 5.0 ( 0.7 12.4 ( 1.9 1.7 ( 0.2 1.2 ( 0.2 47.4 117.9 1.5 -5.1
11 promazine 9.42(60) 4.8 42(31) 78.7( 22.0 131.5 ( 11.0 3.7 ( 0.6 0.0 ( 0.0 62.9 105.0 2 -3.5
12 (R/S)-verapamil 8.92(61) 166.0(15) 90 0.5 ( 0.1 37.3 ( 15.3 1.6 ( 0.1 1.1 ( 0.1 0.4 34.8 5 -3.9
13 reserpine 6.6(62) 2030 99 0.3 ( 0.1 10.7 ( 1.5 1.3 ( 0.1 0.6 ( 0.2 0.6 24.9 8 -2.3
14 trifluoperazine 8.09(63) 342 57.4(31) 3.6 ( 0.0 21.8 ( 3.2 1.6 ( 0.1 0.0 ( 0.0 57.4 349.0 2.5 -2.9
15 triflupromazine 9.1(64) 91.1 50(31) 2.0 ( 0.5 31.1 ( 1.6 1.7 ( 0.1 0.0 ( 0.0 17.0 266.3 2.5 -4.1
a The air-water partition coefficient, Kaw, and the cross-sectional area, AD, were obtained by means of surface activity measurements. The
concentration of half-maximum activation (inhibition), K1 (K2), and of maximum (minimum) transporter activity, V1 (V2), were measured in living
NIH-MDR-G185 cells with a Cytosensor. The mole fraction of drugs in the membrane at half-maximum Pgp activation (inhibition), Xb(1) (Xb(2)),
was calculated according to eq 20 using the lipid-water partition coefficients, Klw (Figure 4A), calculated by means of eq 12 assuming a membrane
packing density of πM ) 30 mN/m and a surface potential of the cytosolic leaflet of ψ ) -30 mV. The number of H-bond acceptors and the free
energy of binding per H-bond, ΔG°Hi, was determined as described in Discussion. b The cross-sectional area of progesterone was estimated in
analogy to the cross-sectional area of cholesterol. The error in the surface activity measurements is generally not larger than (5%. However, for
compounds with low amphiphilicity (e.g. daunorubicin, progesterone) the air-water partition coefficient as well as the cross-sectional area of the
molecule can be affected by the association state of the molecule in solution which depends on the stock solution concentration and data variation
can therefore be larger. Data presented in Table 1 correspond to average values of 1-4 data sets made with cells of different passages (cell passage
number > 4), where one data set consists of 2-3 measurements made with cells of the same passage number as shown in Figure 3.
ΔG°tw(1) = -RT ln(CwKtw(1)) = -RT ln(Cw(1/K1)) )
RT ln(CwK1) (7)
ΔG°lw ) -RT ln(CwKlw) (8)
1/K2 = Ktw(2) = Ktl(2)Klw (9)
ΔG°tw(2) = ΔG°tl(2) + ΔG°lw (10)
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rates were reached again. The acidification rate was normal-
ized to the basal acidification rate (average of the first four
pump cycles before drug addition) which was defined as
100%. It has to be noted that the basal ECAR is the sum of
the Pgp basal activity and other metabolic processes. The
cellular response is given as the percentage of the basal
activity (Figure 1C). As seen in Figures 1B and 1C addition
of chlorpromazine to the flow medium leads to an ECAR
increase in NIH-MDR-G185 cells, but not in wild-type cells.
Figure 2 displays the ECAR changes relative to the basal
acidification rates of NIH-MDR-G185 (circles) and NIH3T3
cells (squares) upon stimulation with either chlorpromazine
(A) or dibucaine (B) at different concentrations as a function
of time. The second measuring point at the end of the drug-
stimulation period (at 180 s) is again indicated by a filled
symbol (Figures 1C, 2A, and 2B).
The response of wild type cells (Figures 2A and 2B) was
negligibly small for all drugs at low concentrations (C < 10
μM). Some drugs induced a fast transient decrease of the
ECAR (to maximally ∼70%) at high concentrations as seen
in Figures 2A and 2B. The largest transient effects were
observed for chlorpromazine and dibucaine, which are given
as examples in Figures 2A and 2B. Due to the protection of
the cells by Pgp this effect was small in NIH-MDR-G185
cells. At high concentrations, C > 10 μM, the cytotoxic
daunorubicin induced metabolic changes in wild-type cells
which were similar to those in MDR1-transfected cells.
Analysis of Pgp ActiVation. Plotting the ECARs of NIH-
MDR-G185 cells at the end of the drug-stimulation period
FIGURE 1: (A-C) ECAR measured by means of a Cytosensor
microphysiometer. MDR1-transfected (NIH-MDR-G185) (solid
lines in Figures 1A and B, circles in Figure 1C) and wild-type cells
(NIH3T3) (dotted lines in Figures 1A and B, squares in Figure
1C) were exposed to 3.4 μM chlorpromazine. (A) Raw data show
changes of the voltage (mV) with time, that are proportional to pH
changes (-1 μV/s ) 0.001 pH unit/min at pH 7.4). When the pumps
are on (gray boxes), the pH in the measuring chamber corresponds
to the pH of flow medium. When the pumps are off (black boxes),
the pH drops due to an accumulation of acidic metabolites in the
extracellular environment. Gray hatched boxes indicate the stimula-
tion period of cells with chlorpromazine and comprise two
measurements, where the second measurement (180 s) indicated
by a filled symbol (C) is used for data evaluation. (B) Same data
as in part A shown on a longer time scale. (C) Rate data show the
acidification rate (-μV/s) in time, determined by a least-squares
fit to the slope from the raw data when pumps are off. Values are
normalized to the basal ECAR defined as 100%.
FIGURE 2: (A, B) Time-dependent ECAR of NIH-MDR-G185
(circles) and NIH3T3 (squares) cells in response to increasing
concentrations of chlorpromazine (A) and dibucaine (B). The cells
were stimulated with drugs for 180 s. Each segment is normalized
to a basal acidification rate (the average of the two data points of
the ECAR before drug addition defined as 100%). The second
stimulation point obtained during the drug-stimulation period is
indicated by a filled symbol and is used for data evaluation. The
subsequent open circles correspond to measurements performed in
the presence of drug-free medium. Measurements were continued
until the ECAR returned to basal values. At low drug concentrations,
where only the activating binding region of Pgp is occupied, the
second stimulation point (filled symbol) corresponds to the ECAR
maximum. At high drug concentrations the ECAR at the second
stimulation point (180 s) is lower than the ECAR at the subsequent
(third) stimulation point. This is due to the fact that reperfusion of
the cells with drug-free medium lowers the membrane concentration
of drugs which leads to the release of the substrate molecule at the
inhibitory binding region of Pgp.
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at 180 s (indicated by solid symbols in Figures 1C, 2A, and
2B) as a function of the logarithm of concentration yields
activation profiles as displayed in Figure 3. The Pgp
activation profiles of all drugs show a characteristic bell-
shaped dependence on the logarithm of concentration, in
agreement with previous investigations in other cell lines
(14, 17), as well as in reconstituted proteoliposomes (33).
The solid lines are fits to the modified Michaelis-Menten
equation (eq 2) assuming Pgp activation upon binding of a
first drug molecule at low, and inhibition upon binding of a
second drug molecule at high, concentration. The error bars
in Figures 3A-C correspond to the average of two to three
measurements made with cells of the same passage (one data
set). For compounds which are especially prone to aggrega-
tion, such as phenothiazines (e.g. chlorpromazine (31)) and
progesterone, the quality of data decreases with increasing
concentration as reflected in an increase in error bars. Data
were evaluated using an automated fit program to eq 2
(described elsewhere, A¨a¨nismaa and Seelig, in preparation)
yielding the concentration of half-maximum activation, K1,
and inhibition, K2, as well as the maximum, V1, and minimum
rate, V2, of Pgp activity. Data obtained with NIH-MDR-G185
are summarized in Table 1 and correspond to average values
of one to four data sets made with cells of different passages.
For the present study the cell passage number was n > 4
(18).
Binding to the Inhibitory Region of Pgp Is ReVersible. A
closer inspection of Figures 2A and 2B is now possible. It
reveals that the data point at the end of the drug-stimulation
period (at 180 s) is identical with the ECAR maximum at
low drug concentrations. At higher drug concentrations the
ECAR maximum is observed at the subsequent measuring
point. At this point the cells have been reperfused with drug-
free medium for 100 s (plus 20 s measuring stop) and the
concentration of the drug in the membrane has therefore
decreased below the value at which the inhibitory binding
region is occupied. The increase in the ECAR is thus due to
the release of the inhibitory substrate molecule from Pgp,
which directly prooves the reversibility of the inhibitory
binding step in eq 1.
Figure 2A further shows that more than 1 h can be required
to reach the basal ECAR after reperfusion with drug-free
medium. This implies that the membrane concentration of
drugs in MDR1-transfected cells decreases only slowly (as
discussed in detail elsewhere).
Drug Partitioning into the Lipid Membrane. For the
electrically neutral extracellular lipid leaflet the lipid-water
partition coefficient, Klw, can be derived from the air-water
partition coefficient, Kaw, and the cross-sectional area of the
drug molecule in its amphiphilic orientation at the air-water
interface, AD ((30, 31), for the present compounds, Li-Blatter
and Seelig, in preparation),
where πMAD is the energy required to create a cavity with a
cross-sectional area, AD, in a membrane exhibiting the lateral
packing density, πM, and kT is the thermal energy per
molecule (35). The air-water partition coefficient, Kaw, was
determined at pH 7.4. The cross-sectional area, AD, was
measured at pH 8.0 to minimize charge repulsion effects (30,
31). The lateral packing density, πM, of mouse embryo
fibroblasts was determined as πM ≈ 30 mN/m (cf. next
paragraph).
After insertion into the outer, electrically neutral membrane
leaflet, the neutral fraction of drugs rapidly crosses the
hydrophobic core region and accumulates in the inner,
cytosolic membrane leaflet. The polar groups of the drug
then reside in the headgroup region of the lipids, and the
hydrophobic groups remain in the hydrophobic core. The
cytosolic lipid leaflet contains ∼25% negatively charged
lipids and thus exhibits a negative surface potential, ψ. Since
FIGURE 3: (A-C) Pgp activation profiles obtained by ECAR
measurements in NIH-MDR-G185 cells stimulated by cis-flupen-
tixol (9), diltiazem ([), glivec (2), lidocaine (0), triflupromazine
(O) (A), amitriptyline (9), cyclosporin A (2), promazine (O),
reserpine (0), and trifluoperazine (b) (B), chlorpromazine ([),
daunorubicin (9) (data in the low concentration range C < 5 μM
are fitted to eq 2, metabolic changes due to effects other than Pgp
activation are observed at C > 10 μM), dibucaine (O), progesterone
(2), and verapamil (0) (C). The solid lines are fits to eq 2 assuming
activation with one and inhibition with two drug molecules bound
to Pgp. Symbols represent average value of n ) 2-3 measurements
with cells of the same cell passage.
Klw ) Kaw e
-πMAD/kT (11)
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it is generally assumed that Pgp binds its substrates when
they are inserted in the cytosolic membrane leaflet (although
other binding locations have been proposed (36)), we
calculated the appropriate cytosolic lipid-water partition
coefficient by taking into account the charge, z, of the drug
and the surface potential, ψ, of the cytosolic membrane
leaflet,
where RT is the thermal energy per mole, and F the Faraday
constant.
The surface potential, ψ, depends not only on the lipid
composition of the membrane but also on the cytosolic ion
concentration. The cytosolic free magnesium concentration
has been estimated to be in the range of C ) (0.5 to 1) mM
(37), and the concentration of monovalent cations is in the
range of C ) (100 to 150) mM. With a binding constant of
K ) 10 M-1 and K ) 0.6 M-1 for magnesium and for
monovalent cations, respectively (38), a surface potential in
the range of ψ ≈ (-30 to -20) mV is calculated using the
Gouy-Chapman theory (39). Binding of cationic drugs also
reduces the membrane surface potential. For most drugs it
reaches a value of ψ ≈ 0 mV at the concentration of half-
maximum Pgp activation. To illustrate the effect of the
surface potential we calculated the lipid water partition
coefficients, Klw, for the two extreme values, ψ ) 0 mV,
and ψ ) -30 mV.2 As seen in Figure 4A the lipid-water
partition coefficients were in the range of Klw ) (102 to 104)
M-1 and Klw ) (2 × 102 to 2 × 104) M-1 for ψ ) 0 mV,
and ψ ) -30 mV, respectively. The lipid-water partition
coefficients, Klw, of the different drugs thus vary by 2 orders
of magnitude under both conditions, whereas an increase of
the negative surface potential from ψ ) 0 mV to ψ ) -30
mV increases the lipid-water partition coefficient only by
maximally a factor of about two. If not otherwise stated the
following data are calculated with a negative surface
potential, ψ ) -30 mV.
The Lateral Packing Density, πM, of the Plasma Membrane
of NIH-MDR-G185 Cells. The lateral packing density, πM,
of a membrane cannot be measured directly; however, it can
be determined in relation to a monolayer or bilayer with a
known lateral packing density (40). As seen from eq 11 the
lipid-water partition coefficient, Klw, decreases exponentially
with increasing lateral packing density, πM, of the membrane
(35, 41). If the lipid-water partition coefficients, Klw(A) and
Klw(B), and the surface potential difference, ψB - ψA, of two
membranes, A and B, are known, the packing density
difference between the two membranes, πM(B) - πM(A), can
be determined as
In the comparison of cells the surface potential difference
can be neglected to a first approximation and the last term
in eq 13 thus cancels. With a reference membrane, A, of
known packing density, πM(A), the packing density of the
cell membrane, B, πM(B), can then be evaluated.
According to eq 5 the binding constant of the substrate
from water to the transporter, Ktw(1) (or 1/K1), corresponds
to the product of the lipid-water partition coefficient and
the binding constant of the substrate from the lipid membrane
to the transporter, where Ktl(1) is likely to be packing density
independent (cf. Discussion). The binding constant of the
substrate from water to the transporter, Ktw(1), thus shows
the same exponential dependence on the membrane packing
density, πM, as the lipid-water partition coefficient, Klw.
Therefore, the packing density difference, πM(B) - πM(A),
between two different cell membranes, A and B, can be
evaluated by measuring the concentrations of half-maximum
activation, K1(A) and K1(B), of Pgp embedded in two different
membranes,
where the surface potential difference can again be neglected
2 Inside-out plasma membrane vesicles of MDR1-transfected (NIH-
MDR-G185) and wild-type cells (NIH3T3) exhibit the same -potential.
The -potential of the inside-out plasma membrane vesicles is moreover
similar to that of the intact cells from which they were derived. The
negative -potential of inverted plasma membrane vesicles is due to
the negatively charged lipids in the cytosolic membrane leaflet, and
that of intact cells is due essentially to the extracellular glycocalix
located above the level of electrically neutral lipid headgroups. In the
absence of drugs the -potential is (-23 ( 3) mV (E. Gatlik, X. Li-
Blatter, A. Seelig, unpublished results) and is thus in good accordance
with the surface potential, ψ, used in the present investigation.
Klw ) Kaw e
-πMAD/kT e
-ψFz/RT (12)
(πM(B) - πM(A)) ) kTAD(ln(Klw(A)Klw(B)) - FzRT(ΨB -ΨA)) (13)
FIGURE 4: The inverse of the concentration of half-maximum Pgp
activation, (1/K1), obtained by measurements of the ECAR in NIH-
MDR-G185 cells, is plotted as a function of the lipid-water
partition coefficient, Klw (A), and as a function of the air-water
partition coefficient, Kaw (B). Open triangles and filled squares in
Figure 4A refer to a membrane surface potential, ψ ) 0 mV and
ψ ) -30 mV, respectively. Surface activity measurements were
performed at pH 7.4. (1) amitriptyline, (2) chlorpromazine, (3) cis-
flupenthixol, (4) cyclosporin A, (5) daunorubicin, (6) dibucaine,
(7) diltiazem, (8) glivec, (9) lidocaine, (10) progesterone, (11)
promazine, (12) (R/S)-verapamil, (13) reserpine, (14) trifluopera-
zine, and (15) triflupromazine. The straight line in Figure 4B
exhibits a slope m ) 1.
(πM(B) - πM(A)) ) kTAD(ln(K1(B)K1(A)) - FzRT(ΨB -ΨA)) (14)
3026 Biochemistry, Vol. 45, No. 9, 2006 Gatlik-Landwojtowicz et al.
 
 
                                                                                7. Reprints and Unpublished Manuscripts 62
 
 
in most cases (cf. Table 2). To estimate the lateral packing
density of the plasma membrane of different MDR1-
transfected cell lines we used as reference membrane a
DMPC bilayer for which the lateral packing density has been
determined previously as πM ) (30 ( 1) mN/m (42). DMPC
bilayers have been used to reconstitute Pgp and to measure
the concentration of half-maximum Pgp activation, K1, by
verapamil (13). With the two reference values for DMPC
bilayers (πM and K1 for verapamil) the lateral packing density
of the plasma membranes of NIH-MDR-G185 cells was
estimated as πM ) 30.5 ( 1 mN/m. For comparison we
estimated the packing density of two other cell membranes
(LLC-MDR1 (17) and CR1R12 cells (14)) and of mixed lipid
bilayers (∼60% Escherichia coli lipids, ∼17.5% egg phos-
phatidylcholine, 10% bovine brain phosphatidylserine and
∼12.5% cholesterol) (34, 43) used for Pgp reconstitution (cf.
Table 2). The membrane packing densities, πM, estimated
for the different membranes are summarized in Table 2. The
type of assays, the kinetic models (rate equations), and the
experimental conditions (e.g. pH, magnesium and ATP
concentrations) differ in the different investigations.
The lateral packing densities of the mammalian plasma
membranes investigated were found to be in the range of
πM = (30 to 35) mN/m, which is in good agreement with
previous investigations (40). The lowest packing density was
found for mouse embryo fibroblasts (NIH-MDR-G185),
which is consistent with the low cholesterol content generally
found in embryonic cell membranes (44), and the highest
packing density was observed in Ehrlich ascites tumor cells,
CR1R12. The packing density of lipid membranes containing
a high percentage of E. coli lipids (33, 43, 45) was
determined as πM ) 46.5 ( 4.5 mN/m, which is distinctly
higher than that of the mammalian plasma membranes. The
high packing density is mainly due to the high percentage
of phosphatidylethanolamines in E. coli lipids. Phosphati-
dylethanolamines exhibit smaller cross-sectional areas and
therefore higher packing densities than the corresponding
phosphatidylcholines (46). The high packing density of E.
coli lipids is also reflected in their high phase transition
temperature (47, 48).
Correlation between the Concentration of Half-Maximum
Pgp ActiVation and the Lipid-Water Partition Coefficient.
Figure 4A shows the inverse of the concentration of half-
maximum Pgp activation, 1/K1 (log scale), versus the lipid-
water partition coefficient, Klw (log scale). No linear corre-
lation is observed. Since log(1/K1) is proportional to the free
energy of binding from water to the activating binding region
of Pgp, ΔG°tw(1), and log Klw is proportional to the free energy
of drug partitioning from water to the membrane, ΔG°lw, it
can be concluded that no correlation exists between the drug
affinity from water to the transporter and the drug affinity
to the lipid membrane for the present set of structurally
diverse drugs. The same conclusion was drawn previously
from octanol-water partition coefficients (14).
Correlation between the Concentration of Half-Maximum
Pgp ActiVation and the Air-Water Partition Coefficient. If
the log(1/K1) (proportional to ΔG°tw(1)) is plotted versus the
logarithm of the air-water partition coefficient, logKaw
(proportional to ΔG°aw) an approximately linear correlation
is obtained as shown in Figure 4B. The air-water partition
coefficients, Kaw, cover a broad range from Kaw ∼ 103 M-1
(very hydrophilic compounds) to Kaw ∼ 107 M-1 (very
hydrophobic compounds). The straight line in Figure 4
corresponds to the product of the air-water partition
coefficient and the concentration of half-maximum Pgp
activation,
The free energy of moving the drug from water to air, ΔG°aw
) -RT ln(CwKaw), is thus approximately identical to the free
energy of substrate binding from water to the transporter,
ΔG°tw,
Rewriting eq 11 in a logarithmic form and combining it with
eq 8 yields
Table 2: The Lateral Membrane Packing Density, πM, of Different Pgp Containing Membranes Estimated by Comparing Concentrations of
Half-Maximum Pgp Activation K1 (or Km) by Verapamila
membrane rate equation
K1 (or Km)
[μM]
Mg2+
[mM]
ATP
[mM]
πM
[mN/m]
ψ
[mV]
Klw
[M-1]
Xb(1)
[mmol/mol]
lipid (DMPC)(13) Michaelis-Menten
equation
0.63b 30(42) 0 336 0.21
NIH-MDR-G185 cells eq 2 0.5 cellular cellular 30.5 -20 514 0.26
LLC-MDR1 cells(17) eq 2 0.89c cellular cellular 33 -20 307 0.27
CR1R12 cells(14) eq 2 2.5 2.5 3 35.5 -20 101 0.25
lipid mixture with
E. coli lipidsd (43)
Michaelis-Menten
equation
4.7 5 5-7.5 42 -20 51.3 0.24
lipid mixture with
E. coli lipidsd (33,45)
eq 4 30
62.2
15
15
10
10
48
51
-5
-5
8.3
4.4
0.25
0.27
a The K1 (or Km) values were taken from literature, and the corresponding experimental conditions (magnesium ion and ATP concentration,
respectively, pH, and temperature) are given. The membrane packing density, πM, was calculated according to eq 14 using the surface potential, ψ,
estimated taking into account 25% negatively charged lipids and the free ion concentration in the different assays. The lipid-water partition coefficient,
Klw, was determined according to eq 12 using the relevant surface potential and lateral packing density. The mole fraction of drugs in the membrane
at half-maximum Pgp activation, Xb(1), was calculated according to eq 20. All measurements discussed were performed at T ) 37 °C and pH 7.4
except those of ref. (13) (T > 30 °C), ref. (14) (pH 7.0) and ref. (43) (pH 6.8). K1 values measured at lower pH were divided by a factor of 2 to
correct for pH (cf. ref (45), and A¨a¨nismaa and Seelig, in preparation) and the Michaelis-Menten constant, Km, in ref. (43) was doubled to adjust
to a K1 value. b Dissociation constant determined by fluorescence quenching. The corresponding concentration of half-maximum activation (13)
obtained by means of an ATPase assay is slightly higher. c Corrected for adsorption to the Cytosensor tubes. d Lipid mixture (E. coli bulk phospholipids,
phosphatidylcholine, phosphatidylserine, cholesterol) (60:17.5:10:12.5 w/w).
KawK1 ) 1 (15)
ΔG°aw ≈ ΔG°tw (16)
ΔG°aw ) ΔG°lw - πMNAAD (17)
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where NA is the Avogadro number. Equation 17 shows that
the free energy of partitioning into the lipid-water interface,
ΔG°lw, corresponds to the free energy of partitioning into
the air-water interface, ΔG°aw, plus the additional work to
penetrate into the lipid bilayers. Combining eqs 16 and 17
leads to the following approximation:
or
Equation 19 suggests that the free energy of binding to the
transporter within the lipid membrane, ΔG°tl(1), is propor-
tional to the cross-sectional area of the molecule, AD, as will
be further discussed below (Figure 6A).
DISCUSSION
The thermodynamic and kinetic methods applied here were
able to reveal the free energy of binding from water to the
activating (inhibitory) binding region of Pgp in its native
lipid membrane, ΔG°tw(1) (ΔG°tw(2)), and the corresponding
free energy of partitioning into the lipid membrane, ΔG°lw(1),
for 15 structurally diverse substrates. With this knowledge
it is possible to determine two parameters which are not
directly measurable, i.e., (i) the mole fraction of drugs in
the membrane, Xb(1) (Xb(2)), at half-maximum Pgp activation
(inhibition) and (ii) the free energy of binding of the substrate
from the lipid membrane to the activating, ΔG°tl(1) (inhibitory,
ΔG°tl(2)) binding region of Pgp. The latter reflects the direct
interplay between the drug and the transporter and provides
the basis for a discussion of the nature of the interactions
between Pgp and its substrates.
The Membrane Concentration of Drugs That Elicits Half-
Maximum Pgp ActiVation. Biological membranes of different
origin differ in their lipid composition and as a consequence
in their lateral membrane packing density, πM. As seen in
FIGURE 5: (A) The free energy of drug binding from water to the
activating binding region of Pgp, ΔG°tw(1) (hatched and crosshatched
bars), in comparison to the free energy of drug partitioning from
water to the lipid membrane, ΔG°lw (crossed-hatched bars). The
difference between ΔG°tw(1) and ΔG°lw represents the free energy
of drug binding from lipid membrane to the transporter, ΔG°tl(1)
(hatched bar). (B) Analogous data for the inhibitory binding region
of Pgp. Numbers correspond to those in Figure 4A. Lidocaine (9)
is not included in Figure 5B since K2 could not be precisely
determined due to the high concentrations required (see Figure 3A).
ΔG°tw ≈ ΔG°aw ) ΔG°lw - πMNAAD (18)
ΔG°tl(1) ≈ -πMNAAD (19)
FIGURE 6: (A) The free energy of drug binding from the lipid
membrane to the activating binding region of the transporter,
ΔG°tl(1), plotted as a function of the cross-sectional area, AD, of
the drug. A straight line corresponds to the diagonal. B: The free
energy of drug binding from the lipid membrane to the activating
binding region of the transporter, ΔG°tl(1), as a function of the
weighted number of hydrogen bond acceptors in patterns determined
according to refs 10 and 23. Data were fitted to a hyperbolic
saturation isotherm. (C) The difference in the free energy of binding
from water to the activating and inhibitory binding region of Pgp,
ΔG°tl(1) - ΔG°tl(2), plotted as a function of the cross-sectional area,
AD, of the drug. Data were fitted to an exponential curve. Numbers
correspond to those in Figure 4. Values of ΔG°tl(1) (ΔG°tl(2)) were
obtained by means of ECAR measurements. Lidocaine (9) is not
included in Figure 6C since K2 could not be precisely determined
due to the high concentrations required (see Figure 3A).
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Table 2 the packing density of mammalian plasma mem-
branes were found to be in the range of πM = (30 to 35)
mN/m, whereas the packing density of membranes with a
high percentage of E. coli lipids was distinctly higher, πM
) 46.5 ( 4.5 mN/m. The membrane packing density, πM,
determines the lipid-water partition coefficient, Klw, as well
as the concentration of half-maximum Pgp activation, K1,
whereby the former decreases (cf. eq 11) and the latter
increases (cf. eq 5 and Table 2) with increasing membrane
packing density, πM. The mole fraction of drugs in the
membrane, Xb(1), that elicits half-maximum Pgp activation
is the product of the concentration of half-maximum activa-
tion, K1, and the lipid-water partition coefficient, Klw (11),
and is thus independent of the membrane packing density,
πM, as illustrated in Table 2 (last column). The mole fraction
of the different drugs in the membrane was estimated to be
in the range of Xb(1) ) (0.02 to 67) mmol/mol lipid (cf. Table
1). If we assume that 1 mol of lipid corresponds ap-
proximately to 1 L of lipid, the membrane concentration
corresponds to about Cb(1) ) (0.02 to 67) mmol/L lipid.
The high drug concentration in the membrane at half-
maximum Pgp activation suggests relatively weak substrate-
Pgp interactions. Similarly weak interactions have also been
observed for transporters that bind their substrates in the
aqueous phase at one side of the membrane and transport
them to the aqueous phase at the other side of the membrane,
such as the fucose transporter which exhibits a dissociation
constant in the mM concentration range (12).
The membrane concentration for half-maximum inhibition
(Xb(2) ) K2Klw) is even higher than that for half-maximum
activation, Xb(1). For small molecules (e.g. promazine) the
mole fraction ratio is small (Xb(2)/Xb(1) ≈ 2), and for large
molecules (e.g. diltiazem, verapamil, cyclosporin A) the mole
fraction ratio is large (Xb(2)/Xb(1) ≈ 80), indicating that the
accommodation of a second large molecule is more difficult.
The Free Energy of Drug-Binding from the Lipid Mem-
brane to the ActiVating Binding Region of Pgp, ΔG°tl(1). The
free energy of drug binding from water to activating binding
region of Pgp, ΔG°tw(1), can be expressed as the sum of the
free energy of drug partitioning into the lipid membrane,
ΔG°lw, and the free energy of drug binding from the lipid
phase to the activating binding region of Pgp, ΔG°tl(1) (cf.
eq 6). Figure 5A displays a comparison of ΔG°tw(1) ) (-30
to -54) kJ/mol (hatched plus crosshatched), the free energy
of drug binding from water to the transporter, with ΔG°lw
) (-23 to -34) kJ/mol (crosshatched), the free energy of
drug partitioning into the lipid membrane, and ΔG°tl(1) )
(-7 to -27) kJ/mol (hatched), the free energy of drug
binding from the lipid membrane to the transporter deter-
mined for NIH-MDR-G185 cells. For the 15 drugs investi-
gated, ΔG°lw, the free energy of drug partitioning into the
lipid membrane, is generally somewhat larger than ΔG°tl(1),
the free energy of drug binding to the activating binding
region of the transporter in the lipid phase. However, the
variation in ΔG°tl(1) is more pronounced (∼factor of 4.0) than
the variation in ΔG°lw (∼factor of 1.5).
Figure 5B displays the free energy of drug binding from
water, ΔG°tw(2) ) (-23 to -44) kJ/mol (hatched plus
crosshatched), and from the lipid membrane, ΔG°tl(2) ) (-1.6
to -16) kJ/mol (hatched), to the inhibitory binding region
of Pgp. The values of ΔG°lw (crosshatched) are identical to
those in Figures 5A and 5B. The free energy of drug binding
from water, ΔG°tw(2), and from the lipid membrane, ΔG°tl(2),
to the inhibitory region of Pgp are thus less negative than
the free energies of drug binding to the activating region of
Pgp, ΔG°tw(1) and ΔG°tl(1).
Kinetic Models and Their Influence on the Estimated Free
Energy of Binding to the Transporter. The kinetic data shown
in Table 1 were evaluated using the rate eq 2 proposed by
Litman et al. (14). It is based on the concept of uncompetitive
inhibition (or substrate inhibition) which was extended to
allow for basal activation in the absence of a substrate and
for breakdown of the complex T(ATP)StSt (eq 1). For
comparison we fitted our data to a simpler version of
uncompetitive inhibition, assuming that the complex T(ATP)-
StSt (eq 1) is catalytically inactive (V2 ) 0) (rate eq 3). While
the concentrations of half-maximum activation, K1, obtained
with the two models were similar, the concentrations of half-
maximum inhibition, K2, calculated with the latter model
were generally higher. As a consequence the corresponding
free energies of binding to the inhibitory binding region of
Pgp, ΔG°tl(2), were less negative (by maximally 15%). The
model proposed by Al-Shawi et al. (33, 34) also considers
basal activation of Pgp in the absence of drugs, drug
activation, and drug inhibition, however, it is based on the
concept of noncompetitive inhibition (rate eq 4). Rate eq 4
differs from rate eq 3 only by an additional term, K1Csw, in
the denominator which is small in comparison to the other
terms. The free energies of binding, ΔG°tl(2), obtained with
the model of Al-Shawi et al. (33, 34) were therefore similar
to those obtained with rate eq 3. The fits to all three models
were of comparable quality.
Concentrations of half-maximum activation evaluated by
means of a simple Michaelis-Menten equation, Km (43), are
generally smaller compared to those obtained with eqs 2-4
(by almost a factor of 2). In terms of free energies of binding,
ΔG°tl(1), the difference is, however, small.
The Nature of Drug-Transporter Interactions. The free
energy of drug binding from water to the transporter,
ΔG°tw(1), was shown to be the sum of the free energy of
drug partitioning into the lipid membrane, ΔG°lw, and the
free energy of drug binding from the lipid phase to the
activating binding region of Pgp, ΔG°tl(1). The interactions
which are relevant for binding of a drug from water to the
transporter are thus the sum of all the interactions relevant
for the two individual binding steps. Drug partitioning into
the lipid membrane is dominated by hydrophobic and van
der Waals interactions, respectively, with a potential con-
tribution of electrostatic interactions (cf. Figure 4A). The
possible nature of the substrate-transporter interactions
within the lipid membrane will be discussed in the following.
We have shown that the free energy of substrate binding to
the transporter within the lipid membrane, ΔG°tl(1), correlates
with the cross-sectional area of the drug, AD (cf. eq 19 and
Figure 6A). However, substrate-transporter interactions are
most likely not determined by the size of the substrate as
such, but rather by a concomitant increase in residues which
can undergo specific interactions with the amino acids in
the transmembrane sequences of Pgp. Interactions which
could play a role are electrostatic (ion-ion or dipole-dipole),
hydrogen bonding (weak dipole-dipole), cation-π, π-π
Xb(1) ) K1Klw (20)
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stacking, and van der Waals interactions, respectively, listed
in the order of decreasing free energy of binding. The X-ray
structure of the multidrug transporter AcrB (at the resolution
of (3.5 to 3.8) Å), crystallized with four different drugs bound
(in the absence of lipids), suggested the presence of all the
different interactions mentioned above (49). It has, however,
to be considered that the energetic contributions of the
diverse interactions differ. Moreover, it has to be considered
that not all compounds which bind to Pgp are charged, or
carry π-electron systems, but that all of them seem to carry
at least one hydrogen bond acceptor pattern (i.e. two
hydrogen bond acceptor groups in a distance of 2.5 Å or
4.6 Å) (23). Since the free energy contribution of hydrogen
bond formation in a hydrophobic environment can be
substantial (for review see ref 50), hydrogen bonding is likely
to contribute significantly to the energetics of drug transporter
interactions. Hydrogen bond acceptor patterns were therefore
suggested to serve as binding modules interacting with the
hydrogen bond donor-rich transmembrane domains of Pgp.
As a consequence the total free energy of binding of a drug
from the lipid membrane to the transporter, ΔG°tl(1), can be
assumed to be the sum of the free energies, ΔG°Hi, of the
individual hydrogen bonds formed (11, 22-24),
where ΔH°Hi is the enthalpy change for hydrogen bond
formation and TΔS° the product of the entropy change upon
drug binding and the absolute temperature.
To test whether the assumption made in eq 21 is energeti-
cally sound we estimated the free energy per potential
hydrogen bond formed, ΔG°Hi, and compared it with
literature values. Figure 6B shows the free energy of substrate
binding from the lipid membrane to the transporter, ΔG°tl(1),
as a function of the number of weighted hydrogen bond
acceptor groups per drug. Since not all hydrogen bond
acceptor groups will form hydrogen bonds with the same
free energy, we arbitrarily divided them into three groups
containing strong (oxygen atoms), intermediate (nitrogen and
sulfur atoms as well as phenyl groups), and weak (fluorine
atoms) hydrogen bond acceptors, weighted as 1, 0.5, and
0.25, respectively. The average free energy per hydrogen
bond, ΔG°Hi, was then estimated by dividing the total free
energy of binding, ΔG°tl(1), by the weighted number of
hydrogen bond acceptor groups per drug. The most negative
free energy of binding per hydrogen bond, ΔG°Hi ) -7.8
kJ/mol, was observed for dibucaine (see Table 1), which
exhibits one hydrogen bond acceptor pattern only (corre-
sponding to two hydrogen bonds). For compounds with more
than one hydrogen bond acceptor pattern the apparent free
energy per hydrogen bond, ΔG°Hi, was less negative. For
compounds with more than four hydrogen bond acceptor
pattern the apparent free energy per hydrogen bond, ΔG°Hi,
reached a limiting value (ΔG°Hi ∼ -2.5 kJ/mol). The
decrease in ΔG°Hi with increasing number of hydrogen bond
acceptors can be explained by a loss in residual motion after
formation of more than one hydrogen bond leading to an
entropy decrease (51). If appropriate membrane packing
densities, πM, are taken into account, comparable values of
ΔG°Hi are also obtained from other investigations (e.g. ref
14). A similar conclusion was drawn previously for undefined
binding modules (25). The free energy of the first single
hydrogen bond formed is therefore most likely ΔG°Hig-7.8
kJ/mol. This value is larger than the free energy estimated
for forming an amide hydrogen bond in water (ΔG ∼ -4
kJ/mol) and somewhat smaller than the free energy of
forming a single hydrogen bond in alkane, determined as
ΔG ∼ -20 kJ/mol without taking into account entropic
effects (52). Considering the fact that different types of
hydrogen bond acceptors are taken into account, and that
possible steric effects are neglected, the resulting free energy
value per hydrogen bond seems reasonable and supports the
assumption of the modular binding concept proposed previ-
ously (eq 21).
The free energy of binding to the inhibitory binding region,
ΔG°tl(2), is on average less negative than that for the
activating binding region, ΔG°tl(1). Nevertheless, it can be
assumed that the same type of interactions between drugs
and Pgp take place. The less negative free energy of binding,
ΔG°tl(2), is most likely due to conformational changes of the
protein upon accommodation of a second molecule which
may lead to a decrease in entropy. This is supported by the
fact that the difference in free energy, ΔG°tl(1) - ΔG°tl(2),
increases with increasing the cross-sectional area, AD, of the
drug as seen in Figure 6C. This shows again that accom-
modation of a large molecule at the inhibitory binding region
of Pgp is less favorable than accommodation a small
molecule.
Conclusions. Binding of a drug from water to the activat-
ing binding region of Pgp occurs in two steps, a partitioning
step from water to the lipid membrane, characterized by a
lipid-water partition coefficient, Klw, and a binding step from
the lipid membrane to the transporter, characterized by a
binding constant, Ktl(1). The binding constant of a drug from
water to the transporter, Ktw(1), can thus be expressed as
product of two individual binding constants Klw and Ktl(1),
and the free energy of binding, ΔG°tw(1), as sum of two
corresponding free energies, ΔG°lw and ΔG°tl(1). The free
energies ΔG°tw(1) and ΔG°lw can be determined indepen-
dently, which allows estimation of the free energy of binding
from lipid to the transporter, ΔG°tl(1). For the 15 drugs
investigated the free energy of drug partitioning into the lipid
membrane, ΔG°lw, was generally somewhat more negative
than the free energy of drug binding to the transporter in
the lipid phase, ΔG°tl(1). However, the variation in ΔG°tl(1)
was more pronounced (∼factor of 4.0) than the variation in
ΔG°lw (less than a factor of 1.5). Drug affinity to the
transporter in the lipid membrane was shown to increase with
the cross-sectional area, AD, of the drug. With increasing size
of a drug the possibility for different types of interactions
also increases. The present analysis suggests that hydrogen
bond formation contributes significantly to the energetics of
substrate-Pgp interactions within the lipid membrane. Data
can be well explained with a modular binding concept, where
the binding module in drugs consists of two hydrogen bond
acceptor groups. Binding of a drug to Pgp (e.g. hydrogen
bond formation) was assumed to be independent of the
membrane packing density, πM, to a first approximation. The
mole fraction of drugs, Xb(1), in the membrane at the
concentration of half-maximum Pgp activation is thus
constant, which implies that higher aqueous drug concentra-
tions are required for membrane penetration and Pgp
activation in the case of densely packed membranes (e.g.
ΔG°tl(1) ≈ ∑
i)1
n
ΔG°Hi ) ∑
i)1
n
ΔH°Hi - TΔS° (21)
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membranes of E. coli bacteria) than in the case of more
loosely packed membranes (e.g. mouse embryo fibroblasts).
Since the lipid membrane acts as a drug scavenger and
interacts synergistically with Pgp, cells are well protected
from intruding substrates despite the relatively weak Pgp-
substrate interactions.
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7.1.1. Appendix: Surface Activity and Gibbs Adsorption Isotherm 
 
Amphiphathic molecules, such as drugs, accumulate at the air-water interface from the 
interior of the solution which causes a decrease in the surface tension of buffer, γ0, to the 
new value, γ. The difference is called as surface pressure, π =  γ0 - γ, and can be detected 
e.g. with a Wilhelmy plate in a monolayer trough.  
The Gibbs adsorption isotherm describes the thermodynamics of adsorption of 
amphiphilic compound to the air-water interface 
 
πγ dCdRTd Saq −=Γ−= ln       (1) 
 
where R is the gas constant, T is the absolute temperature, CSaq is the concentration of 
compound in bulk solution and Γ is the surface excess concentration. The surface excess 
concentration, Γ, describes the molar amount of accumulated solute per surface area 
(mol/m2), and it can be written as 
A
n
NA A
Δ==Γ
0
1       (2) 
 
where Δn is the surface excess of molecules in the interface, A is the area of surface, A0 is 
the surface area of compound required at the interface, and NA is the Avogadro number.  
The surface excess concentration, Γ, increases with CSaq up to the limiting value 
Γ∞ . As long as Γ is constant a plot of π vs logCSaq yields a straight line. The surface excess 
concentration, Γ, can be thus evaluated from the slope of the linear part of π versus 
logCSaq-plot and the surface area of compound required at the interface, A0, from the eq. (2) 
 
SaqCd
d
RT ln
1 π=Γ∞      (3) 
 
The surface adsorption process can also described by a Langmuir adsorption isotherm  
 
Saqaw
Saqaw
CK
CK
+Γ=Γ ∞ 1      (4) 
where Kaw is the air-water partition coefficient.  
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The air-water partition coefficient, Kaw, can be evaluated by using a Szyszkowski equation 
which is an integral version of the Gibbs adsorption isotherm (eq. (3)) and the Langmuir 
adsorption isotherm (eq. (4))  
 
)1ln( +Γ= ∞ SaqawCKRTπ     (5) 
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ABSTRACT: P-glycoprotein (MDR1, ABCB1) is an ATP-dependent efflux transporter of a large variety of
compounds. To understand P-glycoprotein in more detail, it is important to elucidate its activity in the
cellular ensemble as well as in plasma membrane vesicles (under conditions where other ATP dependent
proteins are blocked). We measured P-glycoprotein activity in inside-out vesicles formed from plasma
membranes of MDR1-transfected mouse embryo fibroblasts (NIH-MDR1-G185) for comparison with
previous measurements of P-glycoprotein activity in living NIH-MDR1-G185 cells. In plasma membrane
vesicles activity was measured by monitoring phosphate release upon ATP hydrolysis and in living cells
by monitoring the extracellular acidification rate upon ATP synthesis via glycolysis. P-glycoprotein was
stimulated as a function of the concentration with 19 structurally different drugs, including local anesthetics,
cyclic peptides, and cytotoxic drugs. The concentrations of half-maximum P-glycoprotein activation, K1,
were identical in inside-out plasma membrane vesicles and in living cells and covered a broad range of
concentrations (K1 ∼ (10-8-10-3) M). The influence of the pH, drug association, and vesicle aggregation
on the concentration of half-maximum P-glycoprotein activation was investigated. The turnover numbers
in plasma membrane vesicles and in living cells were also approximately identical if the latter were measured
in the presence of pyruvate. However, in the absence of pyruvate they were higher in living cells. The
rate of ATP hydrolysis/ATP synthesis decreased exponentially with decreasing free energy of drug binding
from water to the transporter, ΔGtw(1)
0 (or increasing binding affinity). This suggests that drug release
from the transmembrane domains has to occur before ATP is hydrolyzed for resetting the transporter.
P-glycoprotein, Pgp1 (MDR1, ABCB1), is an ATP-
dependent efflux transporter of a large variety of structurally
diverse compounds, including toxins, drugs, and metabolites.
Together with metabolizing enzymes and other efflux
transporters with partially overlapping functions Pgp sig-
nificantly contributes to a sophisticated cellular defense and
housekeeping system (for review see refs 3-5). Pgp consists
of two homologous parts, each comprising a cytosolic,
nucleotide-binding domain, NBD (6, 7), and a drug-binding,
transmembrane domain, TMD (8), which together form an
integrated single entity as shown by preliminary X-ray data
(9) and a recent homology model (10). Upon formation of
the transition state each NBD carries one molecule of ATP
which leads to a dimerization of the two domains. However,
just one of the two ATP molecules seems to be hydrolyzed
per dimerization event (11). The interplay between the NBDs
and the TMDs upon drug stimulation is not yet fully
understood. Whether ATP hydrolysis is required for driving
the substrate across the membrane (1), or for resetting the
transporter to the open starting position (after a passive
transport step) (12), or even for both (13) is still a matter of
intensive research.
The difficulty in understanding Pgp arises to a large extent
from the fact that substrates are bound from the cytosolic
membrane leaflet (8, 14) (for review see refs 15, 16) and
not from the aqueous phase as is the case in most well-known
transporters. To reach the site of interaction the substrate
has therefore first to partition from the aqueous phase (w)
into the lipid phase (l). This process is described by the
lipid-water partition coefficient, Klw. Second, the substrate
binds from the lipid phase to the activating (1) region of the
TMDs (t), which is described by the transporter-lipid
binding constant, Ktl(1). As a consequence, the binding
constant describing substrate binding from the aqueous phase
to the activating binding region of the transporter, Ktw(1), can
be expressed as the product of the lipid-water partition
coefficient, Klw, and the transporter-lipid binding constant,
Ktl(1) (Ktw(1) ) Klw‚Ktl(1)). Analogous binding constants can
be defined for the inhibitory (2) binding region of the
transporter. Substrate binding thus strongly depends on the
lipid-water partition coefficient, Klw, of the compound which
in turn depends on the lateral packing density of the lipid
membrane, πM, and the pH of the environment (for detail
see refs 5, 17).
In inside-out membrane vesicles drugs merely have to
intercalate between the lipids with the polar head group
remaining in the head group region of the membrane,
whereas in living cells they have to diffuse across the
* Corresponding author. Phone: +41-61-267 22 06. Fax: +41-61-
267 21 89. E-mail: Anna.Seelig@unibas.ch.
1 Abbreviations: CMCD, critical micelle concentration of drug;
ECAR, extracellular acidification rate; K1 (K2), aqueous substrate
concentration at half-maximum Pgp activation (inhibition); Klw, lipid-
water partition coefficient; Ktl(1) (Ktl(2)), binding constant of the drug
from the lipid membrane to the activating (inhibitory) binding region
of the transporter; Ktw(1) (Ktw(2)), binding constant of the drug from water
to the activating (inhibitory) binding region of the transporter; MDR,
multidrug resistance; NBD, nucleotide binding domain; Pgp, P-
glycoprotein-ATPase (MDR1, ABCB1); TMD, transmembrane domain;
V1 (V2), maximum (minimum) Pgp activity.
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membrane. Permanently charged cationic compounds such
as spin labeled verapamil (18) can, therefore, reach the Pgp
binding site in inside-out vesicles but not in living cells.
Pgp activity has generally been measured in plasma
membrane vesicles of MDR1-transfected cells or in recon-
stituted proteoliposomes which both expose the NBDs to the
extravesicular side and allow monitoring the release of
inorganic phosphate (1, 19, 20) or ADP (20, 21) upon drug
stimulation. In living cells Pgp stimulation with drugs leads
to intracellular ATP hydrolysis which entails enhanced ATP
synthesis via glycolysis, whereby lactic acid is produced as
waste product and is excreted by the cell (22). We exploited
this process to monitor Pgp activity as a function of drug
concentration in real time (2, 23, 24) using a Cytosensor
microphysiometer (25). The experiments have shown that
Pgp activity in living cells is not only controlled by the nature
and the concentration of the drug, and the packing density
of the membrane, but also by the metabolic state of the cell
(2).
A comparison of Pgp activity in living cells and in inside-
out membrane vesicles of the same cells has so far been
published only for verapamil (2). Since the two systems bear
distinct differences we extended the comparison to the 15
drugs measured previously in living mouse embryo fibro-
blasts (NIH-MDR1-G185) (24) and added four additional
drugs to get an even broader selection of compounds. The
19 compounds range from local anesthetics (MW ≈ 200
g/mol) to cyclic peptides (MW ≈ 1200 g/mol) and include
cytotoxic drugs. The wide variety of compounds allows, then,
testing how the binding affinity of the drug for the TMDs
influences the rate of nucleotide hydrolysis at the NBDs.
We show that the concentrations of half-maximum Pgp
activation, K1, in living MDR1-transfected mouse embryo
fibroblasts (24) are identical to those in inside-out plasma
membrane vesicles of the same cells, provided the two
systems are at the same pH and possible artifacts due to drug
and vesicle association are taken into account. The relative
rates of activation are linearly correlated. The turnover
numbers are practically identical if Pgp activity in living cells
is measured in the presence of pyruvate (2, 24). In the
absence of pyruvate Pgp activity in living cells is higher.
The maximum rate of Pgp activity, ln(V1), decreased linearly
with increasing affinity of the drug from water to the TMDs.
Drug release is thus the rate-determining step and the
transporter can only be reset if it is unloaded at the
extracellular side.
MATERIALS AND METHODS
Materials. Amitriptyline‚HCl, cis-flupenthixol‚2HCl,
daunorubicin‚HCl, dibucaine‚HCl, diltiazem‚HCl, lidocaine‚
HCl, progesterone, promazine‚HCl, trifluoperazine‚2HCl,
triflupromazine‚HCl, and vinblastine‚H2SO4 were from Sigma-
Aldrich (Steinheim, Germany), and (R/S)-verapamil‚HCl and
colchicine were from Fluka (Buchs, Switzerland).
Chlorpromazine‚HCl and reserpine‚HCl‚H2O were generous
gifts from Merck (Darmstadt, Germany), and cyclosporin A,
PSC-833, and glivec mesylate were generous gifts from
Novartis AG (Basel, Switzerland). The inhibitor OC144-093
was a gift from Dr. T. Litman. Complete EDTA-free protease
inhibitor cocktail tablets were obtained from Roche Diag-
nostics (Mannheim, Germany), 1,4-dithiol-DL-threitol, DTT,
from Applichem (Darmstadt, Germany), and bicinchoninic
acid, BCA, protein assay reagents from Pierce (Rockford,
IL). All other chemicals were from either Sigma, Fluka, or
Merck. Cell culture media DMEM with and without pyruvate
(liquid and dry, Cat. No. 21969 and Cat. No. 52100,
respectively) as well as other compounds required for cell
culture such as fetal bovine serum, FBS, L-glutamine, and
antibiotics were from Gibco-BRL (Basel, Switzerland).
Cell Lines and Cell Culture. Wild-type (NIH3T3) and
MDR1-transfected mouse embryo fibroblasts (NIH-MDR1-
G185) were generous gifts from Dr. M. M. Gottesman and
Dr. S. V. Ambudkar (The National Institutes of Health,
Bethesda, MD). Cells were grown in the presence of 0.15
μM colchicine and were maintained as described previously
(2, 23).
Plasma Membrane Preparation. The crude plasma mem-
brane vesicles were prepared as described previously with
some modifications (2, 26). Briefly, cells grown in 15 cm
dishes were washed once with PBS buffer, and then scraped
into ice-cold PBS (pH 7.0 at ambient temperature) supple-
mented with protease inhibitors (1 tablet/50 mL PBS). Next,
cells were washed with ice-cold buffer A by centrifugation
at 1000gmax for 10 min at 4 °C. Buffer A consisted of 10
mM Tris-HCl, 10 mM NaCl, 1 mM MgCl2, protease
inhibitors (1 tablet/50 mL), adjusted to pH 7.5 at ambient
temperature. The pellet was resuspended in buffer A (5 mL/
4*15 cm dishes) and was then kept on ice until disruption
with a “One Shot” cell disrupter (Constant Systems Ltd,
Warwickshire, U.K.) at 400 bar. The “One Shot” cell
disrupter uses pressure to force a sample through a small
fixed orifice at high speed. By transferring the cell sample
from a region of high pressure to one of low pressure cells
disrupt. The cell lysate was diluted 1:1 with ice-cold buffer
B (10 mM Tris-HCl, 50 mM N-methyl-D-glucamine, NMDG,
120 mM sucrose, protease inhibitors (1 tablet/50 mL),
adjusted to pH 7.4 at ambient temperature). The unbroken
cells and nuclei were then precipitated by centrifugation at
800gmax for 10 min at 4 °C. Subsequently mitochondria were
removed by centrifugation at 6000gmax for 10 min at 4 °C,
and in the final centrifugation step (100000gmax, 1 h, 4 °C)
the crude membranes were pelleted. The pellet was resus-
pended in buffer B and homogenized by repeated aspiration
through a 23-gauge syringe. Aliquots were rapidly frozen
in dry ice and stored at -80 °C until use.
The average protein content of the plasma membrane
vesicles from five different preparations was determined as
((9.9 ( 1.7) mg/mL) using the BCA protein assay with
bovine serum albumin (fraction V) as a standard. The initial
number of cells per preparation varied from 5.7 × 108 to
1.1 × 109. Western immunoblots made with supernatants
and pellets of the different centrifugation steps after cell
disruption (800gmax, 6000gmax, 100000gmax) suggest a sub-
stantial loss of Pgp. Pgp was detected with monoclonal
antibody C219. The total loss of plasma membrane Pgp
during membrane vesicle preparation was estimated as
approximately 20%. Taking into account the number of Pgp
molecules in NIH-MDR1-G185 cells determined previously
as (1.95 ( 0.53) × 10 6 Pgp/cell (27), the molecular weight
(170 kDa), and a total loss of Pgp (∼20%), the amount of
Pgp per total protein concentration was estimated as (1.1 (
0.3)% (average of five different membrane preparations).
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The orientation of Pgp in plasma membrane vesicles was
tested by permeabilizing the membranes with CHAPS in
order to unmask the occluded nucleotide binding domains
(28). Since increasing concentrations of CHAPS did not lead
to an increase in the rate of ATP hydrolysis, we concluded
that the vesicles obtained by the “One-Shot” procedure
exhibited an essentially inside-out orientation.
Phosphate Release Assay. The Pgp associated ATPase
activity was determined according to Litman et al. (19) in a
96-well microtiter plate (Nunc F96 MicroWell plate, non-
treated) with small modifications. The plasma membrane
vesicles were diluted to a protein concentration of 0.1 mg/
mL in ice-cold phosphate release assay buffer which
consisted of 25 mM Tris-HCl including 50 mM KCl, 3 mM
ATP, 2.5 mM MgSO4, 3 mM DTT, 0.5 mM EGTA, 2 mM
ouabain, and 3 mM sodium azide, adjusted to pH 7.0 at 37
°C, unless stated otherwise. Each series of experiments
contained 5 μg of protein per total assay volume of 60 μL
(total protein concentration 84.7 μg/mL per sample). Incuba-
tion with the various drugs was started by transferring the
plate from ice to a water bath at 37 °C for 1 h, and was
terminated by rapidly cooling the plate on ice. The inorganic
phosphate, Pi, released was determined by addition of ice-
cold solution (200 μL) containing ammonium molybdate
(0.2% (w/v)), sulfuric acid (1.43% (v/v)), freshly prepared
ascorbic acid (1% (w/v)), and SDS (0.9% (w/v)) to each well.
After incubation at room temperature (30 min), the phosphate
released was quantified colorimetrically at 820 nm using a
micro-plate reader Spectramax M2 (Molecular Device,
Sunnyvale). Reference standards were included to each 96-
well plate. Samples incubated with 0.5 mM vanadate to
determine the vanadate-sensitive Pgp activation were ob-
tained in parallel and were subtracted from the measured
values.
Cytosensor Measurements. The rate of ATP synthesis in
living cells was measured by monitoring the extracellular
acidification rate, ECAR, using a Cytosensor (25). The
ECAR was shown to correspond to the rate of lactate efflux
as a result of glycolysis (for details cf. refs 2, 23, 24). The
DMEM flow medium used was buffered with phosphate
(0.91 mM) and thus exhibited a very low buffer capacity.
Moreover, it contained pyruvate (1 mM) which reduces the
basal activity of cells by (50-60)% (2). Measurements were
performed at pH 7.4 and T ) 37 °C. The transformation of
the voltage per time data (μV‚s-1) to protons released per
cell per second (H+‚cell-1‚s-1) was performed as described
previously (2).
Stock Solutions of Drugs. Stock solutions for the phosphate
release assay were made with nanopure water or DMSO (cf.
Table 1). Drug solutions were prepared by further dilution
of the stock solution with either water or DMSO. The
measured drug concentrations were then obtained by adding
5 μL of aqueous drug solution or 1 μL of DMSO drug
solution into the phosphate release assay buffer (total sample
volume per well ) 60 μL). The final DMSO concentration
was constant c ) 1.7% (v/v).
Stock solutions for Cytosensor measurements were made
with DMEM flow medium or DMSO which was diluted with
flow medium to the final DMSO concentration (0.5% (v/
v)). Upon further dilution the DMSO concentration was
decreasing. Stock solution concentrations and the highest
concentrations measured with the two assays are included
in Table 1. At the concentrations applied DMSO affected
neither the ECAR (24) nor the phosphate release rate.
All drugs investigated are amphiphilic and form micelle-
like associates at high concentrations. The critical micelle
concentrations of drugs, CMCD, determined previously by
surface activity measurements in 50 mM Tris-HCl buffer
containing 114 mM NaCl (pH 7.4 at ambient temperature)
are given in Table 1 (refs 29, 30 and X. Li-Blatter and A.
Seelig, unpublished results). For comparison the CMCD value
of triflupromazine was also measured in the phosphate
release assay buffer (pH 7.4 at ambient temperature) and
was found to be very similar. The stock solution concentra-
Table 1: The Critical Micelle Concentration of Drugs, CMCD, the Stock Solution Concentrations, and the Highest Drug Concentrations
Measured in Phosphate Release (Pi) Assay and in ECAR Measurements
no. compound CMCDa [mM]
stock solution
ECAR [mM]
highest measd
ECARd [mM]
stock solution
Pi assay [mM]
highest measd
Pi assay [mM]
1 amitriptyline 5.0 0.4b 0.064 10.6e 0.887
2 chlorpromazine 0.96 0.2b 0.011 2.6e 0.216
3 cis-flupenthixol 0.16 0.06b 0.012 1.5e 0.126
4 cyclosporin A ∼0.001 0.002c 0.002 0.07,f 0.42f 0.001,h 0.007h
5 daunorubicin 0.06 - 0.3j 0.1b 0.087 0.096,e 0.48,f 0.9e 0.008, 0.008,h 0.075
6 dibucaine 2.4 0.2,b 1.0b 0.059 0.47,e 2.3e 0.039, 0.191
7 diltiazem 10 0.6b 0.498 10.2e 0.833
8 glivec ∼1 0.1b 0.092 1.8e 0.151
9 lidocaine 60 1.0b 0.939 24,e 90e 2.0, 7.5
10 progesterone 0.08 0.2c 0.029 10f 0.167h
11 promazine 7 0.4b 0.227 3.45e, 27.8e 0.287, 2.3
12 (R/S)-verapamil 5 0.1c 0.058 0.66,e 1.9e 0.055, 0.160
13 reserpine 0.009 0.01,c 0.008c 0.003 0.55f 0.009h
14 trifluoperazine 0.18 0.1b 0.009 0.4,e 2.0e 0.033, 0.166
15 triflupromazine 0.47 0.1b 0.011 1.7,e 2.0e 0.143, 0.166
16 colchicine 2.6 nd nd 200f 3.3h
17 OC144-093 ∼0.002 nd nd 0.06f 0.001h
18 PSC-833 ∼0.001 nd nd 0.2,f 0.8f 0.001h
19 vinblastine 0.1 0.1c 0.076 0.33g 0.027i
a CMCD determined by surface activity measurements in 50 mM Tris-HCl, 114 mM NaCl, pH 7.4 at ambient temperature. b Stock solution in
DMEM flow medium. c Stock solution in DMEM flow medium containing 0.5% (v/v) DMSO. d Drug concentrations after correction for adsorption.
e Stock solution in water. f Stock solution in 100% (v/v) DMSO. g Stock solution in 6% (v/v) DMSO. h Drug concentration containing 1.7% (v/v)
DMSO. i Drug concentration containing 0.5% (v/v) DMSO. jDepending on stock solution concentration.
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tions were below the critical micelle concentration, CMCD,
for most drugs in ECAR measurements but not in the
phosphate release assay (see Table 1). The direct injection
of the concentrated solutions into small volumes (60 μL) of
ice-cold buffer containing the membrane vesicles generated
high local drug concentrations. Since the pH of the buffer
increases with decreasing temperature (pH 7.9 at T ) 4 °C),
this may have led to irreversible drug association in some
cases which reduces membrane partitioning, and, in turn,
binding to Pgp. Drugs which are especially prone to
association are colchicine, progesterone, daunorubicin, and
phenothiazines.
Drug Adsorption. Some drugs strongly adsorb to plastic
surfaces (31). Drug solutions reaching the measuring cell in
the Cytosensor were therefore corrected for adsorption using
UV spectroscopy (for details see ref 24). Adsorption varied
strongly from compound to compound and was relatively
small for verapamil (∼21% for verapamil (20 μM)) and high
for phenothiazines (∼89.5% for triflupromazine (50 μM)).
The corresponding values for adsorption to the test tubes
(polypropylene) used in the phosphate release assay were
also determined (as ∼3% (per 120 min) for verapamil (40
μM) and as ∼19.0% (per 130 min) for triflupromazine (23
μM)) but were not taken into account.
90° Light Scattering. Light scattering at 90° was measured
with a Hitachi F-4500 spectrofluorometer under constant
stirring at an excitation and emission wavelength of 550 nm
(T ) 37 °C). A quartz cuvette with a cell length of 1 cm
and a volume of 3.5 mL was used. It was filled with 1.8 mL
of phosphate release assay buffer (pH 7.0 at 37 °C)
containing crude plasma membrane vesicles with the same
protein concentration as used in the phosphate release assay
(84.7 μg/mL). Aliquots (μL) of a promazine stock solution
prepared in nanopure water (6.24, 12.4, 25.7, and 27.3 mM)
were added into the buffer. The results were corrected for
dilution (maximally ∼10%) upon promazine titration by
titrating equal amounts of nanopure water into the membrane-
containing phosphate release assay buffer.
The Kinetic Model. We used a modified Michaelis-
Menten model (eq 1) proposed by Litman et al. (19) for data
evaluation. It assumes basal Pgp activity in the absence of
drugs, activation upon drug binding to a first binding region
at low drug concentrations, and inhibition upon drug binding
to a second binding region at high drug concentrations. The
rate of Pgp activity, Vsw, is expressed as follows:
where Csw is the substrate concentration in aqueous solution,
V0 is the basal activity in the absence of drugs, K1 and K2
are the concentrations of half-maximum activation and
inhibition, respectively, V1 is the maximum rate of ATP
hydrolysis, and V2 is the minimum rate of ATP hydrolysis
at infinite substrate concentration. The corresponding reaction
scheme was shown previously (24). At low substrate
concentrations eq 1 reverts to the simple Michaelis-Menten
kinetics which is illustrated in reaction 1, Scheme 1, where
Sw is the substrate in the aqueous phase, Sl is the substrate
in the lipid phase, k0 and k-0 are the partitioning rate
constants, and Klw ) k0/k-0 is the lipid-water partition
coefficient. ATP and the substrate, Sl, bind to the transporter,
T, to form the T(ATP)St complex. St is the substrate bound
to the activating binding region of the transporter, k1 and
k-1 are the rate constants for association to and dissociation
from the activating binding region, and Ktl(1) ) k1/k-1 is the
binding constant of the substrate for the activating binding
region of the transporter within the lipid membrane, under
the assumption that the association/dissociation reactions are
rapid compared to catalytic step; k′cat is the catalytic rate
constant, and Srel is the substrate released. For simplicity only
one ATP (ADP) molecule per Pgp is shown. As seen in
reaction 2 under the anaerobic conditions in the Cytosensor
one molecule of glucose is transformed to two molecules of
ATP and two molecules of lactic acid which is then exported
out of the cell. The synthesis of ATP comprises several steps,
and k′lac is the over-all catalytic rate constant.
RESULTS
Basal Pgp ActiVity. For calibration, the time dependence
of phosphate release upon Pgp activation at 37 °C was
measured in plasma membrane vesicles of MDR1-transfected
mouse embryo fibroblasts (NIH-MDR1-G185) in the pres-
ence and absence of 0.5 mM vanadate and 31.7 μM
verapamil, respectively (Figure 1A,B). Samples were ana-
lyzed every 15 min, and the reaction was stopped by cooling
the samples on ice. The amount of phosphate released was
determined as described in Materials and Methods. ATP
hydrolysis as a function of time was linear under each
condition throughout the time period investigated (75 min).
The phosphate release assay buffer contains sodium azide,
ouabain, and EGTA to inhibit, e.g., Na/K- and Ca-ATPases,
which reduced the basal activity of all ATP consuming
enzymes by 75.1% in comparison to a buffer lacking these
inhibitors. Sodium azide had the strongest effect (results not
shown).
The ATPase activity of plasma membrane vesicles in
phosphate release assay buffer is shown in Figure 1A (open
triangles). Addition of verapamil (31.7 μM) increased the
hydrolysis of ATP by Pgp (solid squares). In the presence
of vanadate (0.5 mM) the release of phosphate was reduced
(open down triangles) and remained at the same level upon
addition of verapamil (open squares), indicating that Pgp
activity was inhibited by vanadate (Figure 1A). The remain-
ing phosphate released arises most likely from the ATPase
activity of enzymes that are not sensitive to the inhibitors
used. Figure 1B shows the vanadate-sensitive basal and
verapamil-stimulated ATPase activity (assumed to cor-
respond to the ATPase activity of Pgp) as a function of the
incubation time at 37 °C. In the following, a single time
point measurement (60 min) of Pgp activity was used. For
five different plasma membrane preparations the average
vanadate-sensitive basal Pgp activity expressed as phosphate
released per total protein concentration and time was
Scheme 1
Vsw )
K1K2V0 + K2V1Csw + V2Csw
2
K1K2 + K2Csw + Csw
2 (1)
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determined as V0 ) (12.3 ( 1.3) nmol‚mg-1‚min-1 (n ≈
126).
Drug-Stimulated Pgp ActiVity Profiles Measured in Plasma
Membrane Vesicles of MDR1-Transfected Mouse Embryo
Fibroblasts. Pgp activity in inside-out plasma membranes
vesicles of NIH-MDR1-G185 cells was measured for the 19
drugs listed in Tables 1 and 2. Figure 2A-D shows the rate
of Pgp activity as a function of the substrate concentration
in aqueous solution (Log scale). Drug-stimulated Pgp activity
is expressed as percentage of the basal activity (taken as
100%).
Maximum Pgp activity requires high millimolar concen-
trations for very hydrophilic drugs, e.g., lidocaine (Figure
2A, filled squares) and colchicine (Figure 2C, filled down
triangles), micromolar concentrations for more hydrophobic
drugs, e.g., cis-flupentixol (Figure 2A, filled triangles) and
verapamil (Figure 2B, filled squares), and nanomolar con-
centrations for even more hydrophobic drugs, e.g., OC144-
093 (Figure 2D, open circles). Compounds of intermediate
hydrophobicity show the characteristic bell-shaped Pgp
activity profiles as a function of concentration observed
previously in living NIH-MDR1-G185 cells (24). For very
hydrophilic compounds inhibition could not be reached,
whereas for the very hydrophobic compounds activation is
barely visible or not present at all. The solid lines in Figure
2A-D are fits to the modified Michaelis-Menten model
(eq 1) proposed by Litman et al. (19) (for details see ref
24). The kinetic parameters derived from phosphate release
measurements in plasma membrane vesicles are summarized
in Table 2.
Vesicle Aggregation Can Hamper Measurement of the
Inhibitory Part of the Pgp ActiVity Profile. The inhibitory
part of the activity profile was easily reached in the ECAR
assay (24). In the phosphate release assay this was more
difficult since the highly concentrated drug solutions used
in the phosphate release assay can lead to drug association
as outlined in Materials and Methods; moreover, vesicle
aggregation can occur as will be shown below.
In the absence of drugs inside-out membrane vesicles
exhibit a negative surface potential, ψ, which prevents their
aggregation. Upon partitioning of positively charged drugs,
the negative surface potential decreases or even disappears
(24, 32), which can lead to vesicle aggregation. To investigate
this phenomenon in more detail three compounds (verapamil,
chlorpromazine, and promazine) with high lipid-water
partition coefficients, Klw (24), and high pKa values were
chosen and 90° light scattering measurements were per-
formed in parallel to the spectroscopic phosphate release
assay. Figure 3A-C displays the raw data of the phosphate
release assay made with plasma membrane vesicles of
MDR1-transfected and wild-type cells in the presence and
absence of vanadate (0.5 mM) and drug. Plasma membrane
vesicles of wild-type cells show some residual vanadate-
sensitive activity in the presence of sodium azide, ouabain,
and EGTA (Figure 3A-C) which is most likely due to a
low concentration of Pgp (2). Nonenzymatic ATP hydrolysis
was not observed.
At high drug concentrations the plasma membrane vesicles
of wild-type and MDR1-transfected cells with and without
vanadate both show a decrease in the optical density (820
nm). The effect increases in the order verapamil (pKa 8.9)
e chlorpromazine (pKa 9.2) < promazine (pKa 9.4). As seen
in Figure 3C a concomitant increase in light scattering
intensity was observed at promazine concentrations, C >
10-4 M. At even higher concentrations, C > 7 × 10-4 M,
light scattering started to increase strongly not only with
concentration but also with time, suggesting the formation
of larger aggregates. As seen in Figure 3A-C the aggregation
phenomenon was independent of the presence of Pgp and
was merely a result of charge neutralization of inside-out
cellular vesicles of wild-type and MDR1-transfected cells
which exhibit approximately the same negative surface
potential (cf. footnote 1 in ref 24). Vesicle aggregation most
likely hampered drug access to the membrane and ATP
binding to the NBDs. Partitioning of electrically neutral drugs
(progesterone, cyclosporin A, and PSC-833) or cationic drugs
with low pKa values (reserpine, glivec, daunorubicin, and
OC144-093) (Figure 2A-D) induced no vesicle aggregation
even at high concentrations (data not shown). Since problems
due to drug association, as well as vesicle aggregation, are
less pronounced at pH 7.0 than at pH 7.4, we chose the lower
pH for the phosphate release assay despite the fact that the
ECAR measurements were performed at pH 7.4.
The Influence of pH on the Kinetic Parameters of Drug-
Stimulated Pgp ActiVity. To investigate the influence of the
pH on Pgp activity we chose three representative examples,
the electrically neutral progesterone and the cationic com-
FIGURE 1: Time dependence of vanadate-sensitive Pgp activity in
plasma membranes from NIH-MDR1-G185 cells in the presence
of verapamil (31.7 μM) and vanadate (0.5 mM). A: Phosphate
release measurements were made under four different conditions:
in the absence of verapamil and vanadate (4), in the presence of
verapamil and in the absence of vanadate (9), in the absence of
verapamil and in the presence of vanadate (3), and in the presence
of verapamil and vanadate (0). B: Vanadate-sensitive Pgp activity
in the presence (9) and in the absence of verapamil (4). Values
are expressed as the mean of three measurements ( SD. The solid
lines are the linear regressions to the data. For further analysis a
single time point measurement (60 min) of Pgp activity was used.
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pounds, promazine (pKa 9.4) and verapamil (pKa 8.9). The
pH dependence of Pgp activity as a function of concentration
was investigated in the range of pH 6.2 to pH 7.4 at 37 °C
using the phosphate release assay (Figure 4A,B). The basal
Pgp activity, V0, does barely change in the pH range
investigated (Figure 4A), which is in good agreement with
previous experiments (33).
For the uncharged progesterone the maximum activity, V1
(Figure 4A), and the concentration of half-maximum activa-
tion, K1 (Figure 4B), were practically identical at two
different pH values. However, for verapamil and promazine
the maximum activity, V1, increased with increasing pH
(Figure 4A) and the concentration of half-maximum activa-
tion, K1, decreased (Figure 4B). This is due to an increase
Table 2: Kinetic Parameters of Pgp Activation for 19 Drugs. The Concentration of Half-Maximum Activation (Inhibition), K1 (K2), and the
Maximum (Minimum) Transporter Activity, V1 (V2), Obtained from Phosphate Release Measurements in Plasma Membrane Vesicles of
NIH-MDR1-G185 Cellsa
no. compound
MWbase
[g/mol] pKac
K1
[μM]
K2
[μM]
V1
[fold]
V2
[fold]
no. of
experiments
1 amitriptyline 277.4 9.4 14.2 ( 0.7 1239.5 ( 110.5 2.3 ( 0.1 1.1 ( 0.2 3
2 chlorpromazine 318.9 9.2 10.5 ( 0.5 125.0 ( 15.0 2.2 ( 0.1 1.2 ( 0.1 2
3 cis-flupenthixol 434.5 7.8 1.8 ( 0.6 28.3 ( 5.8 2.4 ( 0.1 0.3 ( 0.1 3
4 cyclosporin A 1202.6 0.02 ( 0.01 1.5 ( 1.0 0.9 ( 0.1 0.4 ( 0.2 3
5 daunorubicin 527.5 8.4 5.5 ( 1.5 43.5 ( 3.5 1.4 ( 0.1 0.8 ( 0.1 2
6 dibucaineb 343.5 8.5 4.1 ( 0.9 nd 2.9 ( 0.2 nd 4
7 diltiazem 414.5 8.9 6.7 ( 1.3 1678.5 ( 1.5 3.2 ( 0.1 1.0 ( 0.1 2
8 glivec 493.6 8.07 1.2 ( 0.3 241.8 ( 49.4 1.6 ( 0.1 0.10 ( 0.02 2
9 lidocaine 234.3 7.6 1630 ( 70 nd 2.7 ( 0.1 nd 4
10 progesterone 314.4 13.9 ( 0.4 144.7 ( 27.3 3.3 ( 0.2 0.7 ( 0.4 4
11 promazine 284.4 9.42 82.0 ( 10.0 2150 ( 200 2.5 ( 0.1 0.1 ( 0.0 2
12 (R/S)-verapamil 454.6 8.92 1.0 ( 0.3 843.6 ( 159.1 2.5 ( 0.1 1.0 ( 0.4 15
13 reserpine 608.7 6.6 0.2 ( 0.1 1.0 ( 0.2 1.7 ( 0.2 1.0 ( 0.1 2
14 trifluoperazine 407.5 8.09 2.3 ( 0.2 58.3 ( 14.4 2.4 ( 0.2 1.0 ( 0.2 5
15 triflupromazine 352.4 9.1 8.0 ( 2.7 140.0 ( 26.5 2.0 ( 0.1 1.0 ( 0.2 4
16 colchicine 399.4 227.6 ( 20.1 nd 1.7 ( 0.1 nd 2
17 OC144-093 494.7 6.3 0.008 ( 0.002 0.95 ( 0.15 0.9 ( 0.1 0.3 ( 0.1 2
18 PSC-833 1214.6 0.008 ( 0.001 2.6 ( 0.1 0.8 ( 0.1 0.4 ( 0.1 4
19 vinblastine 811.0 7.4 1.6 ( 0.2 40.5 ( 4.5 1.8 ( 0.1 0.9 ( 0.1 2
a Kinetic parameters for the inhibitory part of the Pgp activation profiles, K2 and V2, have to be taken as the estimates because for many compounds
the inhibitory part is affected by vesicle aggregation and drug association appearing at high drug concentrations (discussed in detail in text). b Data
fitted to simple Michaelis-Menten equation. c For references of pKa values see ref 24; the pKa values for OC144-093 and vinblastine are taken
from SciFinder and Merck Index, respectively.
FIGURE 2: Vanadate-sensitive Pgp activity profiles obtained from phosphate release measurements in plasma membrane vesicles of NIH-
MDR1-G185 cells. Measurements were performed at T ) 37 °C and at pH 7.0. A: Chlorpromazine (]), cis-flupenthixol (1), diltiazem
(O), lidocaine (9), promazine (b), and vinblastine (0). B: Amitriptyline (0), progesterone (1), reserpine (2), trifluoperazine (4), and
verapamil (9). C: Daunorubicin (2), dibucaine (9), colchicine (1), glivec (b), and triflupromazine (0). D: Cyclosporin A (9), PSC-833
(2), and OC144-093 (O). Data are expressed as the average of at least two measurements. Solid lines are fits to the modified Michaelis-
Menten equation (eq 1), except for dibucaine, which is fitted to the simple Michaelis-Menten equation (Vsw ) V0 + (Vmax - V0)Csw/(KM
+ Csw), where Vmax is the maximum activity and KM the Michaelis-Menten constant).
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in the fraction of unprotonated drug and, in turn, to an
increase in membrane partitioning and Pgp binding.
ECAR Measurements with Cytotoxic Compounds. The
basal ECAR of NIH-MDR1-G185 cells in pyruvate contain-
ing DMEM flow medium was determined as V0 ) ((1.4 (
0.6) × 107) H+‚cell-1‚s-1 (n ) 74 measurements, passage
number >4). In the absence of pyruvate the value is at least
twice as large as shown previously (2). Figure 5A shows
the stimulation of MDR1-transfected and wild-type cells with
a single concentration of vinblastine (22.9 μM). First, cells
were perfused with drug-free DMEM flow medium until a
stable ECAR was reached. The first two points in Figure
5A correspond to the ECAR at the end of the equilibration
phase (∼1 h) and were taken as basal values (100%). The
ECAR comprises all the metabolic effects of the cell
including basal Pgp activity. Cells were then stimulated for
3 min with vinblastine (hatched bar) during which two ECAR
measurements (first and second stimulation point) were
performed. The second stimulation point indicated as a solid
symbol was used for the evaluation of Pgp activity (24). Cells
were then again flushed with vinblastine-free flow medium.
Nevertheless, the pronounced metabolic down regulation
which had started already during the stimulation phase
continued in wild-type and in transfected cells. Figure 5B
shows the ECAR signals in MDR1-transfected cells as a
function of time for different concentrations of vinblastine,
and Figure 5C shows the evaluation of two different
metabolic effects observed in MDR1-transfected cells. The
upper solid line is the fit to the modified Michaelis-Menten
equation (eq 1) and represents Pgp activation. The estimated
concentration of half-maximum activation is somewhat
higher than that for plasma membrane vesicles. The lower
line is a fit to a Hill equation with an estimated half-
FIGURE 3: The amount of ATP hydrolyzed in plasma membrane
vesicles of wild-type (open symbols, 0, O)) and NIH-MDR1-G185
cells (filled symbols, 9, b) with increasing concentration of
verapamil (A), chlorpromazine (B), and promazine (C). Circles (O,
b) refer to measurements in the presence of 0.5 mM vanadate and
squares (0, 9) in the absence of 0.5 mM vanadate. The results are
expressed as optical densities at 820 nm (A-C, labels on left-hand
side). The solid lines are fits to the modified Michaelis-Menten
equation (eq 1). Labels at right-hand side in (C): 90° light scattering
intensity at 550 nm as function of increasing concentration of
promazine in the membrane-containing phosphate release assay
buffer in the absence of 0.5 mM vanadate (1) and in the presence
of 0.5 mM vanadate (2). Light scattering intensities are normalized
to the light scattering intensity of the sample without promazine.
Data were fitted to an exponential curve. All measurements were
performed at T ) 37 °C and pH 7.0.
FIGURE 4: The effect of pH. A: Basal Pgp activity, V0 (0) (labels
at the right-hand side), and maximum Pgp activity, V1 (labels at
left-hand side), for verapamil (9), promazine (b), and progesterone
(1) as a function of pH. B: Concentration of half-maximum Pgp
activation, K1, as a function of pH. Phosphate release measurements
were performed in either 25 mM Tris-HCl or 25 mM Hepes-KOH
buffer at 37 °C. The pH of phosphate release assay buffer was
adjusted taking into account the temperature coefficient of the
buffer. Data are expressed as the average of two to four measure-
ments. Solid lines are linear regressions to the data. For data
evaluation the average basal activity value in the pH range (pH
6.2 to pH 7.4) was used.
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maximum inhibitory constant, IC50 ≈ 2.9 μM, and may
represent the inhibition of proton excretion by microtubules
(34).
In wild-type cells (Figure 5D) low vinblastine concentra-
tions caused a decrease in the ECAR which may again be
attributed to the inhibition of proton excretion by microtu-
bules starting, however, at even lower concentrations than
in MDR1-transfected cells. Higher concentrations of vin-
blastine induced a strong continuous acidification which
seems to be superimposed to the decrease in acidification at
low concentrations. This strong continuous ECAR increase
is typical for cell poisoning. Except daunorubicin, the other
drugs measured so far showed no significant metabolic
effects in wild-type cells (24).
DISCUSSION
We measured the activity of Pgp in inside-out vesicles
formed from plasma membranes of mouse embryo fibroblasts
(NIH-MDR1-G185) by monitoring the phosphate release rate
for comparison with the Pgp activity measured previously
in the corresponding living cells by monitoring the ECAR
(24). For the present analysis Pgp was stimulated in a
concentration-dependent manner with 19 different drugs,
including cytotoxic compounds. Data were evaluated with a
model proposed by Litman et al. (19) which assumes basal
Pgp activity in the absence of drugs, activation of Pgp at
low drug concentrations due to drug binding to a first binding
region located in the cytosolic membrane leaflet, and
inhibition at high drug concentrations due to drug binding
to a second binding region (cf. eq 1). The large set of kinetic
parameters is then used to get better insight into the relation
between drug binding to the TMDs and ATP hydrolysis at
the NBDs.
Comparison of the Kinetic Parameters from Plasma
Membrane Vesicles and LiVing Cells. The comparison of Pgp
activity in inside-out plasma membrane vesicles and living
cells is shown in Figure 6A,B. The measurements in intact
cells were performed at pH 7.4 (24), whereas the present
phosphate release measurements were performed at pH 7.0.
The slightly more acidic conditions were chosen to minimize
drug association (cf. Materials and Methods) and vesicle
aggregation (cf. Results). The basal activity of Pgp is
practically not affected by the small pH difference as seen
in Figure 4A which is in good agreement with previous
investigations (33).
For the uncharged compounds or compounds with low
ionization constants (pKa e 8.5) (open symbols) the con-
centrations of half-maximum actiVation, K1, are identical
within error limits, with the exception of three outliers,
daunorubicin (5), lidocaine (9), and progesterone (10), which
showed higher K1 values in the phosphate release assay than
expected. Daunorubicin and progesterone self-associate at
high concentrations. Self-association may also partially
explain the large divergence of published concentrations of
half-maximum activation for daunorubicin (19, 33, 35).
Daunorubicin moreover induces metabolic effects in living
NIH3T3 and NIH-MDR1-G185 cells above 10 μM (24)
which coincide with the concentration range of Pgp activity
in plasma membrane vesicles. The hydrophilic local anes-
thetic, lidocaine, had to be applied up to high concentration
(Csw > 1 mM), which exhausted the buffer capacity of the
FIGURE 5: Time dependent ECAR of NIH-MDR1-G185 and
NIH3T3 cells in response to increasing concentrations of vinblastine
measured with a Cytosensor microphysiometer. A: ECAR of NIH-
MDR1-G185 (squares) and NIH3T3 cells (circles) stimulated with
22.9 μM vinblastine as a function of time. The hatched box indicates
the 3 min vinblastine stimulation period which comprises two
measurement points, where the second measurement point is
indicated as a filled symbol and is used for evaluation of Pgp
activity if not otherwise stated. After the 3 min drug stimulation
period cells were flushed again with drug-free flow medium. B:
Time dependent ECAR of NIH-MDR1-G185 cells with increasing
concentration of vinblastine (same type of measurement as in (A)
but performed at different concentrations). C: ECAR of NIH-
MDR1-G185 cells as function of vinblastine concentration. The
second measurement point under vinblastine stimulation (9) most
likely reflects Pgp activity and was fitted to a modified Michaelis-
Menten equation (eq 1). The fit takes into account an estimated
value for vinblastine adsorption to the Cytosensor tubing and
debubbler membranes. Open squares (0) represent the fourth
measurement point (indicated by arrow in (A)) and are fitted to a
Hill equation. D: Time dependent ECAR of NIH3T3 cells with
increasing concentration of vinblastine. The second measuring point
is indicated as filled circles (b). Thirty minute time bars are
included.
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phosphate release buffer and led to an acidification of the
solution (pH 6.83). As a result the lipid-water partition
coefficient, Klw, of the cationic compound decreased and the
aqueous concentration required for half-maximum Pgp
activation, K1, increased concomitantly.
In the case of the highly charged compounds (pKa > 8.5)
(filled circles) the concentrations of half-maximum activation,
K1, were generally somewhat higher in the phosphate release
assay (pH 7.0 at 37 °C) than in the ECAR assay (pH 7.4 at
37 °C), since the lipid-water partition coefficient, Klw, was
lower and the concentration for half-maximum Pgp activa-
tion, K1, was higher. To illustrate the effect of the pH the
K1 values for verapamil and promazine obtained from
phosphate release measurements performed at pH 7.4 (Figure
4B) were included in Figure 6A (filled triangles). As
expected the K1 values of the charged compounds moved to
lower values and were in excellent agreement with those
obtained by ECAR measurements (pH 7.4). In the pH range
investigated the effect of pH on the activity of Pgp can
therefore be attributed entirely to the pH dependence of the
lipid-water partition coefficients, Klw. Taking into account
the possible artifacts and the pH difference, the concentra-
tions of half-maximum activation obtained in plasma mem-
brane vesicles and living cells are in good agreement over
the broad range investigated (K1 ∼ 10-8 M for cyclosporin
A to K1 ∼ 10-3 M for lidocaine) (Figure 6A). The fact that
exogenous substrates (e.g., drugs) approach Pgp from the
extracellular side in living cells and from the cytosolic side
in inside-out cellular membrane vesicles does not play a role,
as long as the molecules can deprotonate and cross the bilayer
in their uncharged form (2). The membrane concentration
of substrates (which is much higher than the aqueous
concentration) can thus be assumed to be identical in the
two different systems.
Figure 6B shows a comparison of the maximum activities,
V1, expressed as relative values ([%] of the basal value). A
good linear correlation is observed, whereby promazine (11)
is an outlier. In the phosphate release assay the V1 value of
promazine was too low due to vesicle aggregation (cf. Figure
3). In the ECAR assay the V2 value was too low due to an
acidification of the medium at high promazine concentrations
which led in turn to a too high V1 value. Data evaluation
using simple Michaelis-Menten kinetics (neglecting the
inhibitory part) yields comparable V1 values (see filled square
in Figure 6B). Overall, the relative rates of Pgp activity, V1,
are higher in plasma membrane vesicles than in living NIH-
MDR1-G185 cells since the basal phosphate release rates
are lower than the basal ECARs which include basal Pgp
activity and all other metabolic processes of the cell.
Pgp activity expressed as phosphate released per total
protein concentration and time was determined as V0 ) (12.3
( 1.3) nmol‚mg-1‚min-1 (n ≈ 126). Taking into account an
average number of (1.9 ( 0.3) × 108 cells/mL, a molecular
weight of 170 kDa, and 1.95 × 106 molecules of Pgp per
cell, the basal and maximum verapamil-stimulated turnover
number was calculated as 3.4 s-1 and 5.2 s-1, respectively.
Ambudkar et al. (27) and Al-Shawi et al. (1) obtained slightly
lower basal (2.9 s-1 and 2.75 s-1, respectively) and higher
verapamil-stimulated values (9.9 s-1 and 8.8 s-1,2 respec-
tively). The differences may be due to the different lipid
composition and the different lateral packing density of the
membranes.
In living cells the ECAR was measured in the presence
of pyruvate which reduces the basal value by (50-60)%.
The basal ECAR obtained with the Cytosensor was in the
absence and presence of pyruvate ((3.0 ( 0.6) × 107)
H+‚cell-1‚s-1 and ((1.4 ( 0.6) × 107) H+‚cell-1‚s-1,
respectively (2). The drug-stimulated ECAR was linearly
related to the basal value at low acidification rates. However,
it flattened out at high basal acidification rates (Figure 93 in
ref 2). Since the buffer capacity of the medium was low,
the solution acidified, which led in turn to a decrease in the
ECAR (36, 37). This negative feedback was recently
corroborated by 13C NMR measurements using 13C-labeled
glucose (unpublished result, G. Kohler, P. A¨a¨nismaa, A.
Seelig, and J. Seelig). The maximum verapamil-stimulated
turnover number measured with the Cytosensor in the
2 The turnover number corresponds to the measured maximum Pgp
activity for verapamil taken from Figure 1 in ref 1.
3 Verapamil-induced and basal ECAR in buffer with glucose without
pyruvate (g+) is an average of data obtained with cells of low and
high passage numbers whereas the other data points were obtained with
cells of high passage numbers. If only data from high passage numbers
were used, the value was higher (2).
FIGURE 6: Comparison of kinetic data obtained with living cells
(24) and inside-out membrane vesicles of NIH-MDR1-G185 cells.
A: The concentration of half-maximum activation, K1. B: Maxi-
mum Pgp activity, V1. Phosphate release and ECAR assay,
respectively, were performed at T ) 37 °C, pH 7.0 and T ) 37 °C,
pH 7.4. Open circles (O) represent drugs with pKa e 8.5, filled
circles (b) drugs with pKa > 8.5. Triangles (2) represent values
obtained with the phosphate release assay performed at pH 7.4.
Data are expressed as the average of 2-15 measurements. The solid
line in (A) is the diagonal to guide the eye, in (B) it is a linear fit
without promazine (11). The Pgp activation profile for dibucaine
(6) obtained from Cytosensor measurements was fitted to the simple
Michaelis-Menten equation. In (B) the Pgp activation profiles for
promazine (9) obtained from the Cytosensor and phosphate release
assay, respectively, are also fitted to the simple Michaelis-Menten
equation for comparison.
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presence of pyruvate (4.3 s-1) was in close agreement with
the number obtained with the phosphate release assay (5.2
s-1). The effective value estimated from ECAR measure-
ments in the absence of pyruvate must therefore be at least
twice as large as supported by NMR measurements.
The Maximum Rate of ATP Hydrolysis by Pgp Depends
on the Binding Affinity of the Drug from Water to the
Transporter. To investigate the interplay between ATP
hydrolysis at the NBDs and substrate binding and release at
the TMDs, the maximum rate of Pgp activity, V1 (Log scale),
measured in inside-out membrane vesicles (at pH 7.0) and
in living cells (at pH 7.4) was plotted as a function of the
free energy of binding of the drug from the aqueous phase
to the activating binding region of the transporter, ΔGtw(1)
0
(Figure 7A,B). The values of ΔGtw(1)0 were derived from the
concentration of half-maximum activation, K1, as discussed
previously (24). A linear correlation is observed which shows
that the rate of phosphate release (Log scale) decreases with
decreasing free energy of binding of the drug from water to
the transporter, ΔGtw(1)
0 (or increasing binding affinity of
the drug from water to the transporter).
A similar result was obtained previously by plotting the
rate of Pgp activity either vs the free energy of binding from
the lipid membrane to the transporter, ΔGtl(1)
0 (17), or vs the
estimated free energy of hydrogen bond formation between
substrate and transporter (10, 38). Since the value of ΔGlw0
is rather constant for the majority of compounds, the two
free energies, ΔGtl(1)
0
and ΔGtw(1)
0
, tend to be linearly
correlated (24). Litman et al. (19) have shown that the rate
of intrinsic drug transport decreases with increasing molec-
ular weight, which often correlates with the number of
hydrogen bond acceptor groups in Pgp substrates and thus
with the free energy, ΔGtl(1)
0
. Exceptions are the so-called
third generation inhibitors such as OC144-093 (cf. ref 17)
which show a very high affinity to the lipid membrane (E.
Gatlik and A. Seelig, unpublished results) but only a
moderate affinity from the lipid membrane to the transporter
(ΔGlw0 < ΔGtl(1)0 ). The classical “inhibitor” cyclosporin A
exhibits in contrast an intermediate affinity for the lipid
membrane and a high affinity from the lipid membrane to
the transporter (ΔGlw0 > ΔGtl(1)0 ). Since the free energy of
binding from water to the transporter, ΔGtw(1)
0
, which is the
sum of ΔGlw
0
and ΔGtl(1)
0
, is large for both, they are both
effective so-called inhibitors.
The linear decrease of the rate of ATP hydrolysis (Log
scale) with increasing binding affinity of the drug from water
to the transporter (Figure 7A,B) suggests that drug release
in the extracellular leaflet is the rate-determining step. This
is consistent with the fact that high drug concentrations,
which impede drug release, reduce the rate of ATP hydroly-
sis. It is also consistent with the fact that compounds such
as cyclosporin A and OC144-093 with a high affinity from
water to the transporter and thus a slow release from the
TMDs function as inhibitors or modulators of Pgp. ATP
hydrolysis to reset Pgp for a new transport cycle thus seems
to start only after drug unloading.
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The Rate of P-Glycoprotein Activation Depends on the Metabolic State of the Cell†
Ewa Gatlik-Landwojtowicz, Pa¨ivi A¨a¨nismaa, and Anna Seelig*
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ABSTRACT: P-glycoprotein ATPase activity has been studied almost exclusively by measuring inorganic
phosphate release from inside-out cellular vesicles. We have recently proposed a new method based on
measurements of the extracellular acidification rate (ECAR) of living cells with a Cytosensor
microphysiometer. This method allows for systematic investigation of the various factors influencing
P-glycoprotein activation in living cells. Basal metabolic rates or ECARs of different MDR1-transfected
cell lines were compared with those of the Mdr1a-/-1b-/- knockout, MRP1-transfected, and corresponding
wild-type cell lines. Basal ECARs of all cells were on the order of 107 protons/cell/s, whereby those of
genetically modified cells were on average (over all cell lines) slightly lower than those of wild-type
cells. The expression level of P-glycoprotein in MDR1-transfected cells had no influence on basal ECARs.
Verapamil-induced ECARs were specific for MDR1-transfected cells and increased with the expression
level of P-glycoprotein. Moreover, ECARs were dependent on the metabolic state of the cell and were
(2.8 ( 1.2) × 106 and (8.0 ( 1.5) × 106 protons/cell/s in glucose-deficient and glucose-fed NIH-MDR-
G185 cells, respectively, after verapamil (10 μM) stimulation. The ECARs were practically identical to
the rates of lactate extrusion and thus reflect the rates of ATP synthesis via glycolysis. Taking into account
the number of P-glycoprotein molecules per cell, the rate of ATP hydrolysis in inside-out vesicles of the
same cells was determined as (9.2 ( 1.5) × 106 phosphates/cell/s, in good agreement with the rate of
ATP synthesized in glucose-fed cells. The energy required for P-glycoprotein activation relatiVe to the
basal metabolic energy was twice as large in glucose-deficient as in glucose-fed cells, suggesting cellular
protection by P-glycoprotein even under conditions of starvation.
P-glycoprotein (Pgp),1 a product of the multidrug resis-
tance gene, MDR1, is an efflux transporter with broad
substrate specificity. It binds a large variety of exogenous
and endogenous toxic compounds within the plasma mem-
brane and exports them to the extracellular environment (1-
3). Transport of substrates by Pgp out of the cell is driven
by metabolic energy. Per substrate transported one to two
(or even three) molecules of ATP are hydrolyzed (4-8). The
first molecule is proposed to drive drug transport and the
second to reset the conformation of the transporter (7).
However, even in the absence of exogenous substrates Pgp
shows basal ATPase activity in plasma membrane vesicles
(9-11) as well as in proteoliposomes (12, 13). Basal Pgp
activity was suggested to arise either from transport of
endogenous lipids (14, 15) or from uncoupled ATPase
activity (16, 17).
Pgp activation can be measured with reconstituted pro-
teoliposomes or inside-out membrane vesicles of MDR1-
transfected cells by monitoring ATP hydrolysis via either
inorganic phosphate release (8, 9, 13) or ADP formation (10,
18).
In intact MDR1-transfected cells Pgp activation can be
analyzed noninvasively via extracellular proton secretion. As
demonstrated, extracellular acidification rates, ECARs, of
living cells can be quantified with a silicon-based potentio-
metric sensor (Cytosensor microphysiometer) (19), and the
first systematic measurement of the effect of drugs on living
MDR1-transfected cells has been published recently (20).
Plots of the ECAR as a function of the logarithm of the drug
concentration were bell-shaped, indicating activation at low
and inhibition at high drug concentrations, and were con-
sistent with Pgp activation/inhibition profiles measured
previously by means of phosphate release measurements in
inverted membrane vesicles for the same drugs (9). The
concentrations of half-maximum activation for the different
compounds investigated were practically identical for the two
methods. Furthermore, a linear correlation between the rate
of extracellular proton release and the intracellular phosphate
release was obtained, indicating the quantitative equivalence
of assays with plasma membrane vesicles and liVing cells
(20).
Previous measurements of extracellular pH changes by
conventional methods have led to conflicting results, arguing
either in favor of (21, 22) or against extracellular acidification
(21, 23). The bell-shaped activation/inhibition curves mea-
sured with the Cytosensor can partly explain these discrep-
ancies since both activation and inhibition of extracellular
acidification can be induced depending on the drug concen-
tration employed.
† Supported by the Swiss National Science Foundation, Grant No.
31-58800.99.
* To whom correspondence should be addressed. Phone: +41-61
267 22 06. Fax: +41-61 267 21 89. E-mail: Anna.Seelig@unibas.ch.
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Extracellular acidification reflects, in some general way,
the oVerall metabolism of the cell (24). In contrast, the ATP
hydrolysis assay involving proteoliposomes or inside-out
vesicles is focused on a single metabolic event, analyzed
without any relation to the metabolic state of the intact cell.
Three general questions then emerge in this context. (i) To
what extent is the metabolic activity of a living cell
influenced by the expression level of Pgp? Whether Pgp
overexpression influences the basal cellular metabolism is
discussed controversially in the literature. Intracellular al-
kalization in cells overexpressing Pgp in comparison to wild-
type cells has been observed by some investigators (21, 25-
30), whereas neither intracellular (23, 31-33) nor extracellular
basal pH changes were observed by others (23, 32). Also
no difference was found between cells overexpressing the
multidrug resistance-associated protein, MRP1, and wild-
type cells (34). (ii) How do variations of the metabolic state
of the cell, such as starvation, regulate, in turn, the drug-
induced activation of Pgp? ATP concentrations used in Pgp
activation assays with inside-out membrane vesicles are
rather high (3-7.5 mM) (9, 10) since the Michaelis-Menten
constant of ATP is Km ) 0.33 ( 0.04 mM (10). In living
cells, ATP concentrations are in a similar range or even
higher under optimal conditions; however, they can vary with
the metabolic state of the cell. Moreover, ATP has to be
shared by different energy-dependent proteins. It is therefore
of interest to test how the process of cellular detoxification
by Pgp changes with the metabolic state of the cell. (iii) How
is the general mechanism of extracellular acidification, under
conditions of Pgp activation, linked to the specific process
of Pgp-induced ATP hydrolysis?
The aim of the present work is therefore (i) to clarify the
influence of the expression level of Pgp on basal metabolism,
(ii) to measure the basal and verapamil-induced ECARs in
living, MDR1-transfected cells under different metabolic
conditions by means of a Cytosensor, (iii) to identify the
export pathways of the acidic metabolites, and (iv) to
compare the different ECARs obtained in living cells with
the rate of Pgp ATP hydrolysis in inside-out vesicles of the
same cells. Basal and verapamil-stimulated ECARs were
assessed for different MDR1-transfected cell lines (MDR1-
transfected pig kidney cells LLC-MDR1 (35), mouse embryo
fibroblasts NIH-MDR-G185 (36)), for three other genetically
modified cell lines (LLC-PK1 transfected with the human
MRP1 gene (37), cells 77.1 and 88.6, lacking functional Pgp,
obtained from Mdr1a-/-1b-/- mouse embryos (38)), and for
the corresponding wild-type cell lines. In addition, special
attention was given to the number of passages the various
cell types had experienced since this turned out to be a further
parameter influencing the basal extracellular acidification
rates. The experiments will provide new insight into the
mechanism of Pgp activation in living cells.
MATERIALS AND METHODS
Compounds. Colchicine, phloretin, and 2-deoxy-D-glucose
were obtained from Fluka (Buchs, Switzerland), 4,4′-
diisothiocyanatostilbene-2,2′-disulfonic acid, DIDS, vera-
pamil, vincristine, and sodium pyruvate from Sigma (Stein-
heim, Germany), and lactate reagents and lactate standard
solutions (Cat. Nos. 735-10 and 826-10, respectively) from
Sigma Diagnostics Inc. (St. Louis, MO). The other chemicals
were from Fluka, Merck, or Sigma. Complete EDTA-free
protease inhibitor cocktail tablets were obtained from Roche
Diagnostics (Mannheim, Germany), 1,4-dithiol-DL-threit(ol),
DTT, was from Applichem (Darmstadt, Germany), and BCA
protein assay reagents were purchased from Pierce (Rock-
ford, IL). DMEM (liquid and dry, Cat. Nos. 21969 and
52100, respectively) without pyruvate, IMDM medium, and
other compounds required for cell culture such as fetal bovine
serum, FBS, bovine serum albumin, BSA, and antibiotics
were from Gibco-BRL (Basel, Switzerland). P-glycoprotein
antibody, MRK16, and unspecific antibody, IgG2ak, were
from Kamiya Biomedical Co. (Seattle, WA), and the IgG2a
FITC-labeled antibody was from PharMingen (San Diego,
CA).
Cell Lines. The mouse embryo fibroblast wild-type lines
(2ac.1 and 2ac.2) and lines lacking functional Pgp (77.1 and
88.6) from Mdr1a-/-1b-/- mouse embryos were generously
provided by Dr. A. H. Schinkel (The Netherlands Cancer
Institute, Amsterdam, The Netherlands), the pig kidney
epithelial cell lines LLC-PK1, LLC-PK1 transfected with the
human MDR1 gene (LLC-MDR1), and LLC-PK1 transfected
with the human MRP1 gene (LLC-MRP1) by Dr. P. Borst
(The Netherlands Cancer Institute), and the mouse embryo
fibroblast lines NIH3T3 and NIH3T3 transfected with the
human MDR1 gene (NIH-MDR-G185) by Dr. M. M.
Gottesman (The National Institutes of Health, Bethesda,
MD).
Cell Culture. All cell lines were grown under the same
conditions in monolayer culture in DMEM medium (4.5 g/L
glucose) supplemented with fetal bovine serum (10% v/v),
penicillin (100 units/mL), streptomycin (100 μg/mL) and
L-glutamine (146 mg/L) at 37 °C in an atmosphere containing
CO2 (5%). NIH-MDR-G185 and LLC-MDR1/V cells were
grown in the presence of colchicine (0.15 μM) and vincris-
tine, V (0.32 μM), respectively. The cells were passaged
every 3-4 days. For quantitative comparisons cells with
identical passage numbers were used. The cells were counted
with a hemocytometer.
Detection of Pgp Expression. The expression level of Pgp
in wild-type (LLC-PK1 and NIH3T3) and transfected (LLC-
MDR1, LLC-MDR1/V, and NIH-MDR-G185) cells was
estimated using the monoclonal antibody MRK16, which
recognizes only human Pgp. Aliquots of (2-3) × 105 cells
were incubated in IMDM containing 5% FBS at 37 °C for
30 min in the presence of MRK16 or the unspecific antibody
IgG2ak. After washing, the cells were reincubated at 37 °C
for 30 min in the dark, in the presence of the fluorescent
FITC-labeled antibody. The cells were resuspended in
phosphate-buffered saline (containing 1% BSA), and the
fluorescence intensities for 10000 events per cell sample were
analyzed using a FACSort flow cytometer (Becktron, Dick-
inson) and the software Win MDI for data analysis.
Cytosensor Measurement. ECARs of intact cells were
measured using an eight-channel Cytosensor microphysi-
ometer (Molecular Devices, Menlo Park, CA) described
elsewhere in detail (20, 39). The cells were seeded into 12
mm diameter polycarbonate cell capsule cups at a density
of 3 × 105 cells per cup in culture medium. Usually the cells
were incubated overnight at 37 °C before the measurement
(20). This protocol was followed for measurements of relative
ECARs (data shown in Figures 4, 7, and 8). For quantifica-
tion of ECARs (data shown in Figures 2, 3, 5, 6, and 9) the
cells were prepared 4 h prior to the Cytosensor experiment,
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since the number of cells seeded remained approximately
constant within this period of time. After incubation, capsule
spacers and inserts were put into the cups, and the cells were
thus located between two polycarbonate membranes which
together with the spacer ring form a tight chamber of 2.8
μL with fluid contact to the potentiometric sensor chip.
Measurements were performed at 37 °C. The acidification
rates were measured during periodic interruptions of the flow
of the medium through the flow chambers (for details see
ref 20). Each pump cycle lasted 2 min, during which time
the pumps were on for 1 min 40 s and were then switched
off for the remaining 20 s. During the pump-off period (from
1 min 45 s to 1 min 58 s) in each pump cycle the rate of
extracellular pH changes were calculated by the Cytosoft
program. The ECAR was determined as the slope of a linear
least-squares fit to pH versus time data (μV/s), where -1
μV/s corresponds to an acidification rate of 0.001 pH unit/
min at pH 7.4. After a constant acidification rate was reached
(∼60-70 min), the flow medium was replaced by drug-
containing medium. The cells were exposed to a 40 s pulse
of a drug. The flow was then stopped, and the acidification
rate was measured for 13 s. Perfusion with the drug solution
was continued for another 2 min (the total drug perfusion
interval was thus 160 s), and the ECAR was measured again
(see ref 20, Figure 1). The acidification rate was normalized
to a basal acidification (defined as 100%) averaged over the
two pump cycles before drug addition. The actual cellular
response is given either in percentage over the basal activity
or in absolute values of protons per cell, per second (H+/
cell/s).
Flow Medium and Buffer. The flow medium was prepared
from the commercially available dry powder DMEM medium
lacking sodium bicarbonate to have a low buffer capacity
and to avoid formation of bubbles during the measurement.
To preserve osmotic balance, sodium bicarbonate was
replaced by sodium chloride (0.7 g of NaCl instead of 1 g
of NaHCO3). To adapt the cells to the conditions required
for glucose deprivation and quantitative experiments, the flow
medium was exchanged for flow buffer containing CaCl2
(0.3 mM), MgCl2 (0.6 mM), KH2PO4 (0.5 mM), KCl (3
mM), Na2HPO4 (0.5 mM), and NaCl (130 mM), with glucose
(10 mM), bufferg+, glucose and sodium pyruvate (1 mM),
bufferg+p+, no glucose but pyruvate, bufferg-p+, or neither
glucose nor pyruvate, bufferg-p-. At the beginning of a
measurement the pH of the solution was always adjusted to
7.4 at room temperature.
Quantification of Acid Export. To quantify the number of
protons excreted by the cells within a certain time interval,
the buffer capacity, , and the number of cells in a flow
chamber (V ) 2.8 μL) have to be known. For flow buffer at
pH 7.4 containing KH2PO4 (0.5 mM) and Na2HPO4 (0.5 mM)
the buffer capacity was calculated according to Owicki (24)
as  ) 0.40 mM. For the phosphate salts we used a pKa of
6.83 (6.865 at 25 °C) (40), which is in agreement with a
value measured in our laboratory (X. Li Blatter, unpublished
results) instead of the pKa of 6.76 at 37 °C used previously
(20, 24). The buffer capacity of the DMEM flow medium is
 ) 0.56 mM, calculated as the sum of the buffer capacities
of phosphate salts (0.91 mM) and amino acids, in particular
glutamine (4 mM), histidine (0.2 mM), and cysteine (0.4
mM).
Due to the space limitation by the spacer, the number of
cells in the measuring chamber, which give rise to the ECAR
recorded by the sensor chip, corresponds to about 25% of
the total cells seeded, that is Nc ) 0.75 × 105 cells, provided
the cells are equally distributed in the capsule cup. Each of
the sensors was calibrated at 37 °C with pH standard buffer
solutions (Schott Glas, Mainz, Germany) within a range of
pH of 6.81-8.87. According to the calibration, cal ) 61.0
( 1.1 mV corresponds to 1 pH unit. The ECARs (μV/s)
recorded were transformed to protons released per cell per
second as follows:
where NA is the Avogadro number. Units are given in
parentheses.
Determination of Lactate Concentration. Total lactate
production by NIH3T3 and NIH-MDR-G185 cells during
basal and verapamil-induced metabolic rates was determined
using a standard lactate spectrophotometric assay based on
lactate oxidase and peroxidase activity (Sigma, Cat. No. 735-
10, St. Louis, MO). The cells from 17-20 passages (9-10
weeks) were prepared as described before. The cells were
perfused for ∼1 h in the Cytosensor with bufferg+. Next,
the cells were stimulated continuously for another 1 h with
verapamil (6 μM) containing bufferg+. The phosphate buffer
leaving the Cytosensor chambers was collected, condensed
by lyophilization, diluted 15 times with water, and assayed
using the protocol provided by the lactic acid assay kit
obtained from Sigma (which is adapted with minor changes
from ref 41). The number of lactate molecules produced per
cell per second were calculated taking into account the total
number of cells (3 × 105) placed on the capsule cup and an
average flow rate of 83 μL/min, including pump-on and
pump-off periods. In contrast to ECAR measurements where
only about 25% of the cells are in contact with the sensor
chip, all cells in the sensor chamber contribute to the
acidification of the waste buffer leaving the sensor chamber.
Plasma Membrane Vesicle Preparation. The cell mem-
branes were prepared as described previously (42) with some
modifications. Briefly, cells washed once with PBS buffer
were scraped into ice-cold PBS, pH 7.0, supplemented with
protease inhibitors (1 tablet/50 mL of PBS). Next the cells
were washed with hypotonic lysis buffer (10 mM Tris-HCl,
pH 7.5, 10 mM NaCl, 1 mM MgCl2, 1 protease inhibitor
cocktail tablet/50 mL) by centrifugation at 2100gmax for 10
min at 4 °C. The pellet was resuspended in lysis buffer (5
mL per each of four 15 cm dishes) and was then frozen
rapidly in dry ice. The frozen cell suspension was stored at
-80 °C until later use. The cell suspension was thawed at
room temperature and was then incubated on ice 30-45 min
prior to the disruption of cells with a “One Shot” cell
disrupter (Constant Systems Ltd., Warwickshire, U.K.) at
400 bar. The cell lysate was diluted 1:1 with ice cold isotonic
buffer (10 mM Tris-HCl, pH 7.4, 250 mM sucrose, 50 mM
N-methyl-D-glucamine, NMDG, 1 protease inhibitor cocktail
tablet/50 mL buffer), and the unbroken cells and nuclei were
precipitated by centrifugation at 800gmax for 10 min at 4 °C.
Subsequently mitochondria were removed by centrifugation
at 6000gmax for 10 min at 4 °C, and in the final centrifugation
(100000gmax, 1 h, 4 °C) the crude membranes were pelleted.
ECAR (H+/cell/s) )
[ECAR (V/s)][ (M)][V (L)]NA/[cal (V)]Nc
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The pellet was resuspended with isotonic buffer, homog-
enized by aspiration through a 23-gauge syringe, and stored
at -80 °C until use. The protein content of the membrane
vesicles (9-10 mg/mL) was determined by BCA protein
assay using bovine serum albumin as a standard.
ATPase ActiVation Assay. The P-glycoprotein-associated
ATPase activity in plasma membrane vesicles was measured
as described previously (42) with an adjustment to the assay
carried out in a 96-well microtiter plate, with a reaction
volume of 40 μL/well. The membrane suspension (5-13 μg
of protein) was first incubated for 5 min at 37 °C with
ATPase assay buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NMDG, 5 mM sodium azide, 1 mM EGTA, 1 mM ouabain,
2 mM DTT, and 10 mM MgCl2) with or without 0.3 mM
sodium vanadate. The reaction mixture was then incubated
for 3 min at 37 °C with 5 μL of verapamil stock solution
(80 μM in water, containing 5% DMSO). The final verapamil
concentration was 10 μM and the final DMSO concentration
was 0.625% (v/v). The reaction was initiated by addition of
ATP solution (final concentration 5 mM in 40 μL). After
20 min of incubation at 37 °C the reaction was stopped by
addition of 30 μL of 10% (w/v) SDS. For the estimation of
released inorganic phosphate (Pi) 250 μL of ice-cold medium
(0.2% (w/v) ammonium molybdate, 1.3% (v/v) sulfuric acid,
2.3% (w/v) trichloroacetic acid, and freshly prepared 1% (w/
v) ascorbic acid) was added to each well. After 100 min of
incubation at room temperature the absorbance at 820 nm
was measured using a Spectramax M2 microplate reader
(Molecular Devices, Sunnyvale, CA). Control measurements
were performed with the appropriate DMSO concentrations.
Error Calculations. The error bars given in Figures 2, 3,
and 5-9 correspond to standard deviations, SDs. The
statistical significance of the data in Figure 6 was calculated
with the Student’s t test.
RESULTS
Expression LeVel of Pgp in MDR1-Transfected Cell Lines.
The level of Pgp expression in MDR1-transfected cells (LLC-
MDR1, LLC-MDR1/V, and NIH-MDR-G185) and the cor-
responding wild-type cells (LLC-PK1 and NIH3T3) was
studied by FACS using the monoclonal antibody MRK16
and a fluorescent, FITC-labeled second antibody. Figure 1
displays the cell count as a function of the relative fluores-
cence intensities (logarithmic scale) for the different cell lines
studied. Cells overexpressing human Pgp (lines 1, 2, and 4)
exhibit distinctly higher fluorescence intensity than wild-
type cells (lines 3 and 5). Whereas LLC-MDR1/V cells
grown in the presence of vincristine (line 1) and NIH-MDR-
G185 grown in the presence of colchicine (line 4) show one
population at high fluorescence intensity, LLC-MDR1 cells
grown in the absence of vincristine show two populations,
the first one at low (∼25% of the cells) and the second one
at high fluorescence (∼75% of the cells) intensity. The
content of human Pgp in the whole cell population was
expressed as the ratio of the median fluorescence intensities
(MFIs) of MRK16-labeled cells and isotype control IgG2a-
labeled cells. It increases in the order wild-type cells (MFI
) 1) < LLC-MDR1 (MFI ) 23) < LLC-MDR1/V (MFI )
38) < NIH-MDR-G185 (MFI ) 79). The expression level
of endogenous Pgp in wild-type (2ac.1, 2ac.2, NIH3T3 (38),
LLC-PK1 (43)), Mdr1a-/-1b-/- knockout (38), and LLC-
MRP1 (37) cells has been estimated previously by means
of Western blot analysis and was not further analyzed. The
expression level of Pgp thus increases in the order
Mdr1a-/-1b-/- knockout cells (77.1, 88.6) < wild-type cells
(2ac.1, 2ac.2, LLC-PK1, NIH3T3) ≈ LLC-MRP1 < LLC-
MDR1 < LLC-MDR1/V < NIH-MDR-G185. Experiments
were performed with cells of higher passage number (pn >
4). In the following we assume that the expression level of
Pgp does not change with the passage number in the range
of 2-20 passages after defreezing.
Basal ECARs of the Different Genetically Modified Cell
Lines. ECARs were monitored by means of a Cytosensor
microphysiometer with four or eight parallel measuring
chambers. Each chamber contained a potentiometric sensor
chip measuring the extracellular acidification rate (μV/s)
during periodic interruptions of the flow of the medium
through the flow chambers (19). At 61 mV/pH unit and
taking into account the buffer capacity, , of the flow
medium, the net flow of protons per second per cell was
calculated (cf. Materials and Methods).
In our previous investigations MEM or DMEM was used
as the flow medium to measure Pgp activation (20).
However, since the effect of nutrients on the Pgp-induced
cell activity was to be studied, the present measurements
were made with simple buffer solutions. We first compared
the basal ECARs of the different cell lines in DMEM with
those obtained with phosphate buffer containing 10 mM
glucose (bufferg+) to test whether cellular metabolism was
affected by the omission of the amino acids and vitamins
present in DMEM. For this purpose, the cells were first
exposed to DMEM (buffer capacity  ) 0.56 mM) until
stable basal ECARs were reached (75 min). DMEM was then
replaced by glucose-containing bufferg+ (buffer capacity 
) 0.40 mM). Parts A (DMEM) and B (bufferg+) of Figure
2 display the ECARs of the 10 cell lines employed in this
study, ordered according to increasing expression levels of
Pgp, that is, Mdr1a-/-1b-/- knockout cells (77.1, 88.6) <
wild-type cells (2ac.1, 2ac.2, LLC-PK1, NIH3T3) ≈ LLC-
MRP1 < LLC-MDR1 < LLC-MDR1/V < NIH-MDR-
FIGURE 1: Expression of human Pgp monitored by immunoflow
cytometry, FACS. Histograms represent the cell number versus
fluorescence intensity expressed as the logarithm of the relative
fluorescence intensity. Each distribution was obtained from col-
lecting 104 cells labeled with MRK16 antibody. Transfected cell
lines LLC-MDR1/V (grown in the presence of vincristine (0.32
μM)) (line 1), LLC-MDR1 (line 2), and NIH-MDR-G185 (grown
in the presence of colchicine (0.15 μM)) (line 4) are shown in light
gray and the corresponding wild-type cells LLC-PK1 (line 3) and
NIH3T3 (line 5) in dark gray. Cells of high passage numbers (pn
> 4) were used.
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7. Reprints and Unpublished Manuscripts 
 
91
 
  
G185. After correction for the different buffer capacities,
the ECARs of a given cell line in DMEM and in glucose
bufferg+ were practically identical. Furthermore, parts A and
B of Figure 2 demonstrate that the basal ECARs of the
different cell lines are similar and in the range of (1.4 (
0.1) × 107 to (2.4 ( 0.5) × 107 H+/cell/s (-66 ( 5 to -117
( 26 μV/s) for DMEM and (1.3 ( 0.2) × 107 to (2.7 (
0.3) × 107 H+/cell/s (-89 ( 10 to -183 ( 18 μV/s) for
bufferg+. However, the ECARs of wild-type cells (gray
columns) are on average 30 ( 10% larger than those of
knockout (white columns) and transfected (patterned col-
umns) cells. Considering only MDR1-transfected and the
corresponding wild-type cells, the difference is lower (20 (
4%). For the experiments shown in Figure 2 cells from a
narrow range of cell passages after defreezing (pn ) 2-3)
were used to get optimal synchronization of cells.
The number of cell passages had a distinct influence on
the ECAR as exemplified in Figure 3 for NIH-MDR-G185
cells, knockout cells (77.1), and the corresponding wild-type
cells. At low passage numbers (pn ) 2-3) the ECARs were
lower than at higher passage numbers (pn g 4). Basal
ECARs of the second data set with high passage numbers,
analogous to those in Figure 2, were on average over all
cell lines 60 ( 40% higher than those of low passage
numbers, whereby the difference between the basal ECARs
of low and high passage numbers was lower (∼20%) for
Mdr1a-/-1b-/- knockout cells (77.1, 88.6) and the corre-
sponding wild-type cells (2ac.1, 2ac.2) and higher (80-
100%) for transfected cells (LLC-MRP1, LLC-MDR1, LLC-
MDR1/V, NIH-MDR-G185). At higher passage numbers (pn
> 4) the difference in ECARs between NIH-MDR-G185 and
the corresponding wild-type cells therefore practically disap-
peared (Figure 5A).
Basal ECARs under StarVation Conditions. Next the
activity of NIH-MDR-G185-transfected cells was tested after
withdrawal of exogenous carbon sources. The metabolic
response is seen in Figure 4. During period A, cells were
perfused with bufferg+ until a stable basal ECAR was
reached. A preequilibration period of ∼60 min is not shown.
The basal ECAR was normalized and defined as 100%. As
a control, perfusion with glucose buffer (bufferg+) was
continued in one chamber (9, no change in the ECAR
occurring).
When sodium pyruvate (1 mM) was added to glucose
buffer (bufferg+p+, 1), a significant decrease in the ECAR
was observed. Pyruvate (1 mM) without glucose (bufferg-p+,
O) led to an even larger decrease in the ECAR. Complete
FIGURE 2: Basal extracellular acidification rates, ECARs (A, B), and verapamil (10 μM)-induced ECARs after subtraction of the basal
ECARs (C, D) of Mdr1a-/-1b-/- knockout cells 77.1 (1) and 88.6 (2) (white columns), wild-type cells 2ac.1 (3) 2ac.2 (4), LLC-PK1 (5),
and NIH3T3 (6) (gray columns), and cells transfected with MRP1 or MDR1 genes, LLC-MRP1 (7), LLC-MDR1 (8), LLC-MDR1/V (9),
and NIH-MDR-G185 (10) (patterned columns). The cells were exposed to DMEM (A, C) or to phosphate buffer containing 10 mM glucose
(B, D). The cells were defrozen 2-3 passages prior to the measurements. Error bars correspond to n ) 3-4 measurements.
FIGURE 3: Basal extracellular acidification rate as a function of
the passage number of NIH-MDR-G185 (9), NIH3T3 (0),
Mdr1a-/-1b-/- knockout cells 77.1 (b) and 2ac.2 (O) cells as a
function of the passage number. Measurements were performed in
phosphate buffer containing 10 mM glucose. Error bars correspond
to n ) 2-6 measurements.
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elimination of all carbon sources (bufferg-p-, 2) caused a
further small decrease.
Comparing the different cell lines, the average reduction
of basal ECARs due to addition of pyruvate was more
pronounced for mouse embryo fibroblasts (50 ( 10%, wild-
type and transfected NIH cells) than for pig kidney cells (15
( 4%, wild-type and transfected cells) (not shown). If
glucose was removed or replaced by its nonmetabolizable
analogue deoxyglucose, the basal ECARs of all cell lines
tested were reduced by 75-90%.
Figure 5A then compares the basal ECARs of wild-type
and transfected cells in the presence (0, 9) and absence (O,
b) of glucose, where open and closed symbols represent
ECARs of cells with low (pn ) 2-3) and high (pn ) 4-20)
passage numbers, respectively. Basal ECARs (logarithmic
scale) are plotted as a function of the median fluorescence
intensity representing the expression level of human Pgp.
As a general conclusion it follows that under equivalent
conditions of nutritional state and passage number wild-type
and MDR1-transfected cells exhibit rather similar metabolic
activity.
Verapamil-Induced Extracellular Acidification Rates. Fig-
ure 4, period C, displays the variation of the ECARs of NIH-
MDR-G185 cells upon addition of verapamil under different
nutritional conditions. We first discuss verapamil effects
under normal nutritional conditions, that is, when the cells
are perfused with bufferg+ (uppermost curve in Figure 4, 9).
At the beginning of period C, verapamil was added to
bufferg+ at a concentration of 6 μM during 160 s (hatched
bar). After this stimulation interval the cells were again
perfused with bufferg+. Immediately after stimulation, the
ECAR increases, indicating a distinct increase in acid
production induced by verapamil. After the return to normal
bufferg+ the ECAR returns to basal values. Analogous
measurements were performed for all 10 cell lines, and the
quantitative evaluation for cells with pn ) 2-3 is sum-
marized in Figure 2C,D. The values given correspond to the
ECAR increase measured at the end of the 160 s stimulation
interval. The verapamil-induced ECARs in DMEM (Figure
2C) and bufferg+ (Figure 2D) are practically identical. Parts
C and D of Figure 2 show that an increase in ECARs upon
verapamil stimulation is observed only for cells overexpress-
ing P-glycoprotein (columns 8-10), and that the increase
in ECARs is proportional to the expression level of Pgp (see
also Figure 5B,C).
We then tested whether Pgp activation by verapamil was
still possible under starvation conditions. As seen in Figure
4, period C, verapamil stimulation induced a distinct ECAR
increase under all buffer conditions, even in the absence of
exogenous carbon sources. The stimulation cycle in Figure
4 (periods A-C) was then repeated. In period A2 the cells
were again perfused with bufferg+ in all four chambers. Cells
treated with bufferg+p+ (1) and bufferg-p+ (O) during periods
B and C reversed to the initial ECARs within 5 min, whereas
cells treated with bufferg-p- (2) did not recover completely
even after 15 min. Verapamil stimulation in period B2
yielded results very similar to those of period B. Even cells
in bufferg-p- which had not recovered completely showed a
similar ECAR upon the second verapamil stimulation.
The verapamil stimulation cycle in Figure 4 was repeated
for a third time (data not shown) to test inhibition of
verapamil-induced ECARs by cyclosporin A. For this
purpose, cyclosporin A (1 μM) was added to the four
different buffers and NIH-MDR-G185 cells were preincu-
bated for 20 min followed by stimulation with verapamil,
again in the presence of cyclosporin A. This led to an
inhibition of the verapamil-induced ECARs by 50-60%
under all buffer conditions, in agreement with previous
inhibition values (20).
Parts B and C of Figure 5 display the absolute and relatiVe
increase in ECARs upon verapamil stimulation (10 μM) of
MDR1-transfected and wild-type cells in the presence (0,
FIGURE 4: Effect of glucose and sodium pyruvate on the basal and verapamil-induced acidification rate of NIH-MDR-G185 cells. Cells of
high passage numbers were used (pn > 20). During period A (indicated in white), the cells in all four chambers were exposed to phosphate
buffer with glucose, bufferg+. During periods B and C (indicated in gray) only one chamber was perfused with bufferg+ (9); the others were
perfused with buffer containing in addition 1 mM sodium pyruvate, bufferg+p+ (1), buffer containing 1 mM sodium pyruvate without
glucose, bufferg-p+ (O), or buffer containing neither glucose nor pyruvate, bufferg-p- (2). Periods A-C were repeated (A2, B2, C2).
Hatched bars indicate the interval (160 s) during which the cells were perfused with verapamil (6 μM). The basal ECAR of cells in bufferg+
was defined as 100%. Results are normalized to the baseline and are expressed as a percent of the basal acidification rate.
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9) and absence (1) of glucose plotted as a function of the
expression level of Pgp. Under all conditions ECARs
increased with the expression level of Pgp. Absolute ECARs
(Figure 5B) were higher in the presence (0, 9) than in the
absence (1) of glucose. However, if expressed as percent
changes relatiVe to the corresponding basal ECAR (Figure
5C), glucose-deprived cells showed a distinctly larger
verapamil-induced stimulation than glucose-fed cells.
ECARs of cells with higher passage numbers (pn ) 4-20)
(9) are higher than those of cells from low passage numbers
(pn ) 2-3) (0) if given in absolute values (Figure 5B).
However, if again expressed as percent changes of basal
ECARs, the two data sets are practically identical (Figure
5C). For the sake of clarity, the data obtained for glucose-
deprived cells with low and high passage numbers were
averaged in Figure 5B,C (1). The largest relative increase
is clearly observed for cells under starvation conditions (cf.
also Table 1).
Rate of Lactic Acid Efflux. NIH-MDR-G185 and NIH3T3
cells were perfused with glucose-containing bufferg+ in the
Cytosensor. The buffer was collected after leaving the
chamber and was tested for lactate using a spectrophoto-
metric assay based on lactate oxidase and peroxidase activity.
Figure 6 shows the rate of lactate molecules exported
(hatched columns) by NIH3T3 and NIH-MDR-G185 cells
under basal conditions (-) and when stimulated continuously
with 6 μM verapamil (+) for ∼1 h. The lactate rates are
compared to the proton efflux rates (ECARs) measured in
parallel (gray columns).
In the absence of verapamil, NIH3T3 and NIH-MDR-
G185 cells exported (3.5 ( 0.5) × 107 and (3.0 ( 0.9) ×
107 lactates/cell/s, respectively. The basal ECARs determined
in parallel corresponded to (3.4 ( 0.1) × 107 and (3.0 (
0.6) × 107 H+/cell/s for NIH3T3 cells and NIH-MDR-G185
cells, respectively (see also Table 1).
Verapamil (6 μM) induced an increase in the rate of lactate
export and in the ECAR of (4.8 ( 1.5) × 107 lactates/cell/s
and (4.5 ( 0.4) × 107 H+/cell/s, respectively, in Pgp-
overexpressing cells. In wild-type cells, the rate of lactate
export and the ECAR remained at (3.4 ( 0.5) × 107 lactates/
cell/s and (3.3 ( 0.5) × 107 H+/cell/s. Data in Figure 6 thus
demonstrate that the rate of lactic acid leaving the measuring
chambers of the Cytosensor corresponds to the rate of
extracellular acidification registered by the pH-sensitive
potentiometric sensor chip in the measuring chamber of the
Cytosensor.
Route of Lactic Acid Efflux. To identify the pathway of
lactic acid efflux, we incubated the cells in the Cytosensor
chambers with DIDS and phloretin, which inhibit inorganic
anion exchange mechanisms and monocarboxylate carriers,
respectively (44, 45). Figure 7 shows the influence of DIDS
and phloretin on basal ECARs of NIH-MDR-G185, LLC-
MDR1, and NIH3T3 cells. Exposure of cells to increasing
concentrations of DIDS (50-600 μM) leads to a slow
decrease in basal ECARs. After 20 min of incubation with
DIDS a reduction by about 10-15% was reached in wild-
type and transfected cell lines. In contrast, exposure of NIH-
MDR-G185 and NIH3T3 cells to phloretin leads to a fast
decrease by ∼60% and ∼70%, respectively, which remained
constant after 6 min.
Figure 8 shows the effect of DIDS and phloretin on
verapamil-induced ECARs in NIH-MDR-G185 and NIH3T3
cells. The cells were preincubated with DIDS or phloretin
for 20 and 6 min, respectively, and were then stimulated
with 6 μM verapamil for 160 s in the presence of DIDS or
phloretin. DIDS had no effect on the ECAR in the whole
FIGURE 5: Basal (A) and verapamil (10 μM)-induced ECAR as a
function of the expression level of human Pgp in cells given in
absolute values (B) and relative values, where basal ECARs were
taken as 100% (C). The expression level of Pgp was determined
by FACS analysis and is expressed in MFIs for wild-type cells
(MFI ) 1) (LLC-PK1 (label 5), NIH3T3 (label 6)) and MDR1-
transfected cells (LLC-MDR1 (MFI ) 23), LLC-MDR1/V (MFI
) 38), NIH-MDR-G185 (MFI ) 79)). The cells for ECAR
experiments were defrozen either 2-3 passages or 4-20 passages
prior to the measurements, and the values given correspond to an
average of n ) 3-4 (0, O) or n ) 2-17 (9, b) measurements.
Both sets of data were measured in the presence (bufferg+) (squares)
and absence (bufferg-p-) (circles) of glucose. Verapamil-induced
ECARs (B, C) in the absence of glucose are shown as average
values of all measurements (n ) 4-21) for cells defrozen 2-20
passages prior to the measurements (1).
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concentration range investigated (50-300 μM) (Figure 8A),
suggesting that inorganic ion exchange mechanisms play no
significant role in lactate efflux in intact cells. On the other
hand, phloretin completely inhibited the Pgp-specific ECAR
at a concentration of 100 μM, suggesting that monocarboxyl-
ate carriers are involved in lactate export (Figure 8B). As
will be discussed below phloretin may, however, also affect
glucose import. The concentration of 50% inhibition of
lactate export by phloretin was IC50 ) 47 ( 20 μM (40 (
19 μM) for wild-type (transfected) cells under basal condi-
tions and IC50 ) 22 ( 8 μM for transfected cells upon drug
activation.
ATPase ActiVation Assay. Basal Pgp activation led to a
phosphate release of 10.7 ( 0.9 (nmol/mg of total protein)/
min. Activation of the Pgp ATPase in plasma membrane
vesicles of NIH-MDR1-G185 cells at pH 7.5 by verapamil
Table 1: Basal and Verapamil-Induced Rate of Proton and Lactate Export by NIH-MDR-G185 and NIH3T3 Cells in Bufferg+ under Different
Conditions
no. of cell
passages
after
defreezing
verapamil
(μM)
10 mM
glucose
stimulation
time
basal ECAR
for NIH3T3
[107 H+/cell/s]
basal ECAR
for NIH-MDR-G185
[107 H+/cell/s]
verapamil-induced
ECAR for
NIH-MDR-G185
[106 H+/cell/s]
verapamil-induced
relative to basal
(100%) ECAR for
NIH-MDR-G185 (%)
2-3 10 + 160 s 1.87 ( 0.25 (3)a 1.63 ( 0.24 (4)a 4.1 ( 0.6 (4)a 125
4-20 10 + 160 s 2.97 ( 0.80 (10) 2.98 ( 0.60 (17) 8.0 ( 1.5 (16) 127
2-20b 10 - 160 s 0.54 ( 0.17 (13) 0.60 ( 0.21 (21) 2.8 ( 1.2 (20) 148
17-20 6c + 60 min 3.40 ( 0.14 (3) 3.05 ( 0.58 (9) 14.7 ( 4.2 (9) 148
17-20 6 + 60 min 3.48 ( 0.45d (3) 3.03 ( 0.91d (9) 17.4 ( 15d (9) 157d
a Numbers in parentheses correspond to the numbers of measurements. b Since ECARs are relatively weak for glucoses-deprived cells, an average
value of low (2-3) and high (>4) passage numbers is given. c ECAR measurements as a function of verapamil concentration have shown that
ECAR values for 6 and 10 μM verapamil are very similar (20). d Amount of lactate determined spectrophotometrically (lactates/cell/s).
FIGURE 6: Comparison between the rate of lactic acid efflux as
determined spectrophotometrically (hatched columns) and the
extracellular acidification rate as determined by means of the
Cytosensor microphysiometer (gray columns) for NIH3T3 (n ) 3)
and NIH-MDR-G185 (n ) 9) cells in the absence (-) and presence
(+) of 6 μM verapamil. The cells were defrozen 17-20 passages
prior to the measurements. The differences in lactate efflux (and
ECAR) between NIH-MDR-G185 without and with verapamil are
statistically significant (p < 0.05) (and p < 0.001).
FIGURE 7: Effect of increasing concentrations of DIDS (open
symbols) and phloretin (solid symbols) on the basal ECARs of NIH-
MDR-G185 (circles), NIH3T3 (squares), and LLC-MDR1 (tri-
angles) cells. The basal ECAR was defined as 100%. Results are
normalized to the baseline and are expressed as a percent of the
basal rate.
FIGURE 8: Effect of increasing concentrations of DIDS (A, open
symbols) and phloretin (B, solid symbols) on verapamil (6 μM)-
induced ECARs of NIH-MDR-G185 (circles) and NIH3T3 (squares).
The ECARs of cells stimulated with verapamil for 160 s minus
the corresponding basal ECARs (in the absence of inhibitors) were
defined as 100%. Results are normalized and expressed as a percent
of the verapamil-induced ECAR subtracted from the basal ECAR.
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(10 μM) led to an increase in phosphate release by 14.1 (
2.3 (nmol/mg of total protein)/min.
Taking into account the number of cells, the molecular
mass of Pgp (170 kDa), and the total protein concentration
determined experimentally, the content of Pgp was calculated
as 0.85 ( 0.23% of total protein, in good agreement with
previous results (46, 47). By combining these results with
the estimate of the number of Pgp molecules per cell in NIH-
MDR1-G185 (8), we calculated the turnover number of
verapamil-induced activity as 4.7 ( 0.8 ATP hydrolyzed/
Pgp/s. The errors correspond to four measurements.
DISCUSSION
Up to now, the classical method to determine Pgp-ATPase
activation was based on inorganic phosphate release mea-
surements made with inside-out vesicles prepared from Pgp-
overexpressing cells. This method has the disadvantage that
it is rather time-consuming and also requires destruction of
the living cell. Therefore, little is known on the role of the
basal metabolic state of the cell for Pgp activation. We have
recently shown (20) that measuring the extracellular acidi-
fication rate of living MDR1-transfected cells by means of
a Cytosensor (19) provides a much faster and more conve-
nient method to monitor Pgp-ATPase activation. In the
present study we have developed this method further. Our
main interest is to investigate the influence of the metabolic
state of the cell, which depends on the cell culture time
(passage numbers) as well as on the nutritional state of the
cell. We considered drug-induced stimulation of Pgp under
conditions of starvation in some detail to understand the
mechanism of extracellular acidification in relation to the
general glycolytic metabolism of the cell and to show how
it is linked to Pgp-induced ATP hydrolysis under conditions
of Pgp activation.
The Different Genetically Modified Cell Lines Show
Similar ECARs. For a comparison of the different cell lines
the cells were kept in culture for identical periods of time
after defreezing. Basal ECARs of wild-type (2ac.1, 2ac.2,
LLC-PK1, NIH3T3) and genetically modified (Mdr1a-/-1b-/-
knockout, MDR1- and MRP1-transfected (LLC-MDR1, LLC-
MDR1/V, NIH-MDR-G185, LLC-MRP1)) cell lines were
on the order of 107 H+/cell/s, whereby those of genetically
modified cells were on average slightly lower than those of
wild-type cells (Figure 2 and 5, Table 1). The expression
level of Pgp as such had no influence on the basal
extracellular acidification rate of the different cell lines
(Figures 2 and 5).
Basal Metabolic Rates Depend on Cell Culture Time. The
rate of cellular metabolism reflected by the ECAR depends
on many factors such as temperature, pH, ionic strength, and
nutritional conditions (glucose concentration). The present
data demonstrate that it also depends on the time which cells
spend in culture after defreezing. For the comparison of
different cell lines we collected two data sets, one for cells
of low passage numbers (pn ) 2-3) and one for cells of
higher passage numbers (pn ) 4-20), where the former
show lower acidification rates than the latter (Figure 3, Table
1). A stable situation was reached after about two weeks in
culture (pn g 4). Basal ECARs in bufferg+ as well as in
medium (DMEM) were in the range of 1.3 × 107 to 2.7 ×
107 H+/cell/s for cells of low passage numbers (pn ) 2-3).
The basal metabolism reflected by the ECAR is thus
generally more affected by variations in the cell culture time
(60 ( 40%, depending on the cell line) than by transfection
(30 ( 10% for pn ) 2-3, depending on the cell line).
ECARs due to Verapamil Stimulation Increase with the
Expression LeVel of Pgp and Depend on the Metabolic State
of the Cell. A metabolic response to verapamil stimulation
was observed for MDR1-transfected cells only (Figures 2C,D
and 5) and increased with the expression level of Pgp. In
absolute terms, the response to verapamil stimulation was
higher for cells of high passage numbers (pn ) 4-20) than
of low passage numbers (pn ) 2-3). However, verapamil-
induced ECARs relative to basal values were practically
identical for the two data sets (cf. Figure 5C). This suggests
that Pgp activation and the concomitant protection of cells
against drugs and toxins are directly proportional to the basal
metabolic state of the cell.
The metabolic conditions of the cells were modified by
perfusing the cells in the Cytosensor either with buffers
containing pyruvate in the presence or absence of glucose
or with a buffer lacking a carbon source. To illustrate the
amount of energy spent by NIH-MDR-G185 cells on
detoxification by Pgp relative to the basal metabolic energy
under different nutritional conditions, basal ECARs were
plotted versus the verapamil-induced ECARs (Figure 9).
Addition of pyruvate (1 mM) to glucose-containing buffer
(bufferg+p+) led to a 50% decrease of the basal ECAR.
Despite the decrease in basal metabolism, the verapamil-
induced ECAR remained as high as in bufferg+. The energy
required to activate Pgp in the presence of pyruvate
(bufferg+p+) thus required on average ∼50% of the basal
ECAR in contrast to only ∼25% in bufferg+.
If pyruvate was the only carbon source (bufferg-p+) or if
exogenous carbon sources were lacking (bufferg-p-), the
absolute ECAR or the rate of basal metabolism decreased
further (cf. Table 1). Nevertheless, Pgp activation by
FIGURE 9: Contribution of exogenous carbon sources to the basal
and verapamil-induced ECARs of NIH-MDR-G185 cells. The cells
were perfused with phosphate buffer without any carbon sources
(bufferg-p-), with 1 mM pyruvate (bufferg-p+), 1 mM pyruvate and
10 mM glucose (bufferg+p+,), or 10 mM glucose (bufferg+). Data
in bufferg-p+ correspond to an average of the data shown in Figure
4, data in bufferg+ correspond to an average of the data from Figures
2B,D and 4, and data in bufferg+p+ and bufferg-p- correspond to
an average of the data from Figure 4 and two additional sets of
measurements (n ) 3-4), not shown. The line is drawn to guide
the eyes.
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verapamil was still possible and comprised again 50-60%
of the basal value.
An analogous behavior was observed for LLC-MDR1 and
LLC-MDR1/V cells. While the ECARs of LLC-MDR1 and
LLC-MDR1/V cells upon verapamil stimulation (10 μM)
were 108 ( 3% and 116 ( 7%, respectively, in the presence
of glucose, they amounted to 124% and 131%, respectively,
in the absence of exogenous carbon sources.
The reduction of the basal ECAR in the presence of high
pyruvate concentrations led to substrate inhibition of lactate
dehydrogenase (48). However, when Pgp was stimulated by
verapamil and the ATP requirement was enhanced, glycolysis
was up-regulated even in the absence of exogenous carbon
sources. This suggests that endogenous carbon sources are
used to drive Pgp under conditions of starvation.
Somewhat higher ECARs were also observed upon long-
time (60 min) exposure to drugs (cf. Table 1). The value
measured is in good agreement with previous results obtained
in cancer cells under comparable conditions (22).
Glycolytic Pathway for Energy Production. For all cell
lines basal ECARs were strongly reduced in the presence of
pyruvate or deoxyglucose and in the absence of glucose as
shown in Figure 4 for NIH-MDR-G185 cells, which is
consistent with a primarily glycolytic pathway for energy
production. Related results were obtained previously with
Chinese hamster ovary cells CHO-K1 (19), swim bladder
gas gland cells (49), and human rhabdomyosarcoma TE671
cells (50).
An analysis of the flow buffer leaving the Cytosensor
measuring chambers containing NIH-MDR-G185 or NIH3T3
cells perfused with glucose-containing bufferg+ revealed that
the rate of lactate export was identical to the rate of proton
export as determined by the potentiometric sensor chip
(Figure 6), which further supports the primarily glycolytic
pathway of these cells. We thus conclude that one molecule
of lactate is exported per molecule of ATP synthesized.
To maintain cellular homeostasis, lactic acid molecules
produced upon ATP synthesis must be transported across
the cell membrane to the extracellular space. Multiple
mechanisms exist, including facilitated transport by mono-
carboxylate carriers and anion exchange proteins as well as
diffusion of the protonated acid across the membrane (24).
Whether facilitated lactate export occurs by inorganic anion
exchange mechanisms or by monocarboxylate carriers was
tested by treating the cells with increasing concentrations of
DIDS or phloretin, respectively. While DIDS reduced basal
ECARs only by about ∼10%, in agreement with previous
measurements (51), phloretin reduced basal ECARs by about
70% in wild-type cells, and by about 60% in MDR1-
transfected cells. The concentration of 50% inhibition of
lactate export by phloretin was determined, in good agree-
ment with previous measurements for other cell lines (IC50
) 3-40 μM) (45, 52, 53), suggesting that monocarboxylate
transporters play an important role in lactate-proton cotrans-
port. However, phloretin also inhibits the glucose transporter
with a similar concentration of half-maximum activation
(IC50 ) 0.24-48 μM) (49, 54, 55). On the basis of the
present experiments, it is therefore not possible to unambigu-
ously decide to what extent inhibition of lactate export by
phloretin is due to the inhibition of monocarboxylate
transporters and to what extent it is due to the inhibition of
glucose import and the concomitant reduction in basal
metabolism.
The amount of lactic acid leaving the cell by passive
diffusion is determined by the pKa value of lactic acid (pKa
) 3.8) and the pH close to the cytosolic membrane surface
(pH ≈ 5.5). At pH ≈ 7.0 lactate is fully dissociated, which
prevents passive diffusion. However, close to the inner
cytosolic membrane surface, which exhibits a negative
surface potential, the concentration of protons is higher and
the pH is therefore lower. As a consequence about 1% of
the lactate molecules produced are protonated in this
environment and can leave the cell by passive diffusion.
Proton-Drug Symport? On the basis of the fact that the
large majority of drugs transported by Pgp are cationic (pKa
≈ 8) and that Pgp can transport permanently charged cations
(56), we have previously (20) discussed the possibility that
proton efflux in MDR1-transfected cells could also arise from
the transport of protonated drugs (proton-drug symport). A
drug molecule inserted into the negatively charged cytosolic
membrane interface, which is assumed to be the site of
interaction between Pgp and its substrates, is likely to be
protonated due to the slightly acidic environment close to
the membrane surface and might thus get transported in its
charged form. Since the extracellular aqueous phase is
slightly acidified by lactic acid efflux, the proton would not
dissociate from the drug molecule and would therefore most
likely remain undetected by the Cytosensor. For truncated
LmrA, a bacterial transporter related to Pgp, a proton-
ethidium symport was indeed demonstrated recently, and was
also proposed for the native transporter (57).
ATP Synthesis and ATP Hydrolysis. We have demonstrated
that drug-stimulated ECARs correspond to the rates of lactic
acid export, which suggests that the ECARs reflect in turn
the rates of ATP synthesis. To investigate the relationship
between the rate of ATP synthesis and the rate of ATP
hydrolysis in more detail, we compared the number of lactic
acid molecules exported (or the number of ATP molecules
synthesized) per NIH-MDR1-G185 cell with the number of
phosphate molecules released upon ATP hydrolysis in inside-
out vesicles of the same cells upon stimulation with 10 μM
verapamil. To estimate the number of phosphate molecules,
Pi, released per cell, we multiplied the turnover number,
which gives the number of molecules of ATP hydrolyzed
(or the number of inorganic phosphate molecules released)
per molecule of Pgp, determined as 4.7 ( 0.8 Pi/Pgp/s in
inside-out vesicles, with the number of Pgp molecules per
NIH-MDR1-G185 cell determined previously as n ) 1.95
× 106 Pgp/cell (8). This yields (9.2 ( 1.5) × 106 Pi/cell/s.
For comparison the ECAR data obtained for intact NIH-
MDR-G185 and NIH3T3 cells under different metabolic
conditions are summarized in Table 1. The best agreement
is found for cells with high passage numbers (pn ) 4-20)
in the presence of glucose. The excellent correlation between
ECAR data and data from ATP hydrolysis suggests that ATP
synthesis is kinetically linked to ATP hydrolysis.
Previous data from Pgp reconstituted into lipid vesicles
are in the range of 106 to 107 Pi/cell/s (8, 15, 58, 59). This
variation in ATP hydrolysis data is due to the fact that many
experimental steps are involved in Pgp purification and
reconstitution into lipid membranes and that the lipid chosen
for reconstitution plays a role (60). After careful standardiza-
tion, the error range for ECARs under a given condition is
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generally relatively small. ECAR measurements have more-
over the advantage of giving an in situ determination of Pgp
activation.
Conclusions. (i) Wild-type cells showed on average 30 (
10% higher basal ECARs than genetically modified
cells such as MDR1- and MRP1- transfected cells and
Mdr1a-/-1b-/- knockout cells at least if measured at low
passage numbers (pn ) 2-3). The difference between the
basal ECAR of wild-type and genetically modified cells was
smallest for NIH-MDR1-G185 cells and almost vanished for
cells of higher passage numbers (pn > 4). Although MDR1-
transfected cells consume ATP at a high basal rate (perhaps
due to an endogenous substrate), their basal ECARs were
not higher than those of wild-type cells. Moreover, an
increase in Pgp expression did not lead to an increase in
basal ECARs. We thus conclude that a genetic modification,
whether it is a MDR1 or MRP1 transfection or a Mdr1a-/
-1b-/- knockout, tends to reduce the basal cellular metabo-
lism. (ii) Stimulation of MDR1-transfected cells by verapamil
(6-10 μM) induced an increase in metabolic rates which
was proportional to the expression level of Pgp, whereas
stimulation of wild-type, MRP1-transfected, or knockout cells
gave no response. A comparison of MDR1-transfected cells
of low and high passage numbers (exhibiting low and high
basal metabolic rates, respectively) shows that the rate of
Pgp activation and the concomitant protection of cells against
drugs or toxins are proportional to the basal metabolic rate
of the cell. In glucose-deficient (or pyruvate-fed) NIH-
MDR1-G185 cells the energy spent on detoxification by Pgp
relatiVe to basal values is, however, 2-fold higher than in
glucose-fed cells, suggesting that the energy required to drive
Pgp can be derived from endogenous energy stores under
conditions of starvation. Cells overexpressing Pgp thus seem
to have an efficient mechanism of self-protection against
toxic compounds even under starvation conditions and
consequent low basal metabolic rates. (iii) ATP is generated
mainly by glycolysis, producing one molecule of lactate per
ATP molecule synthesized, whereby lactate seems to be
exported mainly by monocarboxylate transporters. (iv) The
excellent correlation between the number of protons or lactate
molecules excreted per second per cell under optimal
conditions (i.e., for cells with high passage numbers in
glucose-containing buffer) and the number of ATP molecules
hydrolyzed by Pgp in inside-out vesicles of the same cells
suggests that ATP synthesis is kinetically linked to ATP
hydrolysis.
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INTRODUCTION 
 
Nuclear magnetic resonance (NMR) has been established as a powerful tool in many fields 
of science. The great advantage of NMR is its non-invasive character. As the object of 
interest does not need to be destructed repeated investigations of the same object are 
possible. This property of NMR can be used to perform additional measurements with 
NMR beside other techniques. In this manner accuracy of an experiment can be enhanced 
and the risk of systematic errors can be diminished. 
The metabolic rate of mouse embryo fibroblasts NIH3T3, wild -type (NIH-WT) and 
MDR1-gene transfected (NIH-MDR1-G185), has been studied in our lab with and without 
P-glycoprotein (ABCB1, Pgp) stimulation (Chapter 7.3 (1)). The usually used method in 
our lab to determine the metabolic rate of cells is the observation of the extracellular 
acidification rate (ECAR) with a Cytosensor microphysiometer (2) under anaerobic 
conditions. Without aerobic metabolism anaerobic glycolysis is the only pathway for ATP 
production in the studied cells. Thus every mol of glucose (Gluc) is metabolized to two 
mol of lactic acid which dissociates to lactate (Lac-) and protons (H+) at the physiological 
pH. The most important membrane transporters for Lac- release are the monocarboxylate 
transporters (MCTs) which transport Lac- together with H+ (3, 4). However, MCTs are not 
the only transporters involved in H+ release and also a small amount of undissociated lactic 
acid is able to cross the cell membrane by diffusion (5). Furthermore, only the extracellular 
protons can be detected with the Cytosensor microphysiometer. Therefore the ECAR is a 
rather indirect method to detect the metabolic rate of the cells and even if the Cytosensor 
microphysiometer is an established method a more direct method is desirable to validate 
the results obtained with the Cytosensor.  
NMR spectroscopy seems to be an adequate method to measure the metabolic rate 
of cells directly by monitoring the Gluc consumption and the Lac production. In contrast to 
the ECAR, extra- as well as intracellular Gluc and Lac are observed with NMR. 
Furthermore, NMR spectroscopy might offer the possibility to distinguish between the 
intra- and the extracellular Lac. The separation of the intra- and the extracellular Lac is of 
interest to proof whether the Lac transport systems of the used cells are fast enough to 
avoid the intracellular Lac accumulation upon Pgp stimulation. The accumulation of 
intracellular Lac would result in an inhibition of the metabolic rate (3). Gatlik-
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Landwojtowicz et al. (1) (Chapter 7.3) observed an increased ECAR until at least 10 min 
after the stimulation with verapamil was stopped. To exclude that this enhanced ECAR 
after the stimulation is due to a delayed release of lactate because of a limited MCT 
capacity it would be of interest to distinguish between the intra- and the extracellular Lac. 
Chemistry has developed a huge amount of shift reagents (6). These compounds are 
often used to divide NMR signals which are very close together within a spectrum rather 
than to distinguish between the different compartments. However, in biological 
applications it is often of interest to separate the signals of the same substance in the 
different compartments. Therefore the shift reagents which are used to distinguish between 
the intra- and the extracellular volume need to have certain properties. These compounds 
are not allowed to cross the cell membrane. Furthermore, the shift reagents for living cells 
must not be toxic and should not influence the viability or the metabolic rate of the 
observed cells. Even if the shift reagents have already been used to distinguish the NMR 
signals of intra- and extracellular compartments the usage is still not routine. Aime et al. 
(7) have developed a shift reagent (Pr-DO3A) that especially binds to Lac. Thus, the 
needed amount of shift reagent can be kept small. Pr-DO3A has been tested with the ghosts 
of human red blood cells, but up to now its applicability has not been proofed with the 
intact cells. 
In the current study NMR spectroscopy is used as an additionally technique to 
observe the metabolic rate and the Pgp activation in mouse embryo fibroblast cells under 
the stimulation with verapamil. Furthermore, the shift reagent Pr-DO3A was used to 
separate intra- and extracellular Lac to get additional information about the transport 
capacity of MCTs and simultaneously the bio-compatibility of the shift reagent was tested. 
 
 
MATERIALS AND METHODS 
 
Cell Lines and Cell Preparation. Mouse embryo fibroblasts NIH3T3, wild-type (NIH-WT) 
and transfected with human MDR1-gene (NIH-MDR1-G185) were used with various 
numbers of cell passages (pn) after defreezing. The cells were maintained as described 
previously in details (1) (Chapter 7.3). For NMR measurements cells were suspended in 
0.4 ml self-made degassed PBS-buffer (50 mM, 35 mM NaCl, 4 mM KCl, pH 7.4, 154 mM 
ionic strength) containing 10 mM single 1-13C or double labeled 1,6-13C Gluc. Thereafter, 
the cells were transferred in a 5 mm NMR tube which was filled with Ar in order to avoid 
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contact with oxygen. Cell viability was tested with trypan blue and counting the viable and 
not viable cells with a hemocytometer. NMR measurements were performed at two 
different temperatures and with two different cell quantities. The metabolic rate of both 
cells was measured with 3.6·106 cells at 37 °C in the presence and absence of verapamil (9 
µM). Single labeled Gluc was used for these experiments because no homonuclear 
couplings occur on the 1-13C-Gluc NMR signal. To determine the intracellular Lac content 
the measurements with and without Pr-DO3A were performed. For measuring the 
intracellular Lac content a higher number of NIH-MDR1-G185 cells were used (18·106) in 
order to increase the total cell volume and the NMR signal intensity. These experiments 
were performed with a double labeled Gluc to observe all Lac produced. The metabolism 
of cells was lowered in these experiments by reducing the temperature to 23 °C in order to 
avoid fast acidification. With these settings pH of the cell suspensions in the NMR tube did 
not decrease below pH 7.0 during the total experimental time of 90 min. After the 
experiments a small droplet of the cell suspension was used to test the cell viability. The 
remaining suspension was used to determine the cell volume proportion by centrifugation 
at 4000×g for 20 min.  
NMR Measurements.13C-NMR spectroscopy was performed on a 9 T Bruker 
Avance spectrometer. Distortionless Enhancement by Polarization Transfer (DEPT) 
sequence was used to enhance 13C-NMR signal intensity. Pulse parameters were optimized 
for the Lac methyl group resonance. Repetition time (TR) was 1.7 s. Continuous broad band 
decoupling was used to avoid multiplets. 256 scans were accumulated during 7:30 min. 
Before each NMR measurement magnetic field homogeneity was optimized. The intensity 
of Gluc signal was calibrated with the starting Gluc concentration of 10 mM. The 
quantification of Lac concentration was determined by a constant which was determined by 
a standard solution containing 10 mM 1,6-13C-Gluc and 10 mM 3-13C-Lac in buffer. 
Because of the sedimentation of the cells during the scans the cells were resuspended after 
each NMR measurement. Resuspension was performed by a soft tilting the NMR tube with 
a little gas bubble. 
Shift Reagent. To separate intra- and extracellular NMR Lac signals the shift 
reagent Pr-DO3A was used. Pr-DO3A was prepared as reported previously by Aime et al. 
(7). The basic substance DO3A was kindly provided by Bracco (S.p.A, Milan,Italy). An 
active shift reagent concentration of 7 mM was used to shift extracellular 3-13C-Lac NMR 
signal 0.2 ppm towards low field direction.  
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RESULTS 
 
Metabolic rate. The Gluc and the Lac content as well as the total metabolic rate of both cell 
suspensions in the presence and in the absence of verapamil (9 µM) are shown in the 
Figures 1-4. The absolute Gluc consumption and the Lac production per NIH-WT and 
NIH-MDR1-G185 cell in the presence and absence of verapamil (9 µM) are shown in 
Table 1. Verapamil (9 µM) stimulation at 37 °C increases the metabolic rate of wild-type 
cells only slightly (Gluc consumption 104 % and Lac production 101 % compared to the 
values measured in the absence of verapamil) whereas the metabolic rate of NIH-MDR1-
G185 cells increased more than 50% (Gluc consumption 152 % and Lac production 161 % 
compared to the values measured in the absence of verapamil). By decreasing the 
temperature from 37 °C to 23 °C the metabolic rate of the NIH-MDR-G185 cells was 
reduced to a fifth. The Gluc consumption in NIH-MDR1-G185 cells with Pr-DO3A was 
112 % of the value in the absence of Pr-DO3A (Table 1). The Lac production in the 
presence of Pr-DO3A was not calculated due to the signal bleaching of the extracellular 
NMR signal. The pH of the cell suspensions in the NMR tubes did not fall below pH 7.0 
during all measurements.  
FIGURES 1-4 
TABLE 1 
 
Intracellular Lac concentration (high cell density only). The intra- and the extracellular 
NMR 3-13C-Lac signals were separated by 0.2 ppm in the presence a shift reagent Pr-
DO3A (Figure 5). However, the intensity of the extracellular 3-13C-Lac NMR signal was 
bleached significantly due to the used shift reagent and therefore the extracellular Lac 
concentration was not quantified. The intracellular Lac concentration was calculated by 
taking into account the cell volume and the intracellular NMR signal intensity which was 
not affected by Pr-DO3A. The Gluc and the Lac content as well as the total metabolic rate 
of NIH-MDR1-G185 cells in the presence and absence of Pr-DO3A are shown in Figures 
6-7. The total cell volume was determined by centrifugation to be 10.7 % of the total 
suspension volume, corresponding to a single NIH-MDR1-G185 cell volume of 2.4 pl. The 
cell volume was not affected by Pr-DO3A. In the presence of Pr-DO3A the total Lac was 
calculated according to the Gluc consumption (1 mol Gluc → 2 mol Lac). The total Lac 
production was 7.2 mM·h-1 whereas the intracellular Lac concentration increased by 7.5 
mM·h-1. The total and the intracellular Lac content are shown in Figure 8. The ratio of the 
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intracellular Lac to the total Lac seems to be constant at an average of (10.2 ± 1.3) % 
(±SD). Students t-test shows that there is no significant difference (p > 0.05) between the 
intra- and the total Lac concentrations. 
 
FIGURES 5-8 
 
Cell viability. After each NMR experiments the cell viability was tested with trypan blue 
exclusion. At low cell density and 37 °C the cell viability was 95 % in the presence as well 
in the absence of verapamil. At high cell density and 23 °C the cell viability with the shift 
reagent Pr-DO3A was 94 % after the experimental period of 90 min and 96 % without Pr-
DO3A.  
 
 
DISCUSSION 
 
The aim of the current study was to investigate further the metabolic rate of mouse embryo 
fibroblasts, and to understand better the previous observations from the ECAR 
measurements (1) (Chapter 7.3). The previous ECAR measurements revealed that the basal 
ECAR of MDR1-transfected cells correlated linearly with the verapamil-stimulated ECAR 
under conditions where the metabolic state of cells was low, whereas under conditions 
where the metabolic state of cells was high the correlation flattened out. The increase in the 
verapamil-stimulated ECAR was suppressed compared to the increase in the basal ECAR. 
Therefore the question rose whether the flattening of the linear correlation is due to the 
acidification of the weakly buffered flow medium and, thus, due to the suppression of 
glycolysis by feedback mechanism. As another possibility it was hypothyzed that the 
transport capacity of the MCTs might become a limiting factor when the metabolic rate of 
cells is high (3). In order to better understand these issues the metabolic rate of wild-type 
and MDR1-transfected mouse embryo fibroblasts were further studied with the NMR 
spectroscopy. Furthermore, the intracellular Lac concentration of mouse embryo fibroblast 
cells was determined and the bio-compatibility of the Lac specific NMR shift reagent Pr-
DO3A was tested.  
Gatlik-Landwojtowicz et al. (1) (Chapter 7.3) determined the metabolic rate of 
NIH3T3 mouse embryo fibroblast cells by monitoring the ECAR with a Cytosensor 
microphysiometer. In the current study the metabolic rate (Gluc consumption and Lac 
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production) of the same cells was determined directly with NMR spectroscopy. Under 
anaerobic conditions all three rate aspects are connected by the following formula:  1 Gluc 
→ 2 Lac- + 2 H+. Therefore, the amount of Lac molecules and the protons produced should 
be the same. The absolute metabolic rate of the mouse embryo fibroblasts, wild-type and 
MDR1-transfected, measured with a NMR spectroscopy is about three fold higher than 
determined with a Cytosensor microphysiometer (1.0·108 molecules Lac·cell-1·s-1 compared 
to 3.0·107 H+·cell-1·s-1 for NIH-MDR1-G185 cells without verapamil stimulation). Because 
the amount of lactate extruded in previous investigation (1) (Chapter 7.3) was determined 
also with the spectrophotometric measurements and the results were very close to that 
obtained with the Cytosensor microphysiometer a systematic error was excluded. 
Presently, we can only speculate for the reasons of the difference. One possible 
explanation could be the different cell preparation. It was observed in the preliminary tests 
that the small changes of the cell preparation can affect the metabolic rate of cells 
significantly. The NMR measurements were performed with suspended cells, whereas the 
cells are attached on the surface of a sensor chip during the Cytosensor measurements. A 
further difference in these two methods is the buffer concentration. The NMR 
measurements were performed with a stronger phosphate buffer (50 mM) to avoid the 
acidification during the measurement period. On the other hand, in the ECAR 
measurements the weak buffer is mandatory in order to observe the changes in extracellular 
pH (1 mM) (Chapter 7.3). This could be the reason for the higher absolute metabolic rates 
observed with NMR measurements. The higher buffer concentration reduces the 
acidification of the extracellular medium and, thus, diminishes the suppression of 
glycolysis by a feedback mechanism. This could further give an explanation for the 
previous observations from the ECAR measurements. However, further investigations are 
needed to confirm this. Despite the difference in the absolute values, the relative metabolic 
rate enhancement during the longtime verapamil stimulation (9 µM) of NIH-MDR1-G185 
cells (161 %) determined with the NMR is very close to the values reported by Gatlik-
Landwojtowicz et al. (Chapter 7.3 (1)) (Cytosensor microphysiometer: 148 %; 
Spectrophotometric assay: 157 %).  
The intra- and the extracellular NMR Lac signals are well separated by the shift 
reagent Pr-DO3A (Figure 5). The metabolic rate and the cell viability are not affected by 
Pr-DO3A. Since the extracellular 13C-Lac NMR signal is highly influenced by Pr-DO3A it 
can hardly be used to determine the extracellular Lac content. However, the extracellular 
Lac concentration can be estimated from the total Lac concentration which can be 
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determined from the Gluc consumption if anaerobic conditions are hold. Our 
measurements show that the intracellular Lac concentration is not constant but it increases 
as the total Lac concentration increases. Furthermore, the intracellular Lac concentration 
does not differ from the extracellular Lac concentration significantly. This result indicates 
that transmembrane Lac transport is fast enough to avoid intracellular Lac accumulation. 
We conclude that even if the absolute basal metabolic rates determined by the two 
different methods were not identical the relative rate enhancement by verapamil was very 
close. Therefore, both methods fulfill our purpose to determine the changes in the 
metabolic rate of living cells. Additionally, the shift reagent Pr-DO3A can be used to 
observe the intracellular Lac content of living cells without affecting the metabolic rate and 
the cell viability.  
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TABLE 
 
Table 1. The glucose (Gluc) consumption and the lactate (Lac) production of NIH-WT and 
NIH-MDR1-G185 cells with and without verapamil (9 μM) (3.6·106 cells in 0.4 ml) at 37 
oC and with and without shift reagent Pr-DO3A (7 mM) (18·106 cells in 0.4 ml) at 23 oC. 
Gluc consumption 
[106 molecules·cell-1·s-1] 
Lac production 
[106 molecules·cell-1·s-1] cell T [oC] pn 
no ver ver no ver ver 
NIH-WT 37 12 55 57 100 101 
NIH-MDR1-
G185 37 12 56 85 106 170 
 no Pr-DO3A Pr-DO3A no Pr-DO3A Pr-DO3A 
NIH-MDR1-
G185 23 19 11.2 12.6 22.3 nd 
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FIGURE LEGENDS 
 
FIGURE 1. Glucose concentration in a suspension of NIH-WT cells (3.6·106) in a 
phosphate buffer (50 mM, pH 7.4) at 37 °C. 
 
FIGURE 2. Lactate concentration in a suspension of NIH-WT cells (3.6·106) in a 
phosphate buffer (50 mM, pH 7.4) at 37 °C. 
 
FIGURE 3. Glucose concentration in a suspension of NIH-MDR1-G185 cells (3.6·106) in a 
phosphate buffer (50 mM, pH 7.4) at 37 °C. 
 
FIGURE 4. Lactate concentration in a suspension of NIH-MDR1-G185 cells (3.6·106) in a 
phosphate buffer (50 mM, pH 7.4) at 37 °C. 
 
FIGURE 5. 13C-NMR spectra of NIH-MDR1-G185 cells (18·106 cells) in the absence and 
presence of the shift reagent Pr-DO3A at 23oC. Time separation between the stacked 
spectra is about 17 min. Intra- and extracellular lactate methyl group signals are separated 
22 Hz. Lactate NMR signal intensity in both compartments increases due to glucose 
consumption.  
 
FIGURE 6. Glucose and lactate concentration in a suspension of NIH-MDR1-G185 cells 
(18·106) without the shift reagent Pr-DO3A in a phosphate buffer (50 mM, pH 7.4) at 23 
°C. 
 
FIGURE 7. Glucose and lactate concentration in a suspension of NIH-MDR1-G185 cells 
(18·106) with the shift reagent Pr-DO3A in a phosphate buffer (50 mM, pH 7.4) at 23 °C. 
 
FIGURE 8. Intracellular and the total lactate content of NIH-MDR1-G185 cells (18·106) 
with the shift reagent Pr-DO3A in a phosphate buffer (50 mM, pH 7.4) at 23 °C. Total 
lactate content was calculated according to glucose consumption. 
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ABBREVIATIONS 
ABC, ATP binding cassette transporters in humans include 7 subfamilies 
ABCA to ABCG 
ECAR,  extracellular acidification rate 
MDR,   multidrug resistance 
NBD,   nucleotide binding domain 
Pgp,  human P-glycoprotein-ATPase (MDR1, ABCB1) 
PGP1,  hamster P-glycoprotein-ATPase 
TMD,   transmembrane domain 
 
 
ABSTRACT 
P-glycoprotein (ABCB1) prevents absorption (e.g. blood-brain barrier) or enhances 
excretion (e.g. kidney) by moving substrates from the cytosolic to the extracellular 
membrane leaflet at the expense of ATP hydrolysis. It translocates various drugs and 
functions in membranes exhibiting different lateral packing densities. To gain more 
functional insight we measured the temperature dependence of the P-glycoprotein ATPase 
activity in NIH-MDR1-G185 cell membranes in the absence and presence drugs 
(Promazine, verapamil and PSC833) exhibiting significantly different transporter affinities. 
Activation enthalpies (ΔH‡) and entropies (TΔS‡) were derived from Eyring plots. In the 
absence of drugs, the activation enthalpy and the free energy of activation for P-
glycoprotein ATPase activity was determined as ΔH‡ = 92.6 ± 4.2 kJ/mol and ΔG‡ = 73.1 ± 
7.2 kJ/mol, respectively. Increasing the drug concentration reduced the activation enthalpy, 
whereby the drug with the highest transporter affinity had the strongest effect (ΔΔH‡ = -21 
%). The free energy of activation decreased for activating (ΔΔG‡ = ~ -3.8 %) and increased 
for inhibitory compounds (ΔΔG‡ = ~ +0.7 %). The drug-specific changes of the free energy 
of activation are thus barely above thermal energy. A comparison with literature data 
revealed that a decrease of the lateral membrane packing density reduces the enthalpic and 
the entropic contribution to the free energy of activation. Although, the P-glycoprotein 
ATPase activity increases only slightly with decreasing lateral membrane packing density 
the mode of action changes from strongly entropy-driven at high, to essentially enthalpy-
driven at low packing densities. This suggests that the transporter and the membrane form 
a functional entity.  
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Footnote 
1 Based on the previously measured Michaelis-Menten constants, Km, (23) and eq. (8) the 
free energy of ATP binding from water to the transporter, 0bGΔ , was estimated as 0 ,bATPGΔ  
≈ -31.1 kJ/mol and 0 ,bATPGΔ  ≈ -30.1 kJ/mol in the presence and absence of drugs, 
respectively. The free energy of drug binding from water to the activating binding regions 
of the transporter was estimated as 0 )1(twGΔ  ≈ (- 30 to - 54) kJ/mol, and the free energy of 
drug binding from the lipid bilayer to the activating binding region of the transporter as 
0
)1(tlGΔ  ≈ (-7 to -27) kJ/mol (11). It should be noted that the Michelis-Menten constants and 
the dissociation constants are similar for ATP (49) as well as for substrates (14). Under 
physiological conditions the free energy of ATP hydrolysis is 0 ,hATPGΔ  = - 55 kJ/mol (50). 
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INTRODUCTION 
 
The human ATP-binding cassette transporter, P-glycoprotein, Pgp (MDR1, ABCB1) is 
highly expressed in absorptive membrane barriers such as the intestinal barrier and the 
blood-brain barrier where it reduces or even prevents absorption of drugs and toxins. It is 
also present in membranes of excretory organs such as the liver and the kidney, where it 
enhances excretion (for review see (1)). Moreover, it is abundant in many tumor cells 
contributing to multidrug resistance (MDR) (for review see (2)). The transporter (170 kDa) 
consists of two transmembrane domains (TMDs) each comprising six putative 
transmembrane helices and two nucleotide binding domains (NBDs) exposed to the 
cytosol. The latter dimerize upon nucleotide binding which leads to the formation of an 
outward-facing conformation by the TMDs (3). 
The analysis of substrate binding and transport by Pgp is complex for several 
reasons.  First, Pgp transports chemically very different compounds (4) at different rates 
(5-7). This is in contrast to most well-known transporters which move one single substrate 
or one class of substrates at a constant rate. An example for the latter case is the related 
heterodimer TAP1/TAP2 (ABCB2/ABCB3) associated with antigen processing (8).  
Second, Pgp binds its substrates in the lipid membrane (9) and more precisely in the 
cytosolic membrane leaflet (10) and flips them to the outer leaflet, whereas most well-
known transporters, including TAP1/TAP2, (8) bind and release their substrates in the 
aqueous phase. This implies that exogenous compounds have to cross the membrane by 
passive diffusion to reach the Pgp binding site. It also implies that the concentration of 
half-maximum activation depends on the nature of the lipid membrane (11).  
Although, transport by Pgp has long been suggested to correlate with ATP 
hydrolysis (12), the stoichiometry is still discussed. Compounds that diffuse rapidly across 
the membrane partially escape to the cytosol before they are caught by Pgp. Therefore 
apparent transport tends to be lower than intrinsic transport (13). The direct correlation 
between transport and ATP hydrolysis was demonstrated using permanently charged 
compounds such as fluorescent dyes (14) or a spin-labeled verapamil analog (15) that 
cannot cross the membrane by passive diffusion. However, these compounds partially 
remain bound to the extracellular membrane leaflet after transport, and therefore the 
question of whether one molecule of ATP is required to transport one substrate molecule 
(16) or whether two molecules are required as demonstrated for TAP1/TAP2 (17) is 
difficult to resolve. We quantified the apparent transport of drugs across a cell membrane 
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as the sum of passive influx and active efflux by Pgp, assuming that the rate of transport 
equals the rate of ATP hydrolysis. The excellent agreement with data from transport assays 
provided clear evidence for the direct correlation between the rate of ATP hydrolysis and 
the rate of effective transport by Pgp (13, 18). 
Pgp ATPase activity was assessed by measuring the release of inorganic phosphate 
from inside-out plasma membrane vesicles and proteoliposomes (5, 7, 19) or by measuring 
the release of lactate from living cells (11). In the absence of drugs the Pgp ATPase shows 
basal activity. Upon titration with drugs the activity increases up to a maximum and then 
decreases again at high concentrations for. The bell-shaped activity profiles have been 
analyzed by modified Michaelis-Menten kinetics (5, 7, 11, 19). The kinetic models used to 
evaluate the bell-shaped activity curves take into account an activating drug binding step at 
low and an inhibitory drug binding step at high concentrations, followed by a catalytic 
ATP hydrolysis step. These models provide an adequate description of the drug-induced 
variation of Pgp ATPase activity as discussed in detail elsewhere (11), however, the 
catalytic step includes further steps such as substrate translocation and transporter 
resetting. Despite extensive efforts it is still controversial whether ATP hydrolysis drives 
only the substrate translocation (16, 19, 20), only transporter resetting after release of the 
substrate (21), or both, substrate translocation and transporter resetting (22, 23).  
Insight into the reaction mechanism can be gained by measuring the temperature 
dependence of ATP hydrolysis rates which allows determination of the transition state 
parameters. The first comprehensive transition state analysis for Pgp and hamster P-
glycoprotein (PGP1) was performed by Al-Shawi et al. (19). They determined the 
transition state parameters for ATPase activity in liposomes of different composition in the 
absence and presence of drugs and suggested that the activation enthalpy, ΔH‡, (or 
activation energy, Ea) as a function of drug concentration first decreases and then increases 
(19). No or only negligibly small effects were observed by others (5, 24, 25).  
The activation energies, Ea, reported for basal Pgp ATPase activity in various 
membranes or membrane mimicking systems differ significantly (19, 24, 26). Although, 
several investigators have shown that Pgp senses the lipid composition (19, 27) and the 
phase state of the lipid membrane (14) the role of the lipid membrane in modulating basal 
Pgp ATPase activity has not yet been investigated systematically. 
We therefore first analyzed how the drug, its concentration and its affinity to the 
transporter influence the transition state parameters (i.e the activation enthalpy, ΔH‡, the 
activation entropy, ΔS‡, and the free energy of activation, ΔG‡) for Pgp ATPase activity. 
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As test compounds we used promazine, verapamil, and the Pgp inhibitor PSC833, an 
analog of cyclosporin A, which differ considerably in their affinity to the transporter (11). 
All three compounds are transported by Pgp, although, only verapamil and PSC833 appear 
as substrates in transport assays (13, 18). As membrane system we used inside-out plasma 
membrane vesicles of NIH-MDR1-G185 cells. Second, we analyzed how the nature of the 
membrane influences the activity of the Pgp ATPase. To this purposes we compared the 
transition state parameters for basal Pgp ATPase activity in plasma membranes of NIH-
MDR1-G185 cells with transition state parameters for basal Pgp ATPase activity in other 
systems. A meaningful comparison is possible if the Pgp ATPase containing membranes 
are characterized by the same physical chemical parameter. Parameters used to 
characterize lipid membranes are e.g. fluidity, the order parameter, and the lateral 
membrane packing density. A decrease in fluidity generally correlates with an increase in 
the order parameter and the lateral membrane packing density. Here, we characterized the 
membranes in terms of the lateral packing density, πM, (28, 29) since it can be directly 
estimated from ATPase activity measurements (11).  
Our investigation shows that all three drugs, even those which reduce the Pgp 
ATPase activity such as PSC833, reduced the activation enthalpy, ΔH‡, (and the activation 
energy, Ea) for ATP hydrolysis, whereby the effect was considerable at high drug 
concentrations. The free energy of activation, ΔG‡, for Pgp ATPase activity decreased at 
low and increased at high drug concentrations. The free energy of activation, ΔG‡, for Pgp 
ATPase activity as a function of concentration thus yielded the mirror image of the bell-
shaped activity profiles in good agreement with the Eyring theory. The comparison of the 
transition state parameters for Pgp ATPase activity in the different membrane systems 
revealed that the activation enthalpy, ΔH‡, and the free energy of activation, ΔG‡ for Pgp 
ATPase activity decrease with decreasing lateral membrane packing density, πM, whereby 
the effect is significant in the former and small in the latter case. The catalytic cycle of the 
Pgp ATPase is discussed in the light of the present data.  
 
 
MATERIALS AND METHODS 
 
 Materials. PSC833 was a gift from Novartis AG (Basel, Switzerland). 
Promazine⋅HCl was obtained from Sigma-Aldrich (Steinheim, Germany), (R/S)-
verapamil⋅HCl from Fluka (Buchs, Switzerland), complete EDTA-free protease inhibitor 
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cocktail tablets from Roche Diagnostics (Mannheim, Germany), 1,4-dithiol-DL-threitol, 
DTT, from Applichem (Darmstadt, Germany), and bicinchoninic acid, BCA, protein assay 
reagents from Pierce (Rockford, IL). All other chemicals were either obtained from Sigma, 
Fluka or Merck. Cell culture media DMEM with pyruvate (Cat. No. 21969) as well as 
other compounds required for cell culture such as fetal bovine serum, FBS, L-glutamine, 
and antibiotics were purchased from Gibco-BRL (Basel, Switzerland).  
Stock solutions for the phosphate release assay were made with nanopure water in 
the case of promazine and verapamil and with DMSO in the case of PSC833. The samples 
for measurements were prepared by adding 5 μL of the aqueous drug solution or 1 μL of 
the DMSO/drug solution to the phosphate release assay buffer (total sample volume per 
well = 60 μL). The final DMSO concentration was constant c = 1.7 % (v/v).  
NIH-MDR1-G185 Cells and the Corresponding Plasma Membrane Vesicles. Wild-
type (NIH3T3) and MDR1-transfected mouse embryo fibroblasts (NIH-MDR1-G185) were 
generous gifts from Dr. M.M. Gottesman and Dr. S.V. Ambudkar (The National Institutes 
of Health, Bethesda, MD). Cells were grown in the presence of 0.15 µM colchicine and 
were maintained as described previously (30). The crude plasma membrane vesicles were 
prepared as described in detail elsewhere (7). 
Monitoring Pgp ATPase Activity in Plasma Membrane Vesicles with Colorimetric 
Phosphate Release Assay. The Pgp associated ATP hydrolysis was measured according to 
Litman et al. (5) in 96-well microtiter plate (Nunc F96 MicroWellTM plate, non-treated) 
with small modifications. Briefly, the plasma membrane vesicles were diluted to a protein 
concentration of 0.1 mg/mL in ice-cold phosphate release assay buffer (25 mM Tris-HCl 
including 50 mM KCl, 3 mM ATP, 2.5 mM MgSO4, 3 mM DTT, 0.5 mM EGTA, 2 mM 
ouabain, and 3 mM sodium azide) unless otherwise stated. The buffer was adjusted to pH 
7.0 at the respective temperatures by taking into account the temperature coefficient of the 
buffer. Each sample contained ~5 μg of protein per total assay volume of 60 μL. 
Incubation with drugs was started by transferring the plate from ice to a water bath kept at 
the temperature of choice for 1 h, and was terminated by rapidly cooling the plate on ice. 
The inorganic phosphate, Pi, concentration was determined by addition of ice-cold solution 
(200 μL) containing ammonium molybdate (0.2 % (w/v)), sulphuric acid (1.43 % (v/v)), 
freshly prepared ascorbic acid (1 % (w/v)) and SDS (0.9 % (w/v)). After incubation at 
room temperature (30 min) the released phosphate was quantified colorimetrically at 820 
nm using a Spectramax M2 (Molecular Device, Sunnyvale, USA). Reference phosphate 
standards were included to each 96-well plate. Samples incubated with 0.5 mM vanadate to 
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determine the vanadate-sensitive Pgp activity were obtained in parallel and were subtracted 
from the measured values.  
Reaction Mechanism. The basic reaction for ATP hydrolysis by Pgp at low drug 
concentration where only the activating binding region is occupied is shown in Scheme (1). 
The reaction including the second binding step is shown in detail elsewhere (11). The 
ATP-substrate stoichiometry is still discussed (see Introduction). For simplicity we assume 
a stoichiometry of 1:1 as suggested previously  (16). The transporter, T(ATP), binds the 
transport substrate, S (in the inner leaflet of the lipid membrane), moreover, it binds a 
second ATP molecule from the aqueous phase, yielding the transporter-ATP-substrate 
complex, T(ATP)2S. The catalytic step includes, ATP hydrolysis, the release of Pi, ADP, 
and substrate and yields the starting complex T(ATP), where k is the measured catalytic 
rate constant, and ΔG‡ is the corresponding free energy of activation. In the absence of 
drugs T(ATP) also binds a second molecule of ATP yielding the complex, T(ATP)2, ATP 
is then hydrolyzed and the starting complex T(ATP) is formed.  
 
Scheme 1 
 
Data Evaluation Using Modified Michaelis-Menten Kinetics. For data evaluation we used 
modified Michaelis-Menten kinetics (5) which considers two substrate binding steps 
 
2
swsw221
2
sw2sw12bas21
sw CCKKK
CVCVKVKKV ++
++= ,     (1) 
 
where Vsw is the rate of Pi release (Pgp ATPase activity) as a function of the substrate 
concentration in aqueous solution, Csw; Vbas is the basal activity of Pgp in the absence of 
drugs, V1 is the maximum transporter activity (if only activation occurred) and V2 is the 
minimum activity at large substrate concentration. At a substrate concentration, K1, half-
maximum Pgp activation, and at a substrate concentration, K2, half-maximum Pgp 
inhibition is reached. The catalytic rate constant, k1 or turnover number corresponds to 
V1/[T]0, where [T]0 is the transporter concentration. According to eq. (1) the rate, Vsw, can 
be measured in the presence (Csw > 0) or in the absence of substrates (Csw = 0). In the 
absence of substrates the rate of the reaction corresponds to the basal rate (Vsw = Vbas). For 
practical reasons, i.e. to investigate the role of drug concentration, we further define 
Vsw/[T]0 as ksw. 
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Temperature Dependence of Pgp ATPase Activity and Evaluation of the Transition 
State Parameters. The bell-shaped activity curve described by eq. (1) was measured in the 
present study as a function of temperature yielding the temperature dependence of the 
different rate parameters such as Vsw or ksw. We evaluate the experimental data according 
to the Eyring equation (2), 
 
   R
S
RT
H
BRT
G
B ee
h
Tke
h
Tkk
‡‡‡ ΔΔ−Δ− κ=κ= ,    (2) 
 
where κ is the transmission factor assumed to be unity, kB is Boltzmann’s constant, h 
Planck’s constant, R the gas constant, T the absolute temperature, ΔG‡ the free energy of 
activation, ΔS‡ the activation entropy, and ΔH‡ the activation enthalpy. It is assumed that 
all transition states break down with the same rate, kBT/h. On the assumption that the 
entropy, ΔS‡, of activation, the enthalpy, ΔH‡, of activation, and the constant kB are 
temperature independent and, moreover, a single process is monitored, a plot of ln(k/T) vs. 
1/T (Eyring plot) yields the activation enthalpy, from the slope and the activation entropy, 
ΔS‡/R, from the y-axis intercept. This equation permits a calculation of the free energy of 
activation, ΔG‡, from measured rate constants as 
ΔG‡ = ΔH‡ -TΔS‡     (3) 
The relationship between the activation enthalpy, ΔH‡, and the activation energy, Ea, can 
be expressed as  
RTEH a −=Δ ‡      (4) 
 
The Isokinetic Relationship. It was proposed that for any single rate-limiting 
transition state there is a linear free energy relationship between two rate constants for the 
reaction, kT1 and kT2, measured at two different temperatures, (T1 < T2) (19, 31) 
 
ln kT2 = a + b ln kT1,     (5) 
 
where a and b are constants. A plot of ln kT2 as a function of ln kT1 yields a preliminary test 
of a common mechanism in related reactions. When the plots deviate from one another it 
follows to a high probability that the mechanisms of the two related reactions are different. 
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Estimation of the Free Energies of Drug and ATP Binding to Pgp. The free energies 
of drug binding, 0tw(1)GΔ , were calculated from concentrations of half-maximum activity, 
K1. Based on the assumption that the binding step is much faster than the subsequent 
catalytic step (11), K1 can be considered as dissociation constant and the inverse 1/K1 as 
transporter-water binding constant, Ktw(1) to a first approximation.  
 
1/K1 ≅ Ktw(1)      (6) 
 
The assumption made in eq. (6) is supported by the similarity of the concentrations of half-
maximum activation, Km, for ATP hydrolysis and the dissociation constant, Kd determined 
for ATP binding to MIANS-labelled Pgp. Moreover, the Km for tetramethylrosamine also 
compared favorably with the Kd for MIANS-labelled Pgp (14). 
 
The corresponding free energy relationship is shown below, 
 
0
tw(1)GΔ  ≅ - RTln(CwKtw(1)) ≅ - RTln(Cw (1/K1)).   (7) 
 
The superscript zero refers to a biological standard state (pH 7.4 and 37°C), and Cw = 55.3 
mol/L corresponds to the molar concentration of water at 37°C. The constants Ktw(1) and 
1/K1 with the units [L/mol] are multiplied by the concentration of water, Cw [mol/L], to 
obtain mole fraction units (32). A corresponding expression was formulated for ATP 
binding,  
 
0
bGΔ  = - RTln(Cw (1/Km)).     (8) 
 
 
RESULTS 
 
Pgp ATPase Activity in Inside-Out Plasma Membrane Vesicles as a Function of Drug 
Concentration and Temperature. The test compounds, promazine, verapamil, and PSC833 
are listed in Table 1 together with their molecular weight, cross-sectional area, AD, 
concentration of half-maximum Pgp ATPase activation, K1, maximum activity, V1, and free 
energy of binding from water to the activating binding region of the transporter, 0 )1(twGΔ . 
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The more negative the free energy of binding, 0 )1(twGΔ , the higher is the binding affinity to 
the transporter as shown previously (11). The molecular weight, the cross-sectional area, 
AD, and the binding affinity to the transporter increase considerably in the order: promazine 
< verapamil < PSC833 and the concentrations of half maximum activation, K1, differ by 
orders of magnitude. 
The basal, Vbas, and drug-induced Pgp ATPase activity, Vsw, in inside-out vesicles 
formed from plasma membranes of NIH-MDR1-G185 cells were measured by monitoring 
the phosphate release rate with a colorimetric assay (7). Titrations were performed as a 
function of concentration at different temperatures over the temperature range, ΔT = (25 - 
37) oC, with the buffer adjusted to pH 7.0 at each temperature. The titration curves are 
shown in Figure 1A-C.  
The first point in each titration curve (Figure 1A-C) corresponds to basal activity, 
Vbas, and the subsequent points to drug-induced ATPase activity, Vsw. The solid lines drawn 
in Figure 1 are fits to the measured data using the kinetic model given in eq. (1).Each drug 
shows a specific ATPase activity profile that is characterized by four parameters (see eq. 
(1)), the concentration of half-maximum activation, K1, (with one molecule bound to the 
transporter) the concentration of half-maximum inhibition, K2, (with two molecules bound 
to the transporter), and the maximum, V1, and minimum, V2, ATPase activity, respectively 
(see also ref. (5)). Promazine (Figure 1A) and verapamil (Figure 1B) exhibit the typical 
bell-shaped activity curves as a function of concentration, whereas PSC833 (Figure 1C) 
reduces the ATPase activity relative to basal values in the whole concentration range 
measured. With increasing temperature basal, Vbas, and drug-induced ATPase activity, Vsw, 
increase. However, the shape of the activity curves remains approximately constant for a 
given drug. For comparison with literature data (see below, Figure 8), we also measured 
the Pgp ATPase activity as a function of verapamil concentration at pH 7.5 (Tris buffer) 
and T = 35 °C (see Table 1). The concentration of half-maximum activation, K1, is lower 
than at pH 7.0 due to the higher lipid-water partition coefficient, Klw, of the drug at the 
higher pH, however, the maximum activity, V1, is similar (Table 1).  
TABLE 1 
FIGURE 1A-D 
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The Thermodynamic Transition State Parameters for Pgp ATPase Activity in the 
Presence of Different Drugs. Figure 2A-C displays plots of ln(ksw/T) vs. the reciprocal 
absolute temperature (Eyring plot) in the absence and presence of drugs for inside-out 
plasma membrane vesicles of NIH-MDR1-G185 cells. Each line corresponds to a specific 
concentration in the activity profiles (Figure 1). The lines are linear fits to the data. The 
activation enthalpy, ΔH‡, and activation entropy, ΔS‡, for Pgp ATPase activity were 
determined from the slope and the y-axis intercept, respectively. The transition state 
parameters determined from Eyring plots are summarized in Table 1. As previously 
pointed out by Al-Shawi et al. (19) data derived from these plots have to be considered as 
apparent values, valuable for the particular membrane and the temperature range indicated.  
 
FIGURE 2A-D 
 
Figure 3 shows lnV1 for promazine and verapamil as a function of the reciprocal 
absolute temperature. The maximum rate, V1, is expressed relative to basal value at the 
corresponding temperature. In this representation the maximum rate, V1, decreases with 
increasing temperature. Because the change in activity with temperature is more 
pronounced in the absence than in the presence of drugs. 
Transition State Parameters of the Pgp ATPase Activity as a Function of Drug 
Concentration. We have measured the transition state parameters for the Pgp ATPase 
activity in NIH-MDR1-G185 plasma membranes over a large range of concentrations 
(Figure 2) covering the full activity profiles (Figure 1). Figure 4A-C shows the 
thermodynamic transition state parameters, ΔH‡, TΔS‡ and ΔG‡, derived for Pgp ATPase 
activity as a function of promazine, verapamil and PSC833 concentration, respectively. 
The concentration of half-maximum activation for promazine and verapamil and the 
concentration of half-maximum inhibition for PSC833 are indicated by arrows. In the 
absence of drugs the activation enthalpy for ATPase activity in plasma membrane vesicles 
of NIH-MDR1-G185 cells was determined as ΔH‡ = 92.6 ± 4.2 kJ/mol. Increasing the drug 
concentration reduced the activation enthalpy, ΔH‡, and the activation entropy, TΔS‡, for 
both, activating and inhibitory compounds as seen in Figure 4A-C. The reduction in the 
enthalpy increased in the order verapamil (ΔΔH‡ = -14 kJ/mol, (-15 %) < PSC833 (ΔΔH‡ = 
-19.2 kJ/mol, (-21 %) < promazine (ΔΔH‡= -27.6 kJ/mol (-30 %) at the highest 
concentrations investigated. At high drug concentrations the entropy contribution almost 
vanished, and the Pgp ATPase was therefore essentially enthalpy driven under these 
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conditions. Figure 4A-C shows that the drug-induced changes are not negligible as 
assumed previously (5, 24, 25) but depend on the drug concentration applied. Data in 
Figure 4A-C also differ from those observed by Al-Shawi et al. (19). 
The free energy of activation was determined as ΔG‡ = 73.1 kJ/mol (at T = 37 °C) 
in the absence of drugs. With increasing promazine and verapamil concentration (Figure 
4D, E) the free energy of activation, ΔG‡, first decreased and then increased again, while it 
increased already at low concentrations of PSC833 (Figure 4F). The decrease relative to 
the basal value was ΔΔG‡ = -2.8 kJ/mol (-3.8%) for verapamil, and the increase relative to 
the basal value was ΔΔG‡ = +0.5 kJ/mol (+0.7%) for PSC833. The drug-induced changes 
in the free energy of activation, ΔG‡, relative to basal values are thus small, but drug 
specific.  
To test the relevance of the ΔG‡ values we inserted  them into the Eyring eq. (2) 
and calculated the activity profiles (i.e. the rate constants, ksw, as a function of 
concentration) for comparison with the ATPase activity profiles measured directly at a 
given temperature (Figure 4G-I). Since the ΔG‡ values change with concentration the 
calculated curve is not a simple exponential (see eq. (2)) but is indeed bell-shaped. The 
resulting activity profiles showed a two to three fold increase and a somewhat smaller 
decrease in rate depending on the concentration in excellent agreement with the 
experimentally determined activity profiles.  
The temperature dependence of the Pgp ATPase activity was also measured in 
living NIH-MDR1-G185 cells by monitoring the extracellular acidification rate, ECAR, 
(11) in the absence and in the presence of verapamil. Below 35°C similar Eyring plots 
were obtained (33). 
 
FIGURE 4A-F 
 
One or More than One Rate-Limiting Transition State? As seen in Figure 1 the Pgp 
ATPase works (i) under basal conditions (in the absence of drugs), (ii) under conditions of 
drug-induced activation (at low and intermediate concentrations) and (iii) under conditions 
of drug-induced inhibition (at high concentrations). To see whether the three different 
modes of Pgp ATPase activity are rate-limited by the same transition state we applied the 
isokinetic equation (eq. (5)) (31) as proposed by Al-Shawi et al. (19). The logarithm of the 
rate constants, lnVsw, measured as a function of the drug concentration at T2 = 31°C and T3 
= 37°C were plotted as a function of the corresponding rate constants, lnVsw, measured at 
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T1 = 25°C according to eq. (5) (Figure 5). As seen in Figure 5, data fit linear regression 
lines with a slope, m ≈ 1 (m = 0.99 and m = 0.90, respectively). From these data no 
indication of more than one rate-limiting transition state can be observed which suggests 
that the basal, the drug-induced and the drug-inhibited Pgp ATPase activity are rate-limited 
by the same transition state. 
In a previous investigation (19) data for low and high drug concentrations also fell 
to the same regression line (slope of m ≈ 0.8) which is close to that in the present analysis. 
However, the values for basal ATPase activity deviated and the regression line revealed a 
slope of m ≈ 0.5 only.  As a consequence two different transition states, one associated 
with uncoupled basal activity and the other with coupled drug transport activity, were 
proposed. It should be noted that the investigation was performed with membranes 
exhibiting different lateral packing densities which might affect the slope of the curve 
measured under basal conditions (see Discussion). 
 
FIGURE 5 
 
 
DISCUSSION 
 
We measured the basal and drug-induced Pgp ATPase activity in inside-out plasma 
membrane vesicles of NIH-MDR1-G185 cells over a broad concentration range using 
promazine with low, verapamil with intermediate, and PSC833 with high affinity to the 
transporter. The activity profile for each drug was measured at different temperatures 
which allowed assessment of the transition state parameters, ΔH‡, TΔS‡, and ΔG‡ for Pgp 
ATPase activity from Eyring plots in the absence and presence of drugs. The relevance of 
the free energies of activation, ΔG‡, determined was demonstrated by inserting the values 
into the Eyring equation (eq. (2)) which yielded the rate constants in excellent agreement 
with the primary data. In the following we compare the transition state parameters for Pgp 
ATPase activity in plasma membranes of NIH-MDR1-G185 cells in the absence of drugs 
with those obtained previously in other systems and analyze the influence of the lateral 
membrane packing density, πM. We then discuss the changes in the transition state 
parameters observed upon titration with the different drugs and estimate to which extent 
they are due to direct substrate-transporter interactions and to which extent they are 
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membrane mediated. Models for the catalytic cycle of the Pgp ATPase are discussed on the 
basis of the present data.  
The Transition State Parameters for Pgp ATPase Activity in the Absence of Drugs. 
The transition state parameters for basal Pgp ATPase activity measured in different lipid 
membranes or membrane mimicking systems (19, 26) differ considerably. A meaningful 
comparison with the transition state parameters for Pgp ATPase activity determined in 
plasma membranes of NIH-MDR1-G185 cells is possible if data are plotted as a function 
of the lateral packing density, πM, of the different membranes or membrane mimicking 
systems as seen in Figure 6.  
The lateral membrane packing density, πM, is not directly measurable, but can be 
assessed in comparison to the lateral membrane packing density or surface pressure, π, of a 
lipid monolayer which is directly measurable. Monolayer-bilayer equivalence packing 
densities (or equivalence pressures) were obtained by comparing binding isotherms to lipid 
bilayers with binding isotherms to lipid monolayers at different lateral packing densities 
(28). To assess the lateral packing density, πM, of a lipid membrane containing the Pgp 
ATPase we measured the concentration of half-maximum Pgp ATPase activation, K1, for 
verapamil and compared it with the K1, value for verapamil measured in a membrane with 
known lateral membrane packing density (for details see (11)). For bilayer membranes the 
lateral packing density varied between πM ≅ 51 mN/m as estimated for mixed liposomes 
composed of 60 % (w/w) E. Coli lipids, 17.5 % egg phopshatidylcholine, 10% bovine 
brain phosphatidylserine, and 12.5% cholesterol (19) and πM = 30.5 ± 1.0 mN/m as 
estimated for plasma membranes of NIH-MDR1-G185 cells (11). For CHAPS micelles the 
lateral packing density was estimated as πM ≅ 10 mN/m in analogy to that of SDS micelles 
(34). The extrapolation to zero lateral membrane packing density (πM = 0 mN/m) can be 
considered as the hypothetical situation of Pgp working in an isotropic solvent. For 
comparison the transition state parameters for ATP hydrolysis by the water soluble NBD of 
the glucose ABC transporter of the extreme thermoacidophile Sulfolobus solfataricus, 
GlcV (35) were included in Figure 6. The soluble NBDs of GlcV dimerize upon ATP 
binding and hydrolyze both ATP molecules in the interface (35).  
The free energy of activation for Pgp ATPase activity appears at first sight almost 
packing density independent. However, it slightly decreases from ΔG‡ = 73.9 kJ/mol at πM 
≅ 51 mN/m to ΔG‡ = 72.2 kJ/mol at πM ≅ 0 mN/m (ΔΔG‡ = -1.7 kJ/mol) which translates 
into an approximately 2 fold acceleration of ATP hydrolysis. This is in good agreement 
with previous observations showing that basal Pgp ATPase activity is higher in more 
7. Reprints and Unpublished Manuscripts 131
disordered lipids with low phase transition temperatures, Tc, than in more ordered lipids 
with a higher phase transition temperature (see Figure 7 in ref. (36)). The free energy of 
activation, ΔG‡, has contributions from both, enthalpy, ΔH‡, and entropy, TΔS‡, the 
transporter can thus function either by lowering the enthalpy or enhancing the entropy of 
activation (i.e. decreasing -TΔS‡) (eq. (2)). In membranes or membrane mimicking systems 
with the lowest lateral packing density, πM, the activation entropy, TΔS‡, is close to zero 
and the Pgp ATPase thus functions in an essentially enthalpy-driven manner. A similar 
situation is observed for the soluble NBDs of GlcV (35) which is also enthalpy-driven. 
With increasing lateral membrane packing density, πM, the enthalpy, ΔH‡, and the entropy, 
TΔS‡, contribution increase and the latter becomes significant. This suggests that the lipid 
membrane plays a crucial role in the mode of activation of the Pgp ATPase. The function 
of proteins embedded in densely packed lipid bilayers may thus be supported by the high 
"entropy-producing potential" of lipid membranes as suggested previously (37). 
 
FIGURE 6 
 
All over, the activation energy, Ea, and activation enthalpy, ΔH‡, for Na/K-ATPase 
seem to be smaller than those of the Pgp ATPase. The activation energy was determined as 
Ea ≈ 19 kJ/mol for the Na/K-ATPase in the foot muscle of land snails (38). The activation 
enthalpy was determined as ΔH‡ ≈ 67 kJ/mol and ΔH‡ ≈ 74 kJ/mol for the Na/K-ATPase 
from the shark rectal gland reconstituted into dioleoylphosphatidylcholine and into 
dioleoylphosphatidylcholine containing 40% cholesterol, respectively (39). Land snail 
membranes with a high content of highly unsaturated lipids (40) exhibit most likely the 
lowest lateral packing density, membranes formed from dioleoylphosphatidylcholine 
exhibit an intermediate and the cholesterol containing membranes the highest lateral 
packing density of the three membranes cited. Provided the Na/K-ATPases from the 
different sources are comparable the activation energy, Ea, seems again to increase with the 
lateral packing density of the membrane. For the sarcoplasmic reticulum Ca-ATPase it was 
shown that the lipid fluidity directly modulates the overall protein rotational mobility and 
the ATPase activity (41) which again supports the trends observed in Figure 6. 
The Transition State Parameters as a Function of the Drug Affinity to the 
Transporter and Drug Concentration. Figure 7 displays the drug-induced Pgp ATPase 
activity in plasma membrane vesicles formed from NIH-MDR1-G185 cells, ln k1 
(indicated as lnk in Figure 7), as a function of the binding affinity of the drug to the 
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transporter (i.e. the free energy of drug binding from water to the transporter, 0 )1(twGΔ ) for 
promazine, verapamil, and PSC833 in comparison to other compounds measured 
previously under the same conditions (7). The Pgp ATPase activity, lnk1, decreases linearly 
with increasing affinity of the drug from water to the transporter (or decreasing free energy 
of drug binding from water to the transporter, 0 )1(twGΔ ). A similar linear correlation 
between the rate constant, lnk, and the affinity to the transport system was observed 
previously for maltoporin LamB of E.coli (42) as shown for comparison in Figure 7. 
Maltoporin is a much simpler transport system which allows the translocation of 
maltodextrins of different lengths.  
Maltodextrins interact with maltoporin essentially via transient hydrogen bond 
formation, whereby the substrates provide the hydrogen bond donor groups and the 
transporter the hydrogen bond acceptor groups (42). A related mechanism has been 
proposed for the interaction of the Pgp ATPase with transport substrates. However, in the 
case of the Pgp ATPase the substrate provides the hydrogen bond acceptor groups and Pgp 
the hydrogen bond donor groups (4, 11, 43). It is interesting to note that the overall rate of 
translocation by maltoporin is in the millisecond range, whereas, the rate of substrate 
translocation by Pgp is in the range of seconds. The low rate of transport by the Pgp 
ATPase seems to be due to the requirement for a conformational switch between the 
binding- and the release-competent conformation, respectively.  
According to the Eyring equation (eq. 2) the rate, k, decreases with increasing free 
energy of activation, ΔG‡. Figure 7 thus suggests that the free energy of activation, ΔG‡, 
for Pgp ATPase activity increases with increasing substrate affinity to the transporter (or 
decreasing free energy of activation, 0 )1(twGΔ ). PSC833, the compound with the highest 
affinity to the transporter indeed shows the highest activation energy, ΔG‡, as seen in Table 
2.  
FIGURE 7 
 
In addition to the drug affinity, the drug concentration also plays a substantial role 
for the Pgp ATPase activity (Figure 1A-D and Figure 4 G-I) and the corresponding free 
energy of activation, ΔG‡ (Figure 4D-F). The change in the free energy of activation varied 
from ΔΔG‡ ∼ -3.8% to ΔΔG‡ ∼ +0.7%. The activation enthalpy, ΔH‡, and the activation 
entropy, TΔS‡, for the Pgp ATPase activity in NIH-MDR1-G185 plasma membranes 
decreased with increasing concentration for both activating and inhibitory compounds as 
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seen in Figure 4A-C. At the highest concentrations measured the reduction in the enthalpy, 
ΔΔH‡, increased in the order verapamil < PSC833 < promazine. However, if the 
compounds are compared at identical concentrations the “inhibitor” PSC833 has the 
strongest and promazine the weakest enthalpy lowering effect. The strong effect of 
promazine at the high concentrations measured (Figure 4A-C) may be twofold. First, more 
than one molecule of the drug may be bound to the transporter and the transporter my thus 
feel a cargo of “higher affinity”. The low activation entropy in the presence of more than 
one molecule with low affinity or of one molecule with high affinity may be due to a loss 
of residual motion of the substrate-transporter complex. Moreover, the high drug 
concentration in the membrane (in the case of promazine) may slightly lower the order 
parameter and the lateral packing density of the membrane.  
 The Lateral Packing Density of the Membrane May Vary in the Course of the 
Experiment. Drug partitioning into membranes leads to a reduction of the fatty acyl chain 
order of lipids and a concomitant decrease of the lateral lipid packing density, πM, of the 
membrane, as has been shown by deuterium NMR for verapamil (44), local anesthetics 
(45) and also for cyclosporin A, an analog of PSC833, however, to a lesser extent (46). 
Since the mole fraction of drugs in the lipid membrane at the concentrations of half-
maximum Pgp ATPase activation is rather high (11) a reduction of the membrane order 
and the lateral membrane packing density can be expected for most drugs.  
The fatty acyl chain order of lipid bilayers and the lateral packing density of the 
lipid bilayer, πM, also decrease with increasing temperature as shown by deuterium NMR 
(47). In the limited temperature intervals, ΔT, the lateral membrane packing density 
changes may, however, be small as suggested by the apparently linear Arrhenius or Eyring 
plots for Pgp ATPase activity (ΔT = 18 oC for crude membrane preparations of Chinese 
hamster ovary cells, CR1R12 (5), ΔT = 17 oC for HeLa cells (22), and ΔT = 12 oC for 
proteoliposomes (19) and plasma membrane of NIH-MDR1-G185 cells (present 
investigation)). A much broader temperature range (ΔT = 40 °C) was accessible by using 
radioactively labeled ATP and yielded a convex Arrhenius plot for the Pgp ATPase in 
crude membranes of CHRB30 (25). It is interesting to note that if the activation energy, Ea, 
for crude membranes of CHRB30 (25) is assessed in the temperature range used in the 
present investigation a comparable value is obtained. The water soluble NBD of the 
glucose ABC transporter of the extreme thermoacidophile Sulfolobus solfataricus, GlcV, 
shows in contrast an Eyring plot which is linear over a much broader temperature range 
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(ΔT = 60 °C) (35). Nevertheless, the change in the lipid packing density with temperature 
may not be the only factor responsible for the non-linear Eyring plot of the Pgp ATPase. 
Differentiation between Drug-Induced and Packing Density-Induced Effects. As 
discussed, the enthalpy of activation,  ΔH‡, for Pgp ATPase activity decreases with 
decreasing lateral membrane packing density, πM, (Figure 6) as well as with increasing 
drug concentration (Figure 4A-C). The question arises to which extent the decrease in the 
activation enthalpy in the present experiments is due to a drug-induced reduction in the 
membrane packing density, πM, and to which extent it is due to the direct drug-transporter 
interaction. To address this question in more detail we compared the basal rates of ATP 
hydrolysis with the drug-induced rates, both measured at different lateral membrane 
packing densities (Figure 8A). In Figure 8A all data are given relative to the basal rate at 
the highest lateral packing density, taken as 100 %. The comparison in Figure 8A reveals 
that the maximum possible acceleration achieved by loosening the lateral membrane 
packing density, πM, is lower than that induced by concentrations of verapamil yielding the 
maximum activity, V1, but higher than the effect induced by the inhibitory PSC833. This 
implies that a significant part of the activity modulating effect of drugs is due to the direct 
substrate-transporter interaction and that the acceleration of ATP hydrolysis due to drug-
induced membrane loosening is small. Figure 8A moreover reveals that a specific drug 
(e.g. verapamil) induces approximately the same rate of ATP hydrolysis in different 
membranes if compared to a single reference state, (e.g. the basal rate at the highest lateral 
packing density). This further supports the assumption that the substrate transporter 
interaction is independent of the lateral membrane packing density (11). Generally, drug-
induced Pgp ATPase activity is expressed relative to the basal activity in the respective 
system as shown in Figure 8B. This representation gives the impression that the Pgp 
ATPase works better in densely packed, than in loosely packed membranes which is 
misleading (for review see also Introduction in ref. (48)). A comparable situation is seen in 
Figure 3 which shows a decrease of the fold activity with increasing temperature, due to 
the fact that the basal activity shows stronger temperature dependence than the drug-
induced activity.  
Discussion of the Catalytic Cycle - Does Drug Transport Occur before or after 
ATP hydrolysis by the Pgp ATPase? We first consider the Pgp ATPase as a simple 
enzyme, ignoring its transport function. Under these conditions ATP is the substrate which 
is transformed to inorganic phosphate and ADP. For this reaction three transition states can 
be assumed, one for ATP binding (with the free energy of activation, ΔG‡1), a second one 
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for ATP hydrolysis (with the free energy of activation, ΔG‡2), and a third one for ADP 
release (with the free energy of activation, ΔG‡3), whereby the second step is rate-limiting 
(ΔG‡2 >> ΔG‡1 and ΔG‡3). The free energies of ATP binding and ATP hydrolysis are 
similar1 and are dissipated. The energy levels of the substrate decrease from one step to the 
other, whereas the energy level of the enzyme remains unchanged. A model with a rate-
limiting ATP hydrolysis step could also be considered in the presence of a transport 
substrate (i.e. a drug) which lowers the activation energy, ΔG‡2. If we assume that this 
model is appropriate for the Pgp ATPase, drugs must still be bound when the transition 
state for ATP hydrolysis has formed and drugs are released only after ATP is hydrolyzed. 
On the basis of the apparent linearity of Eyring plots an analogous model was suggested by 
Al-Shawi et al. (19).  
A different interpretation is possible if we assume a model analogous to that 
proposed previously for Na,K-ATPases (50) and adopted for the Pgp ATPase by Higgins 
and Linton (21). In this model ATP binding and hydrolysis serve to switch the protein 
between two conformational states with a high- and a low-affinity binding site for the 
substrate, respectively. The free energy of ATP binding and ATP hydrolysis may be 
transformed into potential energy which is stored in the protein and is then used to drive 
the two conformational changes. If we further assume that the two conformational changes 
of the Pgp ATPase exhibit similar free energies of activation, ΔG‡, the transition state for 
the first conformational change could be modulated by the presence of drugs, and drugs 
could then be released before the ATP-driven resetting step occurs. Based on the 
observation that the rate of ATP hydrolysis depends in an exponential manner on the drug 
affinity to the transporter (Figure 7) we previously suggested that drugs may be released 
before ATP is hydrolyzed (7), which is consistent with the second model. However, for a 
conclusive answer, further experiments are required. 
 
FIGURE 8  
 
Summary. To test how Pgp senses its substrates we measured the temperature 
dependence of the Pgp ATPase activity in inside-out plasma membrane vesicles of NIH-
MDR1-G185 cells over a broad concentration range using three drugs with different 
affinities to the transporter and determined the transition state parameters from Eyring plots 
in the temperature range, ΔT = (25 - 37) oC. To investigate how the Pgp senses the lipid 
composition of the membrane we compared the transition state parameters for basal 
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ATPase activity in inside-out plasma membrane vesicles of NIH-MDR1-G185 cells with 
the transition state parameters for Pgp ATPase activity in other systems exhibiting different 
lateral membrane packing densities, πM. This revealed that the free energy of activation, 
ΔG‡, decreases slightly with decreasing lateral membrane packing density, πM 
(corresponding to a maximally two-fold increase in activity). Moreover, it revealed that the 
transporter works in an essentially enthalpy driven manner at low, and in a more entropy 
driven manner at high lateral packing densities. 
Addition of low-affinity drugs at low and intermediate concentrations lead to a 
small decrease (maximally ΔΔG‡ = ~ -3.8 %) in the free energy of activation, ΔG‡ relative 
to basal values (corresponding to an increase in ATPase activity). Addition of high-affinity 
drugs at low concentrations, or low-affinity drugs at high concentrations, lead, in contrast, 
to a small increase (ΔΔG‡ = ~ +0.7 %) in the free energy of activation, ΔG‡, (corresponding 
to a decrease in the rate of transport). The activation enthalpy, ΔH‡ (or activation energy 
Ea), and the activation entropy, TΔS‡, decreased significantly with increasing 
concentration, and increasing transporter affinity of the drug. At high drug concentrations 
the Pgp ATPase worked in an essentially enthalpy-driven manner which may be due to the 
loss of residual motion of the transporter and, however, to lower extent, to the loosening of 
the lateral membrane packing density upon drug partitioning into the membrane.  
Although, basal activity seems to increases slightly with decreasing lateral packing 
density, πM, the effective transport rate seems not to decrease. The Pgp ATPase is thus able 
to efficiently transport cargo of considerable size at almost constant rate in membranes of 
different lateral packing densities, πM, whereas uncatalyzed flip-flop and diffusion of 
molecules across a lipid membrane decrease exponentially with increasing lateral packing 
density, πM, and increasing cross-sectional area, AD (13, 29). Densely packed lipid 
membranes, expressing a high level of the Pgp ATPase thus guarantee excellent barrier 
properties. The catalytic cycle may be similar to that of Na,K-ATPases, where cargo is 
released before ATP is hydrolyzed, however, further experiments are required to get a 
conclusive answer. 
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TABLES 
Table 1. Characteristic Parameters for Test Compounds and Transition State Parameters 
for ATP Hydrolysis by the Pgp ATPase in the Absence and Presence of Different Drugs.  
Drug 
MWbase   
[g/mol] 
ADa  
[Å2] 
K1           
[μM] 
V1       
[%] 
0
)1(twGΔ  
[kJ/mol]
Concd   
[µM] 
ΔΗ ‡e        
[kJ/mol] 
ΤΔS‡e     
(37 °C) 
[kJ/mol] 
ΔG‡e        
(37 oC) 
[kJ/mol] 
Basal - - - - - 0 92.6 ± 4.2  19.5 ± 1.0  73.1      
promazine 284.4 42  214.5 ± 28.6b 378 ± 15b -31.2b 160.6   83.5 ± 6.5  11.9± 1.1   71.6 
verapamil 454.6 90  1.0 ± 0.2 250 ± 28 -44.5  0.8 88.5 ± 12.7 17.2 ± 2.8 71.2    
PSC833 1214.6 140 0.008 ± 0.001  84 ± 10 -56.6 1.9 73.4 ± 7.7 -0.2 ± 0.1 73.6 
verapamil 454.6 90 0.67 ± 0.09c 274 ± 10c -45.6c - - - - 
aThe cross-sectional area of drugs, AD, were determined from the surface activity measurements in 50 mM 
Tris-HCl, 114 mM NaCl, pH 8.0 at ambient temperature; the cross-sectional area, AD, of PSC833 was 
assumed to be identical to that of cyclosporin A (11). The concentration of half-maximum Pgp activation, K1, 
and the maximum Pgp activity, V1, were determined at 37 oC and pH 7.0. bData for promazine were obtained 
with a membranes prepared from older cells and gave higher values for the concentration of half-maximum 
Pgp activation, K1, than given  in ref. (7). cMeasurements performed at pH 7.5, T = 35 °C. dTransition state 
data are given at the concentrations closest to the concentration of half-maximum activation, K1, for 
promazine and verapamil and for the concentration of half-maximum inhibition, K2, for PSC833. eThe 
transition state parameters are evaluated from Figure 2A-C. The parameters are apparent values and are valid 
in the given temperature range. The ΔG‡ values have to be considered as estimates. Thermodynamic 
parameters for basal values are the average of seven different temperature dependence measurements with 
multiple samples (number of samples, n > 140, four different membrane preparations). Thermodynamic 
parameters for drug stimulated values are the average of one temperature dependence measurement with 
multiple samples. The errors for basal and drug stimulated values represent the goodness of the linear fit.  
 
 
SCHEMES 
 
Scheme 1: Pgp ATPase activity at low substrate concentration considering one ATP 
hydrolyzed per cycle (16). The dotted arrow indicates that the catalytic step is more 
complex than observed by Pgp ATPase measurements. 
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FIGURE LEGENDS 
 
FIGURE 1A-C: Temperature dependence of the Pgp ATPase activity, Vsw, as a 
function of drug concentration in inside-out plasma membranes of NIH-MDR1-G185 cells 
(A-C): Promazine (A), verapamil (B), and PSC833, an “inhibitor” of the Pgp ATPase (C). 
The filled and open symbols represent basal and drug induced Pgp ATPase activity, 
respectively. Pgp ATPase activity was measured by means of a colorimetric phosphate 
release assay at (?, ?) 25, (?, ?) 28, (?, ?) 31, (?, ?) 34 and (?, ?) 37 oC, either in 
25 mM Tris-HCl or 25 mM Hepes-KOH buffer. Buffer were adjusted to pH 7.0 taking into 
account the temperature coefficient of the buffer. Data are expressed as the average of two 
to four experiments. Solid lines are fits to the modified Michaelis-Menten equation (eq. 
(1)). 
FIGURE 2A-C:  Analysis of the thermodynamic transition state parameters by means 
of Eyring plots for Pgp ATPase activity in plasma membrane vesicles: Eyring plots for Pgp 
ATPase activity under basal conditions (?) and increasing concentrations of promazine 
(A), verapamil (B), and PSC833 (C) (open symbols and stars). Each symbol corresponds to 
a specific concentration in Figure 1. Pgp ATPase activity is expressed in absolute values (s-
1) and was calculated as described previously (7). The amount of the Pgp ATPase in 
plasma membrane vesicle preparations used in verapamil and PSC833 measurements was 
estimated as 0.9 % and in promazine measurements as 1.1 % of total protein. The straight 
lines are linear fits to the data.  
FIGURE 3: Temperature dependence of maximum Pgp ATPase activity, lnV1 (where V1 
is given in % values) for verapamil (?) and promazine (?). The straights lines are the 
linear regressions to the data. Data are expressed as the average of two to six experiments. 
 
FIGURE 4A-I: The thermodynamic transition state parameters for Pgp ATPase 
activity in plasma membrane vesicles of NIH-MDR1-G185 cells as a function of drug 
concentration: Promazine (A, D, G), verapamil (B, E, H) and PSC8333 (C, F, I). A-F: 
Activation enthalpy, ΔH‡, (???); activation entropy, TΔS‡, (???); and free energy of 
activation, ΔG‡, (???) at T = 37°C. Filled and open symbols represent data in the 
absence and presence of drugs, respectively. Filled black and open symbols represent data 
from one temperature dependence measurement with multiple samples and filled gray 
symbols represent the average of seven temperature dependence measurements with 
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multiple samples. G-I: Measured Pgp ATPase activity at 37°C (?) (data from Figure 1); 
Pgp ATPase activity (???) calculated according to eq. 2 using ΔG‡ values given in D-
F. The arrows indicate the concentrations of half-maximum activation for verapamil and 
promazine and the concentration of half-maximum inhibition for PSC833. The straight 
lines were drawn to guide the eye. For clarity the error bars were omitted. For the 
activation enthalpy and the activation entropy, the error (representing the goodness of the 
fit) was ~ 20% at very low concentrations and ~ 10% at higher concentrations. 
FIGURE 5: Isokinetic relationship. The logarithm of Pgp ATPase activity, lnVsw (at T2 = 
31 °C) (lower data set) and lnVsw (at T3 = 37 °C) (upper data set) is plotted as a function of 
lnVsw (at T1 = 25 °C). Filled symbols (?) basal activity and open symbols drug-induced 
activity, measured over the whole concentration range given in Figure 1A-C: promazine 
(?), verapamil (?) and PSC833 (?).  
FIGURE 6: The thermodynamic transition state parameters for basal Pgp ATPase activity 
as a function of the lateral packing density, πM, of the membrane surrounding the 
transporter. The lateral membrane packing densities were derived from the concentrations 
of half-maximum Pgp activation, K1, determined at pH 7.4 or pH 7.5 according to ref. (11). 
Different reconstitutions may provide slightly different lateral packing densities. 
Activation enthalpy, ΔH‡ (?, ?), the product of the absolute temperature and the 
activation entropy, TΔS‡ (?, ?), and the free energy of activation, ΔG‡, (?, ?) for Pgp 
ATPase activity at T = 35 °C. 1: MDR1 in native NIH-MDR1-G185 membranes (pH 7.0), 
(present data is an average of seven different temperature dependence measurements with 
multiple samples); 2: MDR1 in mixed E. coli lipids (pH 7.5) (19); 3: PGP1 (hamster Pgp), 
in dimyristoylphosphatidylcholine (26), 4: PGP1 in CHAPS (26). The open symbols 
represent the transition state parameters measured for the water-soluble NBD of Glucose 
ABC transporters, GlcV, (pH 6.5). It works as a dimer and hydrolyzes one ATP per 
monomer (35). The solid lines are the linear regressions to the data presented as filled 
symbols.  
FIGURE 7: Correlation between the rate of substrate transport and substrate affinity to the 
Pgp ATPase and maltoporin. For the Pgp ATPase the logarithm of the rate constants, k1, 
for ATP hydrolysis taken as k is plotted as a function of the free energy of substrate 
binding from water to the activating binding region of the transporter, 0 )1(twGΔ , taken from 
ref. (7) (?). Data obtained from the present investigation are indicated as (?). Substrates: 
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amitriptyline (1), chlorpromazine (2), cis-Flupenthixol (3), cyclosporin A (4), dibucaine 
(5), diltiazem (6), glivec (7), progesterone (8), promazine (9), (R/S)-verapamil (10), 
reserpine (11), trifluoperazine (12), triflupromazine (13), OC144-093 (14), PSC833 (15), 
vinblastine (16). For comparison, the logarithm of the rate constants, k, for transport across 
maltoporin is plotted as a function of the free energy of substrate binding from water to 
maltoporin, 0twGΔ  (?) (42): Maltotriose (17), maltotetraose (18), maltopentaose (19), 
maltohexaose (20), and maltoheptaose (21). 
FIGURE 8: The rate of ATP hydrolysis by the Pgp ATPase in membranes with different 
lateral packing densities. A) Pgp ATPase activity is normalized to the basal activity in the 
membrane with the highest lateral packing density, πM = 51mN/m. B) Pgp ATPase activity 
is normalized to the basal Pgp ATPase activity at the corresponding lateral membrane 
packing density. Basal Pgp ATPase activity is shown as black bars, and verapamil and 
PSC833 stimulated Pgp ATPase activity as hatched and cross-hatched bars, respectively. 
The Pgp ATPase activity at πM = 51mN/m was calculated from the free energies of 
activation,  ΔG‡, at T = 35 oC according the eq. (2), data were taken from ref (19) at pH 
7.5. For comparison, the basal and verapamil induced Pgp ATPase activity was measured 
at T = 35 oC and at pH 7.5 in NIH-MDR1-G185 cell membranes exhibiting an estimated 
lateral packing density of πM = 30.5 mN/m. The Pgp ATPase activity in the presence of 
PSC833 at πM = 30.5 mN/m was calculated from the free energies of activation,  ΔG‡, at T 
= 35 oC according to eq. (2). The amount of the Pgp ATPase in plasma membrane vesicle 
preparation used in the measurements at pH 7.5 and T = 35 oC was estimated as 1.1 %.  
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INTRODUCTION 
 
The first synthetic dye, aniline, was discovered in the 19th century. Since then in the field of 
biology and medicine synthetic dyes have been used for histological studies because they 
provide the possibility for a visual examination of cell and tissue physiology and 
morphology at the microscopic level. Due to their selectivity and furthermore the 
biological activity they formed a basis of modern chemotherapy initiated by Paul Ehrlich. 
In 1891 Ehrlich and Guttmann used for the first time methylene blue for the treatment of 
malaria in humans (1-4).  
 Methylene blue, MB, stains cellular nuclei blue. The mechanism of staining is based 
on the electrostatic interactions between the positive charge of MB and the anionic oxygens 
in DNA and RNA (5). Acridine orange, AO, is a cell permeant cationic dye which interacts 
with DNA and RNA. AO has been used in cell-cycle studies because it emits green 
fluorescence when bound to the double stranded DNA and red fluorescence when bound to 
the single stranded DNA or RNA (6, 7). Basic fuchsin, Fu, is used for carbohydrate 
staining together with periodic acid. Periodic acid opens the sugar rings of carbohydrate 
forming two aldehyde groups and iodate. The =NH2+ group of fuchsin forms a Schiff base 
bond with aldehyde binding the dye to carbohydrate (5). Eosin, Eo, and its derivatives stain 
protein rich regions of cells red. At physiological pH eosin has one to two negative charges 
and, thus, it binds electrostatically to the positively charged amino acids. Figure 1 shows 
the structures of MB, AO, Fu and Eo. 
The applicability of dyes as anticancer and antimicrobial drugs in photodynamic 
therapy, PDT, has also been tested. PDT combines a nontoxic photoactivable dye, also 
called as photosensitizer, PS, with the harmless visible light of relevant wavelength to 
excite the dye to its reactive triplet state, which will then generate reactive oxygen species 
that are toxic to cells (8-11).  
A serious problem in the cancer and antimicrobial chemotherapy is the development 
of multidrug resistance, MDR, for several drugs simultaneously (12, 13). One reason for 
MDR is the overexpression of ATP binding cassette, ABC, efflux transporters that reduce 
the accumulation of active agents inside cells below their therapeutic concentration. In 
mammalian cells P-glycoprotein (Pgp, MDR1, ABCB1) is best characterized among them 
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(for reviews see (14, 15)). Similar efflux transporters are expressed in bacteria (e.g. 
Sav1866 (16), LmrA (17, 18), for review see (19)) and in fungi (e.g Cdr1p (20)). 
Pgp (170 kDa) is a transmembrane protein which transports a wide variety of 
structurally diverse compounds out of the cell membrane extruding them either directly to 
the extracellular medium or flipping them from the inner to the outer leaflet of the lipid 
bilayer (21). The substrate translocation occurs at the expense of ATP hydrolysis (22-25). 
Taking together our previous investigations with the research made in other laboratories 
reveals three requirements for Pgp substrates (26): 1) Pgp substrates have to partition into 
the cytosolic leaflet of the lipid bilayer before they can reach the Pgp binding site (27-30), 
2) Pgp substrates have to be positively charged or non-charged at physiological pH 
(negatively charged compounds are not generally interacting with Pgp), and 3) Pgp 
substrates have to carry a minimum binding element which is composed of two or three 
hydrogen bond acceptor groups in a specific distance ((2.5 ± 0.5) Å or (4.6 ± 0.6) Å) (31, 
32). The third requirement was revealed by screening the 3D structures of hundreds of Pgp 
substrates. It was suggested that Pgp recognize its substrates via hydrogen bonding. 
Furthermore, the importance of hydrogen bonds was supported by the fact that 
transmembrane domains of Pgp contain a high density of hydrogen bond donor side chains.  
Recently, using 15 structurally diverse Pgp substrates as a calibration set we 
demonstrated that Pgp activity depends mainly on the nature and the concentration of the 
substrates as well as on the packing density of membrane, πM, and on the pH of 
environment (33, 34). We further showed that the air-water partition coefficient, Kaw, 
correlated linearly with the inverse of the concentration of half-maximum Pgp activity, 
1/K1, indicating that the substrate concentration in the membrane is relevant for Pgp 
activity (34). Furthermore, we demonstrated that the logarithm of maximum Pgp activity, 
lnV1, increases linearly with increasing free energy of drug binding from the aqueous phase 
to the transporter, 0 )1(twGΔ (33), which in turn depends on the number and the strength of the 
hydrogen bonds formed between the drug and the transporter and on the lipid-water 
partition coefficient of the drug (35).   
The present investigation was made in order to answer the following questions. At 
first, we asked whether MB, AO, Fu, and Eo are substrates for Pgp. This is relevant since 
MB, AO, Fu, and Eo are commonly used in histological studies and the potency of MB and 
AO as PS in PDT for the treatment of cancer and microbial infections has been tested (8, 
36-39). Secondly, we tested whether the three requirements for Pgp substrates hold for MB, 
AO, Fu, and Eo. To our knowledge Fu and Eo were not tested earlier for Pgp interactions 
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and MB and AO have only been tested with indirect methods (37, 40-43). For this purpose 
we measured the Pgp activity in living mouse embryo fibroblasts, NIH-WT and MDR1-
transfected, and in plasma membrane vesicles formed from the same cells. The 
measurements were performed in living cells with a Cytosensor microphysiometer and in 
plasma membrane vesicles with colorimetric phosphate release assay.   
 
 
MATERIALS AND METHODS 
 
Materials. Methylene blue (Cat. No. M9140) and acridine orange (Cat. No. 318337) were 
from Sigma-Aldrich (Steinheim, Germany). Basic fuchsin (Cat. No. 47860) and ethyl eosin 
(Cat. No. 45230) were obtained from Fluka (Buchs, Switzerland). Complete EDTA-free 
protease inhibitor cocktail tablets were obtained from Roche Diagnostics (Mannheim, 
Germany), 1,4-dithiol-DL-threitol, DTT, from Applichem (Darmstadt, Germany), and 
bicinchoninic acid, BCA, protein assay reagents from Pierce (Rockford, IL). All other 
chemicals were either from Sigma, Fluka or Merck. Cell culture media DMEM with and 
without pyruvate (liquid and dry, Cat. No. 21969 and Cat. No. 52100, respectively) as well 
as other compounds required for cell culture such as fetal bovine serum, FBS, L-glutamine, 
and antibiotics were from Gibco-BRL (Basel, Switzerland).  
Cell Lines and Cell Culture. The mouse embryo fibroblasts NIH3T3, NIH-WT 
(NIH-WT) and MDR1-transfected (NIH-MDR1-G185) (grown in the presence of 0.15 µM 
colchicine) were generous gifts from Dr. M.M. Gottesman and Dr. S.V. Ambudkar (The 
National Institutes of Health, Bethesda, MD). Cells were maintained as described 
previously (Chapter 7.3 (44, 45)).  
Plasma Membrane Preparation. The crude plasma membrane vesicles were 
prepared as described previously (cf. Chapter 7.4 (33)).   
Phosphate Release Assay. The Pgp associated vanadate-sensitive ATPase activity 
was determined according to Litman et al. (24) in 96-well microtiter plate (Nunc F96 
MicroWellTM plate, non-treated). The measurements were performed at pH 7.0 and T=37 
°C as described earlier (cf. Chapter 7.4 (33)).  
Cytosensor Measurements. Cytosensor microphysiometer detects the changes in 
extracellular acidification rate, ECAR, of living cells. The measurements were performed 
at pH 7.4 and T=37 °C as described earlier in detail (Chapters 7.1 and 7.3  (34, 44)). The 
DMEM flow medium was prepared from DMEM dry powder supplemented with NaCl (2.6 
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g/L) and pyruvate (1 mM). MB, AO, Fu, and Eo concentrations were corrected for the 
adsorption to the Cytosensor tubes and debubbler membranes via UV-spectroscopy 
measurements.   
Light Microscope Pictures. NIH-MDR1-G185 and NIH-WT cells (8 ·105 cells) were 
seeded to 35-mm dishes and at the same time colchicine was removed from NIH-MDR1-
G185 cells. The cells were incubated at 37°C ~6h in order to let the cells attach to the dish.  
After cell attachment 10 μL of MB stock solution (19.3 mM) was added to the cells in 3 
mL of culture medium obtaining the final MB concentration 64.3 μM. Next the cells were 
incubated at 37°C for 1h and thereafter the light microscope pictures were taken. The 
control pictures were taken just before the addition of MB. For MB and PSC833 pictures 
1.0·105 cells were seeded on glass-bottom dishes one day before the pictures were taken. 
One hour before the addition of the test compounds (MB alone (64.5 μM) or together with 
PSC833 (1μM)) the cells were washed with PBS and fresh DMEM without colchicine was 
added to cells. Next the cells were incubated at 37°C one hour and thereafter the pictures 
were taken.  
The Kinetic Model. The data from proton and phosphate release measurements are 
fitted to a modified Michaelis-Menten equation (eq. (1)) proposed by Litman et al. (24) 
assuming basal Pgp activity in the absence of drugs, activation with one and inhibition with 
two drug molecules bound to Pgp  
 
2
swsw221
2
2sw12bas21
sw CCKKK
CVCVKVKKV sw++
++=     (1) 
 
where Vsw is the rate of phosphate release, Pi, or the rate of proton, H+,  release as a 
function of substrate concentration in aqueous solution, Csw, and Vbas is the basal activity of 
Pgp in the absence of drug. K1 is the concentration of half-maximum Pgp activation, K2 is 
the concentration of half-maximum inhibition, V1 is the maximum Pgp activity and V2 the 
minimum Pgp activity at infinite substrate concentration. 
Surface Activity Measurements. Surface activity measurements were performed in 
50 mM Tris/HCl buffer containing 114 mM NaCl, pH 7.4 and temperature (24 ± 1)oC. For 
details see (46, 47). Shortly, by measuring the surface pressure, π, as a function of tissue 
dye concentration (Gibbs adsorption isotherm) allows determination of air-water partition 
coefficient, Kaw, the surface area of the molecule at the air-water interface, Ad, and the 
critical micelle concentration, CMCD. Lipid-water partition coefficient, Klw, can be then 
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estimated according the (eq. (2)) where membrane packing density, πM, (30 mN/m for 
NIH-MDR1-G185 cells), the negative surface potential,ψ, of the cytosolic lipid leaflet (-30 
mV) and the charge of the drug, z, are taken into account. 
 
RTFzkTA
awlw eeKK dM
// ψπ −−=      (2) 
 
Thermodynamics of Substrate Binding to Pgp. The binding constant of substrate to 
the activating binding region of Pgp from the aqueous phase, Ktw(1), is expressed as a 
product of lipid-water partition coefficient, Klw, and the substrate binding constant from the 
lipid phase to the activating binding region of Pgp, Ktl(1) (Ktw(1)= Klw · Ktl(1)). 
Correspondently, the free energy of substrate binding from the aqueous phase to the 
activating binding region of Pgp, 0 )1(twGΔ , is a sum of the free energy of substrate 
partitioning to the lipid bilayer, 0lwGΔ , and the free energy of substrate binding from the 
lipid phase to the activating region of the transporter, 0 )1(tlGΔ  ( 0 )1(00 )1( tllwtw GGG Δ+Δ=Δ ) (for 
details cf. Chapter 7.1 (34, 35)). The substrate binding constant from the aqueous phase to 
the activating binding region of Pgp, Ktw(1), can be estimated as an inverse of concentration 
of half-maximum Pgp activity (Ktw(1) ~ 1/K1). The lipid-water partition coefficient, Klw, is 
determined from the surface activity measurements according (eq. (2)).  
 Stock Solutions of Dyes. Dyes were used as they were obtained from the 
commercial sources. For the Cytosensor measurements the stock solutions of MB and AO 
were made in DMEM flow medium. Fu and Eo were dissolved in DMSO which were then 
diluted with flow medium to the final DMSO concentration (0.5 % (v/v)). DMSO 
concentration was decreasing upon further dilution with flow medium. For the phosphate 
release assay MB and AO were solubilized in nano-pure water and Fu and Eo in DMSO. 
From the stock solutions the intermediate dye solutions were prepared by further diluting 
them either with water or DMSO. The measured concentrations were obtained by adding 5 
μL aqueous or 1 μL DMSO dye solution into the phosphate release assay buffer (total 
sample volume 60 μL). Final DMSO concentration was 1.7 % (v/v). DMSO did not have 
effect on the ECAR or the phosphate release rate measurements.  
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RESULTS 
 
Dye-Induced ECAR of Wild-Type and MDR1-Transfected Mouse Embryo Fibroblasts. The 
effect of four dyes MB, AO, Fu, and Eo, on the ECAR of mouse embryo fibroblast, wild-
type (NIH-WT) and MDR1-transfected (NIH-MDR1-G185), cells were studied with a 
Cytosensor microphysiometer. Figure 1 shows the structures of dyes. The cells (4·105) 
trapped between two polycarbonate membranes in a flow chamber were in diffusive 
contact with a pH sensitive silicon chip. First cells were flushed with the dye-free flow 
medium to reach a stable ECAR. Thereafter they were flushed with the dye-containing 
flow medium for 3 min comprising two measuring points (indicated as hatched bar in 
Figure 2D). After the 3-min stimulation the cells were again flushed with the dye-free flow 
medium until the basal ECAR was reached. Thereafter a new stimulation with a higher dye 
concentration was performed. The ECAR measurements were performed in every two 
minutes by halting the pumps for 20s, during which the acidic metabolites excreted by cells 
accumulated inside the sensor chamber. The change in pH was then measured during 13s. 
Figures 2A-D display the changes in the ECAR of NIH-WT and NIH-MDR1-G185 cells 
upon stimulation with increasing concentration of MB, AO, Fu, and Eo as function of time. 
The ECAR is normalized to the basal ECAR which is defined as 100 %. 
 
FIGURE 1 
FIGURE 2A-D 
 
As seen in Figure 2A-D all dyes except Fu affected the energy metabolism of living cells in 
complex manner. Upon stimulation with MB (Figure 2A) the ECAR increased in NIH-
MDR1-G185 cells as well as in NIH-WT cells, however, the increase in NIH-WT cells was 
higher and moreover; the maximum ECAR in NIH-WT cells was reached at lower MB 
concentration than in NIH-MDR1-G185 cells.  
AO stimulated the ECAR of NIH-MDR1-G185 and NIH-WT cells in concentration 
dependent manner (Figure 2B). The increase in the ECAR of NIH-MDR1-G185 cells was 
significantly higher than that in NIH-WT cells. Kinetics for reaching the basal ECAR after 
AO stimulation was considerably slower than for other tested dyes. After stimulating the 
NIH-MDR1-G185 cells with 22.6 μM AO, it took approximately two hours to reach the 
basal ECAR again.  
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Fu induced a modest increase in the ECAR of NIH-MDR1-G185 cells (maximally 
~120%), but not in NIH-WT cells (Figure 2C). However, the highest Fu concentration 
studied caused a fast transient increase in the ECAR of NIH-WT cells (up to ~125%) which 
decreased back to the basal value immediately after a 3-min dye-stimulation period.  
Eo caused a sharp decrease in the ECAR that was similar in NIH-WT and in NIH-
MDR1-G185 cells (Figure 2D). Kinetics for reaching the basal ECAR of both cells after Eo 
stimulation was fast (~6 min for 6.5 μM Eo). 
Tissue Dye-Induced Pgp Activation Measured in Plasma Membrane Vesicles 
Prepared from Wild-Type and MDR1-Transfected Mouse Embryo Fibroblasts. Figure 3A 
displays the Pgp activity profiles as a function of tissue dye concentration (log scale) 
obtained from phosphate release rate measurements in the plasma membrane vesicles of 
NIH-MDR1-G185 and NIH-WT cells. The tissue dye-induced Pgp activation is expressed 
as a percentage of the basal Pgp activity. For comparison the ECARs measured in living 
NIH-WT and NIH-MDR1-G185 cells at the end of the 3-min stimulation period (indicated 
as solid symbols in Figures 2A-D) are shown in Figure 3B.  
      
FIGURE 3A-B 
 
As seen in Figure 3A Pgp activity increased at a low concentration of MB, at the 
intermediate concentration the maximum Pgp activity was reached and at the high MB 
concentration Pgp activity decreased again. Similar bell-shaped Pgp activity profiles were 
obtained previously for typical Pgp substrates (cf. Chapter 7.2 (33)) indicating that MB is 
an intrinsic substrate for Pgp. In the plasma membrane vesicles formed from NIH-WT cells 
no increase in the phosphate release rate with increasing concentration of MB was 
observed. A bell-shaped Pgp activity profile was also obtained with increasing 
concentrations of AO in plasma membrane vesicles of NIH-MDR1-G185 cells. Fu 
stimulated Pgp activity; however, the maximum Pgp activity was very modest. Eo, in 
contrary, did not stimulate Pgp activity at all. Only a slight decrease in the phosphate 
release rate was observed at high concentrations. A similar ATPase activity profile was 
observed for Eo in the plasma membrane vesicles of NIH-WT cells (results not shown).  
The data from the phosphate release and the ECAR measurements were fitted to the 
rate equation (eq. (1)) proposed by Litman et al. (24). It assumes basal Pgp activity in the 
absence of exogenous substrates, Pgp activation upon binding of one substrate molecule at 
a low aqueous concentration and Pgp inhibition upon binding of two substrate molecules to 
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transporter at a high aqueous concentration. Data evaluation yielded the concentration of 
half-maximum activation (inhibition), K1 (K2), and the maximum (minimum) Pgp activity, 
V1 (V2). The kinetic parameters are summarized in Table 1. Only the data from the 
phosphate release measurements were evaluated because AO, MB and Eo also affected 
strongly the ECAR of NIH-WT cells. Several metabolic processes are superimposed in the 
ECAR of NIH-MDR1-G185 cells and their differentiation was not possible. The ECAR of 
NIH-WT cells can not be used as a blank sample to subtract them from the ECAR of NIH-
MDR1-G185 cells, because Pgp creates intracellular concentration gradient between the 
NIH-WT and NIH-MDR1-G185 cells.  
       
TABLE 1 
 
Visualization of Wild-Type and MDR1-Transfected Mouse Embryo Fibroblasts after 
Incubation with MB. Figures 4A-D show the light microscopy pictures of NIH-WT and 
NIH-MDR1-G185 cells in the absence and in the presence of MB (64.5 μM). After 1h 
incubation with MB a clear difference between NIH-WT and NIH-MDR1-G185 cells is 
observed. The majority of NIH-WT cells have taken up MB and they were stained blue 
whereas the majority of NIH-MDR1-G185 cells remained uncolored. After 2h incubation 
with MB the pictures were similar (data not shown). We further tested the effect of PSC833 
(1 μM) on the uptake of MB in NIH-MDR1-G185 cells. PSC833 is a known inhibitor of 
Pgp and if the MB uptake is dependent on the function of Pgp, we should observe more 
blue cells after when Pgp is inhibited by PSC833. In Figure 5A-F NIH-WT and NIH-
MDR1-G185 cells in the absence of MB, after 1h incubation with MB and after 1h 
incubation together with MB and PSC833 are shown. Inhibition of Pgp with PSC833 
clearly increased the number of blue NIH-MDR1-G185 cells. In preliminary tests we also 
visualized the cells with fluorescence microscopy after incubation with AO (7.6 μM) at 
various time points. No visible difference was observed between the NIH-WT and MDR1-
transfected fibroblasts after AO incubation. Already after few minutes incubation AO was 
observed in the nucleus of both cells. 
 
FIGURE 4A-D 
FIGURE 5A-F 
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DISCUSSION 
 
In the first step of the present investigation we studied whether the dyes, MB, AO, Fu and 
Eo are intrinsic substrates for Pgp. MB, AO, Fu, and Eo are widely used in histological 
studies and more recently their applicability in photodynamic therapy, PDT, for the 
treatment of cancer and microbial infections was tested. To this purpose we measured the 
Pgp activity as a function of dye concentration in living mouse embryo fibroblasts, NIH-
WT (NIH-WT) and MDR1-transfected (NIH-MDR1-G185) cells, by monitoring the 
changes in the ECAR and in the plasma membrane vesicles obtained from the same cells 
by monitoring the phosphate release rate. In the second step, we tested whether the Pgp 
activity for unknown compounds can be predicted using as a guideline our previous 
investigations with a large set of well-known Pgp substrates. Furthermore, we utilized the 
staining properties of the dyes and visualized the cells after incubation with various dyes. 
Pgp Activation with Dyes in Living MDR1-transfected Cells and in Plasma 
Membrane Vesicles Derived from the Same Cells. Previously, we have shown that the 
stimulation of NIH-MDR1-G185 cells with the well-known Pgp substrates caused increase 
in the ECAR at a low substrate concentration, the maximum ECAR was reached at an 
intermediate substrate concentration and at a high substrate concentration the ECAR was 
decreasing again. The ECAR of NIH-WT cells were not affected or only a fast transient 
decrease at a high substrate concentration was observed. Therefore the effect of Pgp 
substrates on the ECAR of NIH-MDR1-G185 cells was entirely associated to the activity 
of Pgp (Chapter 7.1 (34, 45)). In the present investigation only Fu induced a typical Pgp 
activity profile in NIH-MDR1-G185 cells, however, the inhibition part was not seen most 
likely due to the low solubility of the compound (Figure 2C). Three other dyes MB, AO 
and Eo, caused not only changes in the ECAR of NIH-MDR1-G185 cells but also in the 
ECAR of NIH-WT cells (Figure 2A, 2B and 2D).  
As seen in Figure 2A the MB stimulated increase in the ECAR of NIH-WT cells 
was higher and it occurred at lower MB concentration than that in NIH-MDR1-G185 cells 
suggesting that MB is an intrinsic substrate for Pgp. The other MB induced metabolic 
effect is overwhelming in both cells but its effect is delayed in NIH-MDR1-G185 cells 
because of lower intracellular MB concentration. The lower intracellular MB concentration 
is caused by the active efflux of MB by Pgp. The increase in the ECAR of NIH-WT cells 
upon MB stimulation might be related to the activation of pentose phosphatase pathway 
that causes an oxidative stress in cells (48). 
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AO caused an increase in the ECAR of both cells at similar concentration range, but 
in contrary to MB, the ECAR of NIH-MDR1-G185 cells were higher than in NIH-WT cells 
indicating that AO is an intrinsic substrate for Pgp. AO is known to intercalate to between 
the base pairs of DNA and RNA (49-51) which may contribute to the observed increase in 
the ECAR of NIH-WT cells. 
Eo, in contrary, suppressed the ECAR of both cells below basal ECARs with a 
similar extent and at the same concentration range.  
Since effect of AO, MB and Eo on the ECAR of living cells are complex a more 
direct method was used to investigate the influence of the tissue dyes on Pgp activity in 
order to better understand their interactions. This was done spectroscopically by measuring 
the phosphate release rate from ATP hydrolysis by Pgp (Figure 3A). As seen in Figure 3A 
AO and MB induced an increase in the phosphate release rate in the plasma membrane 
vesicles of NIH-MDR1-G185 cells. MB was also measured in plasma membrane vesicles 
of NIH-WT cells and no increase in the phosphate release rate was observed. These results 
supported the conclusion that both AO and MB are the intrinsic substrates for Pgp. Eo, on 
the other hand, did not stimulated the phosphate release rate at all in the plasma membrane 
vesicles prepared either from NIH-MDR1-G185 or NIH-WT cells. However, high Eo 
concentrations inhibited the phosphate release rate in both membranes with a similar 
extent. The decrease observed in the ECAR of NIH-WT and NIH-MDR1-G185 cells, and 
also in the phosphate release rate upon Eo stimulation may be due to the interaction of 
eosin with the ATP binding sites of other ATPases eg. Ca-, Na/K- and K/H-ATPases (52-
55). From the present data it could not conclusively decide whether eosin also interacts 
with NBDs of Pgp. 
Visualization of NIH-WT and NIH-MDR1-G185 cells in the Presence of MB. When 
NIH-WT and NIH-MDR1-G185 were incubated with MB for 1h at 37°C a clear difference 
in the uptake rate of MB was observed. NIH-WT cells were getting more blue than NIH-
MDR1-G185 cells, however when Pgp was inhibited by PSC833 the difference 
disappeared. These results further suggest that MB is a substrate for Pgp. When cells were 
incubated with AO, no similar difference could be observed (results not shown). This is 
most likely due to the different uptake mechanisms. It has been suggested that positively 
charged MB is reduced at the surface of the cell by an enzyme ‘’thiazine dye reductase’’ 
(56) (cf. below). Most likely the enzyme coupled reaction is much slower than the passive 
influx rate of AO.   
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Requirements for Pgp Substrates and Prediction of Interactions between Pgp and 
Substrates. Three requirements for the intrinsic Pgp-substrates are (26): 1) they have to be 
able to partition into the cytosolic leaflet of the lipid bilayer (27, 29, 30), 2) they are 
positively charged or non-charged (31, 57)), and 3) they carry hydrogen bond acceptor 
groups in a specific distance ((2.5 ± 0.5) Å or (4.6 ± 0.6) Å) (31, 32) . All four tissue dyes 
fulfilled the first requirement. This was tested with the surface activity measurements that 
allow the estimation of the air-water partition coefficient, Kaw, the cross-sectional area of 
compound, Ad, in the lipid bound orientation. However, due to the low solubility of Fu and 
Eo and the high charge of MB and AO, the concentration of surface activity onset, C0, that 
correlates with the air-water partition coefficient, Kaw, was determined (46, 58). Same 
reasons abolished the determination the cross-sectional area, Ad, and, therefore the 
estimates are used in the present calculations (Table 1).  
The C0 was increasing for tissue dyes in order MB, AO, Fu, and Eo. Previously, the 
linear correlation between the air-water partition coefficient, Kaw, (~ the concentration of 
surface activity onset, C0) and the inverse of the concentration of half-maximum Pgp 
activation, 1/K1, were found (Chapter 7.1 (34)). Therefore, it was expected that the 
concentration of half-maximum Pgp activation, K1, for the studied tissue dyes are 
increasing in same order, as they indeed are doing. Figure 6 shows the air-water partition 
coefficient, Kaw, (the inverse of the concentration of surface activity onset, 1/C0, for the 
dyes) obtained from the surface activity measurements versus the inverse of the 
concentration of half-maximum Pgp activation, 1/K1, obtained from the phosphate release 
measurements. The reported values for dyes are rough estimates and give only the 
tendency. For more rigorous evaluation further investigations are needed. It was observed 
that e.g the Kaw of AO depends on the stock solution concentration. 
 
FIGURE 6 
 
The second requirement is fulfilled by MB, AO, and Fu. Eo instead has a negative charge 
at pH 7.0 and pH 7.4 and therefore it was excepted that Eo is not transported by Pgp. The 
experimental data supported the expectations (Figures 2D and 3). However, it is not clear 
from the present data whether Eo interacts with the NBDs of Pgp. Here, it also has to be 
noted that pH of the local environment effects on the protonation state of drugs, which 
usually are weak acids or bases. Thus the compounds which has a negatively charge at pH 
7.4 can be substrates for Pgp at acidic conditions. Interestingly, MB has a fixed positive 
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charge. In inside-out Pgp vesicles permanently charged compounds are able to stimulate 
Pgp activity because the drug binding site is located towards extracellular medium (59). In 
living cells this is unexpected because drugs have to diffuse through the hydrophobic lipid 
bilayer in order to reach the drug binding site of Pgp. Only uncharged compounds diffuse 
through hydrophobic lipid core (60). However, as seen in the microscope pictures (Figure 4 
and 5) MB has clearly been taken up the cells and therefore another uptake mechanism has 
to exist. May et al. (56) suggested that MB enters into the human erythocytes via an 
enzyme ‘’thiazine dye reductase’’ that reduces the oxidized, charged MB (MB+, or 
‘’blue’’) on the extracellular surface of cell. Thus the non-charged form (MBH or 
‘’colorless’’) can diffuse passively across the plasma membrane. Similar uptake 
mechanism has been proposed for endothelial cells (61-63) and it also may exist in mouse 
embryo fibroblasts.  
The third requirement for Pgp substrates is also fulfilled by all studied tissue dyes 
as seen in Figure 1. Also Eo carries at least three hydrogen bond acceptor patterns in the 
distance ((2.5 ± 0.5) Å or (4.6 ± 0.6) Å), but a negative charge abolishes the possible 
interactions with the transmembrane helices Pgp. The binding affinity of drug to Pgp can 
be estimated as the free energy of hydrogen bond formation between the substrate and the 
transporter, EUH, according to the differently weighted hydrogen bond acceptor patterns. 
For the strong (oxygen), the intermediate (nitrogen, sulfur, phenyl ring), and the weak 
hydrogen bond acceptor groups (fluorine) were given the weight 1, 0.5, and 0.25, 
respectively. Fu has only one hydrogen bond acceptor pattern composed of two phenyl 
rings whereas MB and AO have two patterns composed of two phenyl rings and one 
composed of sulfur-nitrogen and nitrogen-nitrogen atoms, respectively. Thus, it was 
expected that the total hydrogen bond energy between Pgp and Fu is weaker than between 
Pgp and MB/AO and correspondently the maximum Pgp activity, V1, for Fu is smaller than 
for MB and AO. In Figure 7 is shown the logarithm of maximum activity of Pgp, lnV1, as a 
function of the free energy of drug binding from the aqueous phase to the transporter, 
0
tw(1)GΔ . The previously studied Pgp substrates are indicated as stars, and the tissue dyes as 
open squares. As seen the tissue dyes are in good agreement with the previously reported 
results and with the expectations. 
 
     FIGURE 7 
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Free-Energy of Substrate Binding to the Transporter Evaluated According to a Two-Step 
Substrate Binding Mechanism. The free energy of substrate binding to the activating 
binding region of Pgp from the lipid phase, 0 )1(tlGΔ , were calculated as a difference between 
the free energy of drug binding from the aqueous phase to the transporter, 0tw(1)GΔ , and the 
free energy of drug partitioning into the lipid bilayer, 0lwGΔ . For MB, AO, and Fu 
0
)1(tlGΔ were -7.8 kJ/mol, -5.8 kJ/mol, and -4.4 kJ/mol, respectively. Eo did not interact with 
Pgp as seen in Figure 3. By dividing the experimental free energies, 0 )1(tlGΔ , by the 
weighted hydrogen bonds (for details cf. Chapter 7.1) we estimated the free energy of 
binding per potential hydrogen bond formed, 0HiGΔ , for AO, MB and Fu as -2.9 kJ/mol, -
3.8 kJ/mol, and -4.4 kJ/mol, respectively (Table 1). These results are in good agreement 
with the values calculated previously with a similar approach for the 15 well-known Pgp 
substrates and they are reasonable values for the weak hydrogen bonds (Chapter 7.1 (34)). 
However, it has to be emphasized that these values have to be taken as rough estimates 
since the experimental difficulties in the determination of the lipid-water partition 
coefficient of the dyes. 
Conclusions. We showed that by applying the established rules for intrinsic Pgp-
substrates the Pgp-substrate interaction can be predicted in reasonable manner. In 
accordance with the established rules it was assumed that MB, AO, and Fu are intrinsic 
substrates for Pgp, whereas Eo is not. This prediction was validated experimentally with 
the phosphate release measurements in plasma membrane vesicles of NIH-MDR1-G185 
cells and with the ECAR measurements in living cells. Furthermore, ECAR measurements 
revealed that MB, AO and Eo influence the energy metabolism of NIH-WT and MDR1-
transfected cells in complex manner. Thus, by evaluating Pgp activity in living cells gives 
further valuable information about the cytotoxicity of drugs.  
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TABLES 
 
Table 1. The kinetic parameters of Pgp activation for the dyes measured with the phosphate 
release measurements in plasma membrane vesicles of NIH-MDR1-G185. K1 (K2) is the 
concentration of the half-maximum Pgp activation (inhibition), and V1 (V2) is the maximum 
(minimum) Pgp activity. 0HiGΔ  is the estimated free energy per hydrogen bond formed 
between Pgp and its substrate. 
Dye MW [g/mol] pKa 
weighted 
number of   
H-bond 
acceptors 
1/C0 a 
 [mM-1] 
pH 7.4 
Adb 
[Å2] 
 
K1 
[μΜ] 
pH7.0 
K2 
[μΜ] 
pH7.0 
V1 
[fold] 
pH7.0 
V2 
[fold] 
pH7.0 
0
HiGΔ  
[kJ/mol] 
MB 284.4 ~13-14(2) 2 14 55 46.5 825 3.1 0.1 -3.8 
AO 265.4 10.3(64) 2 13-455 55 6.2 801.2 3.3 0 -2.9 
Fu 337.9 
2.5  
7.8(65)  
12.5 
1 1280 70 5.7 50.0 1.75 0.3 -4.4 
Eo 714.0 3.2(66) 5 1650 70 - - - - - 
a The concentration of the surface activity onset is obtained from the surface activity measurements at pH 7.4. 
Eo was dissolved in DMSO, MB, AO, and Fu in H2O. C0 for AO is affected by the association state of the 
molecule in solution which depends on the stock solution concentration. C0 for Eo and Fu are affected by the 
low solubility of the compounds. b The cross-sectional area of the molecule are the estimates. They will be 
modelled according to  (67).  
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FIGURE LEGENDS 
 
FIGURE 1. Chemical structures of methylene blue, MB, acridine orange, AO, basic 
fuchsin, Fu, and ethyl eosin, Eo. The dashed line circles and the asterisks indicate the 
hydrogen bond acceptor groups in the distance ((2.5 ± 0.5) Å or (4.6 ± 0.6) Å).  
 
FIGURE 2A-D. Time dependent ECAR of NIH-WT (circles) and NIH-MDR1-G185 
(squares) cells as a function of increasing concentration of A) MB, B) AO, C) Fu, and D) 
Eo. The ECAR is measured with a Cytosensor microphysiometer (37oC, pH 7.4). The cells 
were stimulated with dyes for 3 min which is indicated as a hatched bar in 2D. Each 
segment is normalized to a basal ECAR (the average of two data points before dye-
stimulation period is taken as 100 %). The solid symbols indicate the second stimulation 
point during the 3-min stimulation period which is used for the evaluation of Pgp activity 
(cf. Chapter 3). The time bars (30 min) are shown. Note the difference in the scale of Y-
axis.  
 
FIGURE 3A-B. Dye-induced Pgp activity profiles measured in living NIH-MDR1-G185 
cells (filled symbols) and NIH-WT cells (open symbols) and B) in plasma membrane 
vesicles prepared thereof. MB (?, ?), AO (?, ?), Fu (?, ?), and D) Eo (?, ?). 
Vanadate-sensitive Pgp activation was measured with the phosphate release assay (37oC, 
pH 7.0). The basal vanadate-sensitive Pgp activity is taken as 100%. The ECAR was 
measured with a Cytosensor microphysiometer (37oC, pH 7.4). The second measuring 
point during 3-min stimulation period indicated in Figure 2A-D as filled symbols are 
shown. The solid lines are the fits to the modified Michaelis-Menten equation (eq. (1)). The 
data points correspond to the average of 1-4 measurements.  
 
FIGURE 4A-D. Light microscopy pictures (20x magnification) of NIH-WT (A and C) and 
NIH-MDR1-G185 cells (B and D) before (top row) and after 1h incubation with 64.5 μM 
MB (bottom row).  
 
FIGURE 5A-F. Light microscopy pictures (40x magnification) of NIH-WT (A, B, C) and 
NIH-MDR1-G185 cells (D, E, F). A and D: without drug; B and E: after 1h incubation at 
37°C with MB (64.5 μM); C and F: after 1h incubation at 37°C with PSC833 (1 μM) and 
MB (64.5 μM).  
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FIGURE 6. Correlation between the air-water partition coefficient, Kaw, and the inverse of 
the concentration of half-maximum Pgp activation, 1/K1. The concentrations of half-
maximum Pgp activation, K1, are obtained from the phosphate release measurements (pH 
7.0, 37oC) in plasma membrane vesicles of NIH-MDR1-G185 cells. The air-water partition 
coefficient, Kaw, and the concentration of surface activity onset, C0, are determined from the 
surface activity measurements (pH 7.4, (24 ± 1)oC). Tissue dyes are shown as filled 
squares, and the previously studied Pgp substrates are indicated as stars (adapted from the 
studies presented in Chapters 7.1 and 7.2 ). 1) amitriptyline, 2) chlorpromazine, 3) cis-
flupenthixol, 4) cyclosporin A, 5) daunorubicin 6) dibucaine, 7) diltiazem, 8) glivec, 9) 
lidocaine 10) progesterone, 11) promazine, 12) (R/S)-verapamil, 13) reserpine, 14) 
trifluoperazine, 15) triflupromazine.  
 
FIGURE 7. Logarithm of maximum Pgp activity, lnV1, as a function of the free energy of 
binding of substrate from the aqueous phase to the activating binding region of the 
transporter, 0tw(1)GΔ . Pgp activity was measured in the inverted plasma membrane vesicles 
of NIH-MDR1-G185 cells (pH 7.0, 37oC). Tissue dyes are shown as filled squares, and the 
previously studied Pgp substrates are indicated as stars (adapted from the study presented 
in Chapter 7.2). 1) amitriptyline, 2) chlorpromazine, 3) cis-flupenthixol, 4) cyclosporin A, 
6) dibucaine, 7) diltiazem, 8) glivec, 10) progesterone, 11) promazine, 12) (R/S)-verapamil, 
13) reserpine, 14) trifluoperazine, 15) triflupromazine, 16) colchicine, 17) OC144-093, 18) 
PSC-833, and 19) vinblastine.  
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